Novel heterocyclic compounds for modulating P53 function

Abstract

The invention discloses a new fused ring or large heterocyclic ring compound with a P53 signal channel abnormity regulation effect, and particularly discloses a compound which is used as a P53 mutation target spot regulator and has a structure shown in a formula (I) or pharmaceutically acceptable salt, solvate, hydrate, isotope substitute or isomer thereof.

Description

Novel heterocyclic compounds for regulating P53 function

[0001] The present invention claims:

[0002] Priority to the prior application, patent application number 202310999503.3, filed with the State Intellectual Property Office of China on August 9, 2023, entitled “Novel heterocyclic compounds for regulating P53 function”;

[0003] Priority to the prior application, patent application number 202410754113.4, filed with the State Intellectual Property Office of China on June 12, 2024, entitled “Novel heterocyclic compounds for regulating P53 function”;

[0004] The entire contents of said prior application are incorporated herein by reference. Technical Field

[0005] The present invention belongs to the field of medicinal chemistry and specifically includes novel aromatic ring compounds capable of regulating P53 function, compositions containing such compounds, and methods for using such compounds to prepare drugs for treating or preventing diseases associated with abnormalities in the P53 gene / protein or signaling pathways (such as tumors, autoimmune diseases, etc.). Background Art

[0006] Although the emergence of many drugs in recent years has led to significant progress in the treatment of tumors, cancer remains the leading disease that seriously threatens human health and lifespan. The pathogenic mechanisms of cancer are complex and varied, with P53 being the most prominent example. The P53 tumor suppressor gene is a gene in the body that inhibits cells from transforming into cancer cells. The human P53 gene is located on chromosome 17, P13, is 16-20 kb in length, contains 11 exons, and transcribes 2.8 kb of mRNA, encoding the protein P53, a nuclear phosphorylated protein. P53 is the gene with the highest correlation with human tumors discovered to date. The P53 protein, the expression product of the P53 gene, is composed of 393 amino acid residues and exists as a tetramer in the body with a half-life of 20-30 minutes.

[0007] Under normal circumstances, the level of P53 protein in cells is very low, and due to its short half-life, it is difficult to detect. However, in growing and proliferating cells, the level can increase by 5-100 times or more. The P53 gene constantly monitors the integrity of the cell's chromosomal DNA. Once the cell's chromosomal DNA is damaged, the P53 protein binds to the corresponding binding site on the gene's DNA, acting as a special transcription factor, activating P21 gene transcription, causing the cell to arrest in the G1 phase; inhibiting the activity of helicase; and interacting with replication factor A, participating in DNA replication and repair. If repair fails, the P53 protein initiates a process called programmed cell death (apoptosis), inducing cell suicide, preventing the formation of mutant cells with a tendency to become cancerous, and thus preventing cell malignancy.

[0008] Previously, it was considered an oncogene. It wasn't until 1989 that it was discovered that mutant P53 was the oncogene. Wild-type P53 was later confirmed to be a tumor suppressor gene. Wild-type P53 plays a crucial role in maintaining normal cell growth and inhibiting malignant proliferation, earning it the nickname "gene guardian." When the P53 gene mutates, its spatial conformation affects transcriptional activation and phosphorylation, leading not only to the loss of wild-type P53's tumor-suppressing function but also to the mutation itself, which in turn renders the gene an oncogene. The mutant P53 protein combines with the wild-type P53 protein, forming an oligomeric protein unable to bind to DNA. This leads to uncontrolled transcription of some oncogenic genes, leading to tumorigenesis.

[0009] The P53 gene is associated with 50% of human tumors, including liver cancer, breast cancer, bladder cancer, gastric cancer, colon cancer, prostate cancer, soft tissue sarcoma, ovarian cancer, brain tumor, lymphocytic tumor, esophageal cancer, lung cancer, osteosarcoma, etc. P53 mutations in human tumors are mainly in highly conserved regions, and different types of tumors are different. For example, colon cancer and breast cancer have similar epidemiology, but the P53 mutation spectrum is not consistent. Therefore, there is an urgent need to develop inhibitors against P53 mutations.

[0010] Despite the widespread unmet needs, there are currently only a few patent reports on compounds that are effective in inhibiting P53 protein mutations, such as WO2021231474, WO2021262483, WO2021061643, etc.

[0011] Technical Effects

[0012] The inventors unexpectedly discovered that some of the novel heterocyclic compounds containing phosphorus-oxygen or sulfur-oxygen groups of formula (I) of the present invention not only have significant binding ability to the p53 mutant protein, but also, upon binding, can restore the mutant's DNA-binding function. Compared to similar patented reference compounds with known structures, these compounds also exhibit higher tumor cell proliferation inhibition activity, better pharmacokinetic properties (including improved permeability, lower clearance, longer T1 / 2, and higher exposure), and bioavailability. They are expected to have enhanced human PK properties. Some representative compounds also have excellent brain penetration and are more suitable as candidate drugs for development to prevent or treat diseases associated with the p53 mutant target and its signaling pathway.

[0013] Summary of the Invention

[0014] The object of the present invention is to provide a compound represented by formula (I) or a pharmaceutically acceptable salt, solvate, enantiomer and isotope-substituted product thereof.

[0015] in,

[0016] Ring B arbitrarily represents a 3-20 membered cyclic structure, which can be a monocyclic, bicyclic or tricyclic structure, and the cyclic structure can be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring, or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring;

[0017] Z3 is independently selected from the group consisting of absence, a single bond, -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3)-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic groups, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z3 is further optionally substituted with one or more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 alkoxy;

[0018] X1 and X2 are independently selected from N or CR;

[0019] Each R1 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, -SH and -NH2, -COOH, amide or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfamoylamino, methylsulfonylamino or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute or M group; and the hydrogen on R1 is optionally replaced by 1 to more selected from H, deuterium, halogen, pentafluoride sulfur group, OCH3, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 or any two adjacent R1s together with the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, or a 5-30 membered saturated or partially saturated heterocyclic group, wherein the hydrogen atoms on the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group are optionally selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3- 6 cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 The hydrogen on R1 is optionally replaced by one or more alkyl groups selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0020] Each R2 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, amino, hydroxyl, mercapto, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10 Alkylamino, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamide, N,N-di(C 1-10 Alkyl)amino, C 1-10 Alkyloxy, C 1-10 Alkyl acyl, C 1-10 Alkyloxy, C 1-10 Alkylsulfonyl, C 1-10 Alkylsulfinyl, C 3-10 Cycloalkylamino, C3-10 heterocycloalkylamino, C 3-10 Cycloalkoxy, C 3-10 Heterocycloalkoxy, C 3-10 Cycloalkyl acyl, C 3-10 Cycloalkoxyacetyl, C 3-10 Cycloalkylsulfonyl and C 3-10Cycloalkylsulfinyl, -YQ or M group; or optionally two R2 can be taken together with the atoms to which they are attached to form a 5-6 membered aryl or heteroaryl, a 3-8 membered saturated or partially saturated cycloalkyl, a 3-8 membered saturated or partially saturated heterocyclic group, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic group is optionally substituted by one or more groups selected from hydrogen, deuterium, alkyl, halogen, pentafluoride sulfur group, oxo, CN, CF3, OH, OCH3, OCH2CH3; and the hydrogen on R2 is optionally substituted by one or more groups selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1- 6-alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 cycloalkyl or heterocycloalkyl substitution;

[0021] M is arbitrarily and independently selected from

[0022] Z is independently selected from the group consisting of absent, C(R d1 )(R d2 ), O, NR d1 、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-、-N(R d7 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic groups, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z1 and Z2 is further optionally substituted by 1 to more substituents, wherein the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluorinated sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1- 3 alkyl, C 1-3 alkoxy;

[0023] Y is arbitrarily and independently selected from O, S or NR;

[0024] Q represents any 3-20 membered cyclic structure, which can be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure can be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; and the hydrogen on the ring Q is optionally replaced by one or more selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, oxo, alkyl, alkenyl, alkynyl, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0025] Each R may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, haloalkyl, haloalkoxy, deuterated alkyl, deuterated alkoxy, -OH, -SH and -NH2, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfamoyl, methylsulfonamido or -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute; and the hydrogen on R is further optionally substituted by 1 to more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 alkoxy;

[0026] R a and R b Any independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein, the C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by one or more radicals selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups substituted by saturated cycloalkyl or heterocyclic substituents; or R a and R b or R a and R2 or R a and R1 can also be connected together to form a 3-30 membered ring structure, wherein the ring structure can be a monocyclic, bicyclic, bridged or spirocyclic structure, and can contain 0 to multiple heteroatoms or unsaturated bonds; furthermore, R a The hydrogen on the alkoxy group is optionally replaced by one or more alkoxy groups selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 cycloalkyl or heterocycloalkyl substitution;

[0027] Every R d1、R d2 、R d3 、R d4 、R d5 、R d6 、R d7 may be the same or different and independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3- 10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein, the C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by one or more radicals selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups substituted by saturated cycloalkyl or heterocyclic substituents; or any R d1 、R d2 、R d3 、R d4 、R d5 、R d6 、R d7 Each other or / and R1 or R2 and the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, a 5-30 membered saturated or partially saturated heterocyclic group, and the hydrogen on the heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic alkyl is optionally selected from hydrogen, deuterium, halogen, pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0028] The heteroatom represents any heteroatom or group independently selected from O, N, S, P, -P=O, S=O or SO2 and its isotope;

[0029] The halogen is arbitrarily and independently selected from F, Cl, Br, I and isotopes thereof;

[0030] m is an integer arbitrarily selected from 0, 1, 2, 3, and 4;

[0031] n is an integer arbitrarily selected from 0, 1, 2, 3, 4 and 5.

[0032] The premise is that when ring B is When any two R and / or R1 are connected, they form a 7-30 membered macrocyclic structure or condensed ring structure together with the atoms on the ring.

[0033] In one embodiment of the present invention, the compound or its pharmaceutically acceptable salt, isotope-substituted product or isomer thereof has the structure of formula (IA):

[0034] in,

[0035] Y, Y1, Y2, Y3, Y4, and Y5 are each independently selected from the group consisting of absence, a single bond, -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、N、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(Rd2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-、-N(R d7 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic groups, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Y, Y1, Y2, Y3, Y4, Y5 is further optionally substituted with one or more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 alkoxy;

[0036] Ring B arbitrarily represents a 3-20 membered cyclic structure, which can be a monocyclic, bicyclic or tricyclic structure, and the cyclic structure can be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring, or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring;

[0037] Z3 is independently selected from the group consisting of absence, a single bond, -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(Rd2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic groups, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z3 is further optionally substituted with one or more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluorinated sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 alkoxy;

[0038] X1 is independently selected from N or CR;

[0039] Each R1 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, -SH and -NH2, -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, amide, sulfamoyl, sulfamoylamino, methylsulfonylamino or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute or M group; and the hydrogen on R1 is optionally replaced by 1 to more selected from H, deuterium, halogen, pentafluoride sulfur group, OCH3, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 or any two adjacent R1s together with the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, or a 5-30 membered saturated or partially saturated heterocyclic group, wherein the hydrogen atoms on the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group are optionally selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3- 6 cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 The hydrogen on R1 is optionally replaced by one or more alkyl groups selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0040] Each R2 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, amino, hydroxyl, mercapto, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10 Alkylamino, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamide, N,N-di(C 1-10 Alkyl)amino, C 1-10 Alkyloxy, C 1-10 Alkyl acyl, C 1-10 Alkyloxy, C 1-10 Alkylsulfonyl, C 1-10 Alkylsulfinyl, C 3-10 Cycloalkylamino, C3-10 heterocycloalkylamino, C 3-10 Cycloalkoxy, C3-10 Heterocycloalkoxy, C 3-10 Cycloalkyl acyl, C 3-10 Cycloalkoxyacetyl, C 3-10 Cycloalkylsulfonyl and C 3-10 Cycloalkylsulfinyl, -YQ or M group; or optionally two R2 can be taken together with the atoms to which they are attached to form a 5-6 membered aryl or heteroaryl, a 3-8 membered saturated or partially saturated cycloalkyl, a 3-8 membered saturated or partially saturated heterocyclic group, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic group is optionally substituted by one or more groups selected from hydrogen, deuterium, alkyl, halogen, pentafluoride sulfur group, oxo, CN, CF3, OH, OCH3, OCH2CH3; and the hydrogen on R2 is optionally substituted by one or more groups selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1- 6-alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 cycloalkyl or heterocycloalkyl substitution;

[0041] M is arbitrarily and independently selected from

[0042] Z is independently selected from the group consisting of absent, C(R d1 )(R d2 ), O, NR d1 、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6)-、-N(R d7 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic groups, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z1 and Z2 is further optionally substituted by 1 to more substituents, wherein the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluorinated sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1- 3 alkyl, C 1-3 alkoxy;

[0043] Q represents any 3-20 membered cyclic structure, which can be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure can be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; and the hydrogen on the ring Q is optionally replaced by one or more selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, oxo, alkyl, alkenyl, alkynyl, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0044] Each R may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, haloalkyl, haloalkoxy, deuterated alkyl, deuterated alkoxy, -OH, -SH and -NH2, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfamoyl, methylsulfonamido or -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10Alkyl substituted carboxyl or carboxyl substitute; and the hydrogen on R is further optionally substituted by 1 to more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 alkoxy;

[0045] R a and R b Any independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein, the C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by one or more radicals selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups substituted by saturated cycloalkyl or heterocyclic substituents; or R a and R b or R a and R2 or R a and R1 can also be connected together to form a 3-30 membered ring structure, wherein the ring structure can be a monocyclic, bicyclic, bridged or spirocyclic structure, and can contain 0 to multiple heteroatoms or unsaturated bonds; furthermore, R a The hydrogen on the alkoxy group is optionally replaced by one or more alkoxy groups selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 cycloalkyl or heterocycloalkyl substitution;

[0046] Every R d1 、R d2 、R d3 、R d4 、R d5 、R d6 、R d7 may be the same or different and independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3- 10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein, the C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by one or more radicals selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups substituted by saturated cycloalkyl or heterocyclic substituents; or any R d1 、R d2 、R d3 、R d4 、R d5 、R d6 、R d7Each other or / and R1 or R2 and the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, a 5-30 membered saturated or partially saturated heterocyclic group, and the hydrogen on the heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic alkyl is optionally selected from hydrogen, deuterium, halogen, pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0047] The heteroatom represents any heteroatom or group independently selected from O, N, S, P, -P=O, S=O or SO2 and its isotope;

[0048] The halogen is arbitrarily and independently selected from F, Cl, Br, I and isotopes thereof;

[0049] m is an integer arbitrarily selected from 0, 1, 2, 3, and 4;

[0050] n is an integer arbitrarily selected from 0, 1, 2, 3, 4 and 5.

[0051] In one embodiment of the present invention, the compound or its pharmaceutically acceptable salt, isotope-substituted product or isomer thereof has the structure of formula (IB),

[0052] in,

[0053] Y, Y1, Y2, Y3, Y4, and Y5 are each independently selected from -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1)=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic groups, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Y, Y1, Y2, Y3, Y4, Y5 is further optionally substituted with one or more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 alkoxy;

[0054] Z3 is independently selected from the group consisting of absence, a single bond, -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(Rd2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic groups, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z3 is further optionally substituted with one or more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluorinated sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 alkoxy;

[0055] X is independently selected from O, S, N(R d4 )、-C(R d1 )(R d2 )-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aryl, or -C(R d1 )=C(R d1 )-;

[0056] X1 is independently selected from N or CR;

[0057] Each R1 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, -SH and -NH2, -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, amide, sulfamoyl, sulfamoylamino, methylsulfonylamino or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute or M group; and the hydrogen on R1 is optionally replaced by 1 to more selected from H, deuterium, halogen, pentafluoride sulfur group, OCH3, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 or any two adjacent R1s together with the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, or a 5-30 membered saturated or partially saturated heterocyclic group, wherein the hydrogen atoms on the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group are optionally selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3- 6 cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 The hydrogen on R1 is optionally replaced by one or more alkyl groups selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0058] Each R2 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, amino, hydroxyl, mercapto, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10Alkylamino, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamide, N,N-di(C 1-10 Alkyl)amino, C 1-10 Alkyloxy, C 1-10 Alkyl acyl, C 1-10 Alkyloxy, C 1-10 Alkylsulfonyl, C 1-10 Alkylsulfinyl, C 3-10 Cycloalkylamino, C3-10 heterocycloalkylamino, C 3-10 Cycloalkoxy, C 3-10 Heterocycloalkoxy, C 3-10 Cycloalkyl acyl, C 3-10 Cycloalkoxyacetyl, C 3-10 Cycloalkylsulfonyl and C 3-10 Cycloalkylsulfinyl, -YQ or M group; or optionally two R2 can be taken together with the atoms to which they are attached to form a 5-6 membered aryl or heteroaryl, a 3-8 membered saturated or partially saturated cycloalkyl, a 3-8 membered saturated or partially saturated heterocyclic group, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic group is optionally substituted by one or more groups selected from hydrogen, deuterium, alkyl, halogen, pentafluoride sulfur group, oxo, CN, CF3, OH, OCH3, OCH2CH3; and the hydrogen on R2 is optionally substituted by one or more groups selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1- 6-alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 cycloalkyl or heterocycloalkyl substitution;

[0059] M is arbitrarily and independently selected from

[0060] Z is independently selected from the group consisting of absent, C(R d1 )(R d2 ), O, NR d1 、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(Rd2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-、-N(R d7 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic groups, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z1 and Z2 is further optionally substituted by 1 to more substituents, wherein the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluorinated sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1- 3 alkyl, C 1-3 alkoxy;

[0061] Q represents any 3-20 membered cyclic structure, which can be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure can be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; and the hydrogen on the ring Q is optionally replaced by one or more selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, oxo, alkyl, alkenyl, alkynyl, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0062] Each R may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, haloalkyl, haloalkoxy, deuterated alkyl, deuterated alkoxy, -OH, -SH and -NH2, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfamoyl, methylsulfonamido or -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute; and the hydrogen on R is further optionally substituted by 1 to more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 alkoxy;

[0063] R a and R b Any independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein, the C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by one or more radicals selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups substituted by saturated cycloalkyl or heterocyclic substituents; or R a and R b or R a and R2 or R aand R1 can also be connected together to form a 3-30 membered ring structure, wherein the ring structure can be a monocyclic, bicyclic, bridged or spirocyclic structure, and can contain 0 to multiple heteroatoms or unsaturated bonds; furthermore, R a The hydrogen on the alkoxy group is optionally replaced by one or more alkoxy groups selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 cycloalkyl or heterocycloalkyl substitution;

[0064] Every R d1 、R d2 、R d3 、R d4 、R d5 、R d6 、R d7 may be the same or different and independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3- 10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein, the C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by one or more radicals selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10Saturated or partially substituted groups substituted by saturated cycloalkyl or heterocyclic substituents; or any R d1 、R d2 、R d3 、R d4 、R d5 、R d6 、R d7 Each other or / and R1 or R2 and the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, a 5-30 membered saturated or partially saturated heterocyclic group, and the hydrogen on the heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic alkyl is optionally selected from hydrogen, deuterium, halogen, pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0065] The heteroatom represents any heteroatom or group independently selected from O, N, S, P, -P=O, S=O or SO2 and its isotope;

[0066] The halogen is arbitrarily and independently selected from F, Cl, Br, I and isotopes thereof;

[0067] m is an integer arbitrarily selected from 0, 1, 2, 3, and 4;

[0068] n is an integer arbitrarily selected from 0, 1, 2, 3, and 4.

[0069] In one embodiment of the present invention, the compound or its pharmaceutically acceptable salt, isotope-substituted product or isomer thereof has a structure of formula (IC),

[0070] in,

[0071] Y, Y1, Y2, Y3, Y4, and Y5 are each independently selected from -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(Rd2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic groups, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Y, Y1, Y2, Y3, Y4, Y5 is further optionally substituted with one or more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 alkoxy;

[0072] Z3 is independently selected from the group consisting of absence, a single bond, -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(Rd1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic groups, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z3 is further optionally substituted with one or more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluorinated sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 alkoxy;

[0073] X is independently selected from N or -CR-;

[0074] X1 is independently selected from N or CR;

[0075] Each R1 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, -SH and -NH2, -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, amide, sulfamoyl, sulfamoylamino, methylsulfonylamino or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C1-10 Alkyl substituted carboxyl or carboxyl substitute or M group; and the hydrogen on R1 is optionally replaced by 1 to more selected from H, deuterium, halogen, pentafluoride sulfur group, OCH3, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 or any two adjacent R1s together with the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, or a 5-30 membered saturated or partially saturated heterocyclic group, wherein the hydrogen atoms on the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group are optionally selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3- 6 cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 The hydrogen on R1 is optionally replaced by one or more alkyl groups selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0076] Each R2 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, amino, hydroxyl, mercapto, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10 Alkylamino, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamide, N,N-di(C 1-10 Alkyl)amino, C 1-10 Alkyloxy, C 1-10Alkyl acyl, C 1-10 Alkyloxy, C 1-10 Alkylsulfonyl, C 1-10 Alkylsulfinyl, C 3-10 Cycloalkylamino, C3-10 heterocycloalkylamino, C 3-10 Cycloalkoxy, C 3-10 Heterocycloalkoxy, C 3-10 Cycloalkyl acyl, C 3-10 Cycloalkoxyacetyl, C 3-10 Cycloalkylsulfonyl and C 3-10 Cycloalkylsulfinyl, -YQ or M group; or optionally two R2 can be taken together with the atoms to which they are attached to form a 5-6 membered aryl or heteroaryl, a 3-8 membered saturated or partially saturated cycloalkyl, a 3-8 membered saturated or partially saturated heterocyclic group, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic group is optionally substituted by one or more groups selected from hydrogen, deuterium, alkyl, halogen, pentafluoride sulfur group, oxo, CN, CF3, OH, OCH3, OCH2CH3; and the hydrogen on R2 is optionally substituted by one or more groups selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1- 6-alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 cycloalkyl or heterocycloalkyl substitution;

[0077] M is arbitrarily and independently selected from

[0078] Z is independently selected from the group consisting of absent, C(R d1 )(R d2 ), O, NR d1 、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(Rd1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-、-N(R d7 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic groups, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z1 and Z2 is further optionally substituted by 1 to more substituents, wherein the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluorinated sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1- 3 alkyl, C 1-3 alkoxy;

[0079] Q represents any 3-20 membered cyclic structure, which can be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure can be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; and the hydrogen on the ring Q is optionally replaced by one or more selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, oxo, alkyl, alkenyl, alkynyl, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0080] Each R may be the same or different and is independently selected from hydrogen, deuterium, -CN, haloalkyl, haloalkoxy, deuterated alkyl, deuterated alkoxy, -OH, -SH and -NH2, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfamoyl, methylsulfonamido or -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute; and the hydrogen on R is further optionally substituted by 1 to more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 alkoxy;

[0081] R a and R b Any independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein, the C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by one or more radicals selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups substituted by saturated cycloalkyl or heterocyclic substituents; or R a and R b or R a and R2 or R a and R1 can also be connected together to form a 3-30 membered ring structure, wherein the ring structure can be a monocyclic, bicyclic, bridged or spirocyclic structure, and can contain 0 to multiple heteroatoms or unsaturated bonds; furthermore, R a The hydrogen on the alkoxy group is optionally replaced by one or more atoms selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 cycloalkyl or heterocycloalkyl substitution;

[0082] Every R d1 、R d2 、R d3 、R d4 、R d5 、R d6 、R d7 may be the same or different and independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3- 10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein, the C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by one or more radicals selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups substituted by saturated cycloalkyl or heterocyclic substituents; or any R d1 、R d2 、R d3 、R d4 、R d5 、R d6 、R d7Each other or / and R1 or R2 and the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, a 5-30 membered saturated or partially saturated heterocyclic group, and the hydrogen on the heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic alkyl is optionally selected from hydrogen, deuterium, halogen, pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0083] The heteroatom represents any heteroatom or group independently selected from O, N, S, P, -P=O, S=O or SO2 and its isotope;

[0084] The halogen is arbitrarily and independently selected from F, Cl, Br, I and isotopes thereof;

[0085] m is an integer arbitrarily selected from 0, 1, 2, 3, and 4;

[0086] n is an integer arbitrarily selected from 0, 1, 2, 3, and 4.

[0087] In one embodiment of the present invention, the compound or its pharmaceutically acceptable salt, isotope-substituted product or isomer thereof has a structure of formula (ID),

[0088] in,

[0089] Y1, Y2, Y3, Y4, and Y5 are each independently selected from -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1)=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic groups, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Y1, Y2, Y3, Y4, Y5 is further optionally substituted with one or more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 alkoxy;

[0090] X is independently selected from N or -CR-;

[0091] X1 is independently selected from N or CR;

[0092] Each R1 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, -SH and -NH2, -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, amide, sulfamoyl, sulfamoylamino, methylsulfonylamino or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute or M group; and the hydrogen on R1 is optionally replaced by 1 to more selected from H, deuterium, halogen, pentafluoride sulfur group, OCH3, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 or any two adjacent R1s together with the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, or a 5-30 membered saturated or partially saturated heterocyclic group, wherein the hydrogen atoms on the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group are optionally selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3- 6 cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 The hydrogen on R1 is optionally replaced by one or more alkyl groups selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0093] Each R2 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, amino, hydroxyl, mercapto, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10 Alkylamino, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamide, N,N-di(C 1-10 Alkyl)amino, C 1-10Alkyloxy, C 1-10 Alkyl acyl, C 1-10 Alkyloxy, C 1-10 Alkylsulfonyl, C 1-10 Alkylsulfinyl, C 3-10 Cycloalkylamino, C3-10 heterocycloalkylamino, C 3-10 Cycloalkoxy, C 3-10 Heterocycloalkoxy, C 3-10 Cycloalkyl acyl, C 3-10 Cycloalkoxyacetyl, C 3-10 Cycloalkylsulfonyl and C 3-10 Cycloalkylsulfinyl, -YQ or M group; or optionally two R2 can be taken together with the atoms to which they are attached to form a 5-6 membered aryl or heteroaryl, a 3-8 membered saturated or partially saturated cycloalkyl, a 3-8 membered saturated or partially saturated heterocyclic group, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic group is optionally substituted by one or more groups selected from hydrogen, deuterium, alkyl, halogen, pentafluoride sulfur group, oxo, CN, CF3, OH, OCH3, OCH2CH3; and the hydrogen on R2 is optionally substituted by one or more groups selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1- 6-alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 cycloalkyl or heterocycloalkyl substitution;

[0094] M is arbitrarily and independently selected from

[0095] Z is independently selected from the group consisting of absent, C(R d1 )(R d2 ), O, NR d1 、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(Rd2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-、-N(R d7 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic groups, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z1 and Z2 is further optionally substituted by 1 to more substituents, wherein the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluorinated sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1- 3 alkyl, C 1-3 alkoxy;

[0096] Q represents any 3-20 membered cyclic structure, which can be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure can be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; and the hydrogen on the ring Q is optionally replaced by one or more selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, oxo, alkyl, alkenyl, alkynyl, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0097] Each R may be the same or different and is independently selected from hydrogen, deuterium, -CN, haloalkyl, haloalkoxy, deuterated alkyl, deuterated alkoxy, -OH, -SH and -NH2, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfamoyl, methylsulfonamido or -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute; and the hydrogen on R is further optionally substituted by 1 to more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 alkoxy;

[0098] R a and R b Any independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein, the C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by one or more radicals selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups substituted by saturated cycloalkyl or heterocyclic substituents; or R a and R b or R a and R2 or R a and R1 can also be connected together to form a 3-30 membered ring structure, wherein the ring structure can be a monocyclic, bicyclic, bridged or spirocyclic structure, and can contain 0 to multiple heteroatoms or unsaturated bonds; furthermore, R aThe hydrogen on the alkoxy group is optionally replaced by one or more alkoxy groups selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 cycloalkyl or heterocycloalkyl substitution;

[0099] Every R d1 、R d2 、R d3 、R d4 、R d5 、R d6 、R d7 may be the same or different and independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3- 10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein, the C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by one or more radicals selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups substituted by saturated cycloalkyl or heterocyclic substituents; or any R d1 、R d2 、R d3 、R d4 、R d5 、Rd6 、R d7 Each other or / and R1 or R2 and the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, a 5-30 membered saturated or partially saturated heterocyclic group, and the hydrogen on the heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic alkyl is optionally selected from hydrogen, deuterium, halogen, pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0100] The heteroatom represents any heteroatom or group independently selected from O, N, S, P, -P=O, S=O or SO2 and its isotope;

[0101] The halogen is arbitrarily and independently selected from F, Cl, Br, I and isotopes thereof;

[0102] m is an integer arbitrarily selected from 0, 1, 2, 3, and 4;

[0103] n is an integer arbitrarily selected from 0, 1, 2, 3, and 4.

[0104] In one embodiment of the present invention, the compound or its pharmaceutically acceptable salt, isotope-substituted product or isomer thereof has a structure of formula (IE):

[0105] in,

[0106] Y1, Y2, Y3, Y4, and Y5 are each independently selected from -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(Rd2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic groups, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Y1, Y2, Y3, Y4, Y5 is further optionally substituted with one or more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 alkoxy;

[0107] X is independently selected from N or -CR-;

[0108] X1 is independently selected from N or CR;

[0109] Each R1 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, -SH and -NH2, -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, amide, sulfamoyl, methylsulfonylamino or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute or M group; and the hydrogen on R1 is optionally replaced by 1 to more selected from H, deuterium, halogen, pentafluoride sulfur group, OCH3, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 or any two adjacent R1s together with the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, or a 5-30 membered saturated or partially saturated heterocyclic group, wherein the hydrogen atoms on the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group are optionally selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3- 6 cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 The hydrogen on R1 is optionally replaced by one or more alkyl groups selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0110] Each R2 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, amino, hydroxyl, mercapto, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10Alkylamino, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamide, N,N-di(C 1-10 Alkyl)amino, C 1-10 Alkyloxy, C 1-10 Alkyl acyl, C 1-10 Alkyloxy, C 1-10 Alkylsulfonyl, C 1-10 Alkylsulfinyl, C 3-10 Cycloalkylamino, C3-10 heterocycloalkylamino, C 3-10 Cycloalkoxy, C 3-10 Heterocycloalkoxy, C 3-10 Cycloalkyl acyl, C 3-10 Cycloalkoxyacetyl, C 3-10 Cycloalkylsulfonyl and C 3-10 Cycloalkylsulfinyl, -YQ or M group; or optionally two R2 can be taken together with the atoms to which they are attached to form a 5-6 membered aryl or heteroaryl, a 3-8 membered saturated or partially saturated cycloalkyl, a 3-8 membered saturated or partially saturated heterocyclic group, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic group is optionally substituted by one or more groups selected from hydrogen, deuterium, alkyl, halogen, pentafluoride sulfur group, oxo, CN, CF3, OH, OCH3, OCH2CH3; and the hydrogen on R2 is optionally substituted by one or more groups selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1- 6-alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 cycloalkyl or heterocycloalkyl substitution;

[0111] M is arbitrarily and independently selected from

[0112] Z is independently selected from the group consisting of absent, C(R d1 )(R d2 ), O, NR d1 、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(Rd2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-、-N(R d7 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic groups, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z1 and Z2 is further optionally substituted by 1 to more substituents, wherein the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluorinated sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1- 3 alkyl, C 1-3 alkoxy;

[0113] Q represents any 3-20 membered cyclic structure, which can be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure can be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; and the hydrogen on the ring Q is optionally replaced by one or more selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, oxo, alkyl, alkenyl, alkynyl, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0114] Each R may be the same or different and is independently selected from hydrogen, deuterium, -CN, haloalkyl, haloalkoxy, deuterated alkyl, deuterated alkoxy, -OH, -SH and -NH2, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfamoyl, methylsulfonamido or -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute; and the hydrogen on R is further optionally substituted by 1 to more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 alkoxy;

[0115] R a and R b Any independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein, the C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by one or more radicals selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups substituted by saturated cycloalkyl or heterocyclic substituents; or R a and R b or R a and R2 or R aand R1 can also be connected together to form a 3-30 membered ring structure, wherein the ring structure can be a monocyclic, bicyclic, bridged or spirocyclic structure, and can contain 0 to multiple heteroatoms or unsaturated bonds; furthermore, R a The hydrogen on the alkoxy group is optionally replaced by one or more alkoxy groups selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 cycloalkyl or heterocycloalkyl substitution;

[0116] Every R d1 、R d2 、R d3 、R d4 、R d5 、R d6 、R d7 may be the same or different and independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3- 10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein, the C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by one or more radicals selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10Saturated or partially substituted groups substituted by saturated cycloalkyl or heterocyclic substituents; or any R d1 、R d2 、R d3 、R d4 、R d5 、R d6 、R d7 Each other or / and R1 or R2 and the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, a 5-30 membered saturated or partially saturated heterocyclic group, and the hydrogen on the heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic alkyl is optionally selected from hydrogen, deuterium, halogen, pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0117] The heteroatom represents any heteroatom or group independently selected from O, N, S, P, -P=O, S=O or SO2 and its isotope;

[0118] The halogen is arbitrarily and independently selected from F, Cl, Br, I and isotopes thereof;

[0119] m is an integer arbitrarily selected from 0, 1, 2, 3, and 4;

[0120] n is an integer arbitrarily selected from 0, 1, 2, 3, and 4.

[0121] In one embodiment of the present invention, the compound or its pharmaceutically acceptable salt, isotope-substituted product or isomer thereof has a structure of formula (IF),

[0122] in,

[0123] Y, Y1, Y2, Y3, Y4, and Y5 are each independently selected from -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(Rd2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic groups, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Y1, Y2, Y3, Y4, Y5 is further optionally substituted with one or more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 alkoxy;

[0124] Ring C represents any 3-20 membered cyclic structure, which can be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure can be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; and the hydrogen on the ring Q is optionally replaced by one or more selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, oxo, alkyl, alkenyl, alkynyl, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0125] X is independently selected from N or -CR-;

[0126] X1 is independently selected from N or CR;

[0127] Each R1 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, -SH and -NH2, -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, amide, aminoacyl, sulfamoyl, sulfamoylamino, methylsulfonylamino or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute or M group; and the hydrogen on R1 is optionally replaced by 1 to more selected from H, deuterium, halogen, pentafluoride sulfur group, OCH3, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 or any two adjacent R1s together with the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, or a 5-30 membered saturated or partially saturated heterocyclic group, wherein the hydrogen atoms on the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group are optionally selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 The hydrogen on R1 is optionally replaced by one or more alkyl groups selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0128] Each R2 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, amino, hydroxyl, mercapto, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10 Alkylamino, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamide, N,N-di(C 1-10 Alkyl)amino, C 1-10 Alkyloxy, C 1-10 Alkyl acyl, C 1-10 Alkyloxy, C 1-10 Alkylsulfonyl, C 1-10 Alkylsulfinyl, C 3-10 Cycloalkylamino, C3-10 heterocycloalkylamino, C 3-10 Cycloalkoxy, C 3-10 Heterocycloalkoxy, C 3-10 Cycloalkyl acyl, C 3-10 Cycloalkoxyacetyl, C 3-10 Cycloalkylsulfonyl and C 3-10 Cycloalkylsulfinyl, -YQ or M group; or optionally two R2 can be taken together with the atoms to which they are attached to form a 5-6 membered aryl or heteroaryl, a 3-8 membered saturated or partially saturated cycloalkyl, a 3-8 membered saturated or partially saturated heterocyclic group, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic group is optionally substituted by one or more groups selected from hydrogen, deuterium, alkyl, halogen, pentafluoride sulfur group, oxo, CN, CF3, OH, OCH3, OCH2CH3; and the hydrogen on R2 is optionally substituted by one or more groups selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1- 6-alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 cycloalkyl or heterocycloalkyl substitution;

[0129] M is arbitrarily and independently selected from

[0130] Z is independently selected from the group consisting of absent, C(R d1 )(R d2 ), O, NR d1 、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-、-N(R d7 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic groups, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z1 and Z2 is further optionally substituted by 1 to more substituents, wherein the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluorinated sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1- 3 alkyl, C 1-3 alkoxy;

[0131] Q represents any 3-20 membered cyclic structure, which can be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure can be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; and the hydrogen on the ring Q is optionally replaced by one or more selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, oxo, alkyl, alkenyl, alkynyl, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0132] Each R may be the same or different and is independently selected from hydrogen, deuterium, -CN, haloalkyl, haloalkoxy, deuterated alkyl, deuterated alkoxy, -OH, -SH and -NH2, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfamoyl, methylsulfonamido or -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute; and the hydrogen on R is further optionally substituted by 1 to more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 alkoxy;

[0133] R a and R b Any independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein, the C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by one or more radicals selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups substituted by saturated cycloalkyl or heterocyclic substituents; or R a and R b or R a and R2 or R a and R1 can also be connected together to form a 3-30 membered ring structure, wherein the ring structure can be a monocyclic, bicyclic, bridged or spirocyclic structure, and can contain 0 to multiple heteroatoms or unsaturated bonds; furthermore, R a The hydrogen on the alkoxy group is optionally replaced by one or more alkoxy groups selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 cycloalkyl or heterocycloalkyl substitution;

[0134] Every R d1 、R d2 、R d3 、R d4 、R d5 、R d6 、R d7 may be the same or different and independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3- 10 Cycloalkyl, C 3-10Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein, the C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by one or more radicals selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups substituted by saturated cycloalkyl or heterocyclic substituents; or any R d1 、R d2 、R d3 、R d4 、R d5 、R d6 、R d7 Each other or / and R1 or R2 and the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, a 5-30 membered saturated or partially saturated heterocyclic group, and the hydrogen on the heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic alkyl is optionally selected from hydrogen, deuterium, halogen, pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0135] The heteroatom represents any heteroatom or group independently selected from O, N, S, P, -P=O, S=O or SO2 and its isotope;

[0136] The halogen is arbitrarily and independently selected from F, Cl, Br, I and isotopes thereof;

[0137] m is an integer arbitrarily selected from 0, 1, 2, 3, and 4;

[0138] n is an integer arbitrarily selected from 0, 1, 2, 3, and 4.

[0139] In one embodiment of the present invention, the compound or its pharmaceutically acceptable salt, isotope-substituted product or isomer thereof has a structure of formula (IG),

[0140] in,

[0141] Y, Y1, Y2, Y3, Y4, and Y5 are each independently selected from -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic groups, C 4-10Saturated or partially saturated heteroaryl; and the hydrogen on Y1, Y2, Y3, Y4, Y5 is further optionally substituted with one or more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 alkoxy;

[0142] Ring C represents any 3-20 membered cyclic structure, which can be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure can be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; and the hydrogen on the ring Q is optionally replaced by one or more selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, oxo, alkyl, alkenyl, alkynyl, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0143] X1 is independently selected from N or CR;

[0144] Each R1 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, -SH and -NH2, -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, amide, aminoacyl, sulfamoyl, sulfamoylamino, methylsulfonylamino or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute or M group; and the hydrogen on R1 is optionally replaced by 1 to more selected from H, deuterium, halogen, pentafluoride sulfur group, OCH3, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 or any two adjacent R1s together with the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, or a 5-30 membered saturated or partially saturated heterocyclic group, wherein the hydrogen atoms on the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group are optionally selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 The hydrogen on R1 is optionally replaced by one or more alkyl groups selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0145] Each R2 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, amino, hydroxyl, mercapto, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10 Alkylamino, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamide, N,N-di(C 1-10 Alkyl)amino, C 1-10 Alkyloxy, C 1-10 Alkyl acyl, C 1-10 Alkyloxy, C 1-10 Alkylsulfonyl, C 1-10 Alkylsulfinyl, C 3-10 Cycloalkylamino, C3-10 heterocycloalkylamino, C 3-10 Cycloalkoxy, C 3-10 Heterocycloalkoxy, C 3-10 Cycloalkyl acyl, C 3-10 Cycloalkoxyacetyl, C 3-10 Cycloalkylsulfonyl and C 3-10Cycloalkylsulfinyl, -YQ or M group; or optionally two R2 can be taken together with the atoms to which they are attached to form a 5-6 membered aryl or heteroaryl, a 3-8 membered saturated or partially saturated cycloalkyl, a 3-8 membered saturated or partially saturated heterocyclic group, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic group is optionally substituted by one or more groups selected from hydrogen, deuterium, alkyl, halogen, pentafluoride sulfur group, oxo, CN, CF3, OH, OCH3, OCH2CH3; and the hydrogen on R2 is optionally substituted by one or more groups selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1- 6-alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 cycloalkyl or heterocycloalkyl substitution;

[0146] M is arbitrarily and independently selected from

[0147] Z is independently selected from the group consisting of absent, C(R d1 )(R d2 ), O, NR d1 、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-、-N(R d7 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic groups, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z1 and Z2 is further optionally substituted by 1 to more substituents, wherein the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluorinated sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1- 3 alkyl, C 1-3 alkoxy;

[0148] Q represents any 3-20 membered cyclic structure, which can be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure can be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; and the hydrogen on the ring Q is optionally replaced by one or more selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, oxo, alkyl, alkenyl, alkynyl, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0149] Each R may be the same or different and is independently selected from hydrogen, deuterium, -CN, haloalkyl, haloalkoxy, deuterated alkyl, deuterated alkoxy, -OH, -SH and -NH2, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfamoyl, methylsulfonamido or -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute; and the hydrogen on R is further optionally substituted by 1 to more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 alkoxy;

[0150] R a and R bAny independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein, the C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by one or more radicals selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups substituted by saturated cycloalkyl or heterocyclic substituents; or R a and R b or R a and R2 or R a and R1 can also be connected together to form a 3-30 membered ring structure, wherein the ring structure can be a monocyclic, bicyclic, bridged or spirocyclic structure, and can contain 0 to multiple heteroatoms or unsaturated bonds; furthermore, R a The hydrogen on the alkoxy group is optionally replaced by one or more alkoxy groups selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 cycloalkyl or heterocycloalkyl substitution;

[0151] Every R d1 、R d2 、R d3 、Rd4 、R d5 、R d6 、R d7 may be the same or different and independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3- 10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein, the C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by one or more radicals selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups substituted by saturated cycloalkyl or heterocyclic substituents; or any R d1 、R d2 、R d3 、R d4 、R d5 、R d6 、R d7 Each other or / and R1 or R2 and the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, a 5-30 membered saturated or partially saturated heterocyclic group, and the hydrogen on the heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic alkyl is optionally selected from hydrogen, deuterium, halogen, pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0152] The heteroatom represents any heteroatom or group independently selected from O, N, S, P, -P=O, S=O or SO2 and its isotope;

[0153] The halogen is arbitrarily and independently selected from F, Cl, Br, I and isotopes thereof;

[0154] m is an integer arbitrarily selected from 0, 1, 2, 3, and 4;

[0155] n is an integer arbitrarily selected from 0, 1, 2, 3, and 4.

[0156] In one embodiment of the present invention, the compound or its pharmaceutically acceptable salt, isotope-substituted product or isomer thereof has a structure of formula (IH):

[0157] in,

[0158] Y is independently selected from -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NRd5 )-、-S(=O)2N(R d6 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic groups, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Y is further optionally substituted with one or more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 alkoxy;

[0159] X is independently selected from N or -CR-;

[0160] X1 is independently selected from N or CR;

[0161] Each R1 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, -SH and -NH2, -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, dialkylphosphonyl, alkylsulfonyl, sulfonyl, amide, aminoacyl, alkylsulfinyl, sulfamoyl, sulfamoylamino, methylsulfonylamino or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute or M group; and the hydrogen on R1 is optionally replaced by 1 to more selected from H, deuterium, halogen, pentafluoride sulfur group, OCH3, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 or any two adjacent R1s together with the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, or a 5-30 membered saturated or partially saturated heterocyclic group, wherein the hydrogen atoms on the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group are optionally selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 The hydrogen on R1 is optionally replaced by one or more alkyl groups selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0162] Each R2 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, amino, hydroxyl, mercapto, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10 Alkylamino, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamide, N,N-di(C 1-10 Alkyl)amino, C 1-10 Alkyloxy, C 1-10 Alkyl acyl, C 1-10 Alkyloxy, C 1-10 Alkylsulfonyl, C 1-10 Alkylsulfinyl, C 3-10 Cycloalkylamino, C3-10 heterocycloalkylamino, C 3-10 Cycloalkoxy, C 3-10 Heterocycloalkoxy, C 3-10 Cycloalkyl acyl, C 3-10 Cycloalkoxyacetyl, C 3-10 Cycloalkylsulfonyl and C 3-10Cycloalkylsulfinyl, -YQ or M group; or optionally two R2 can be taken together with the atoms to which they are attached to form a 5-6 membered aryl or heteroaryl, a 3-8 membered saturated or partially saturated cycloalkyl, a 3-8 membered saturated or partially saturated heterocyclic group, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic group is optionally substituted by one or more groups selected from hydrogen, deuterium, alkyl, halogen, pentafluoride sulfur group, oxo, CN, CF3, OH, OCH3, OCH2CH3; and the hydrogen on R2 is optionally substituted by one or more groups selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1- 6-alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 cycloalkyl or heterocycloalkyl substitution;

[0163] M is arbitrarily and independently selected from

[0164] Z is independently selected from the group consisting of absent, C(R d1 )(R d2 ), O, NR d1 、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-、-N(R d7 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic groups, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z1 and Z2 is further optionally substituted by 1 to more substituents, wherein the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluorinated sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1- 3 alkyl, C 1-3 alkoxy;

[0165] Q represents any 3-20 membered cyclic structure, which can be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure can be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; and the hydrogen on the ring Q is optionally replaced by one or more selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, oxo, alkyl, alkenyl, alkynyl, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0166] Each R may be the same or different and is independently selected from hydrogen, deuterium, -CN, haloalkyl, haloalkoxy, deuterated alkyl, deuterated alkoxy, -OH, -SH and -NH2, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfamoyl, methylsulfonamido or -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute; and the hydrogen on R is further optionally substituted with 1 to more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 alkoxy;

[0167] R a and R bAny independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein, the C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by one or more radicals selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups substituted by saturated cycloalkyl or heterocyclic substituents; or R a and R b or R a and R2 or R a and R1 can also be connected together to form a 3-30 membered ring structure, wherein the ring structure can be a monocyclic, bicyclic, bridged or spirocyclic structure, and can contain 0 to multiple heteroatoms or unsaturated bonds; furthermore, R a The hydrogen on the alkoxy group is optionally replaced by one or more alkoxy groups selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 cycloalkyl or heterocycloalkyl substitution;

[0168] Every R d1 、R d2 、R d3 、Rd4 、R d5 、R d6 、R d7 may be the same or different and independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3- 10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein, the C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by one or more radicals selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups substituted by saturated cycloalkyl or heterocyclic substituents; or any R d1 、R d2 、R d3 、R d4 、R d5 、R d6 、R d7 Each other or / and R1 or R2 and the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, a 5-30 membered saturated or partially saturated heterocyclic group, and the hydrogen on the heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic alkyl is optionally selected from hydrogen, deuterium, halogen, pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 Cycloalkyl radical substitution; and at least one R d1 and R d2 Connected to form a 3-20 membered ring structure with the atoms to which they are attached;

[0169] The heteroatom represents any heteroatom or group independently selected from O, N, S, P, -P=O, S=O or SO2 and its isotope;

[0170] The halogen is arbitrarily and independently selected from F, Cl, Br, I and isotopes thereof;

[0171] m is an integer arbitrarily selected from 0, 1, 2, 3, and 4;

[0172] n is an integer arbitrarily selected from 0, 1, 2, 3, and 4.

[0173] In one embodiment of the present invention, the compound or its pharmaceutically acceptable salt, isotope-substituted product or isomer thereof has a structure of formula (II):

[0174] in,

[0175] Y is independently selected from -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2)NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic groups, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Y is further optionally substituted with one or more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 alkoxy;

[0176] X1 is independently selected from N or CR;

[0177] Each R1 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, -SH and -NH2, -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, amide, aminoacyl, sulfamoyl, sulfamoylamino, methylsulfonylamino or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute or M group; and the hydrogen on R1 is optionally replaced by 1 to more selected from H, deuterium, halogen, pentafluoride sulfur group, OCH3, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 or any two adjacent R1s together with the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, or a 5-30 membered saturated or partially saturated heterocyclic group, wherein the hydrogen atoms on the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group are optionally selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 The hydrogen on R1 is optionally replaced by one or more alkyl groups selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0178] Each R2 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, amino, hydroxyl, mercapto, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10 Alkylamino, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamide, N,N-di(C 1-10 Alkyl)amino, C 1-10 Alkyloxy, C 1-10 Alkyl acyl, C 1-10 Alkyloxy, C 1-10 Alkylsulfonyl, C 1-10 Alkylsulfinyl, C 3-10 Cycloalkylamino, C3-10 heterocycloalkylamino, C 3-10 Cycloalkoxy, C 3-10 Heterocycloalkoxy, C 3-10 Cycloalkyl acyl, C 3-10 Cycloalkoxyacetyl, C 3-10 Cycloalkylsulfonyl and C 3-10Cycloalkylsulfinyl, -YQ or M group; or optionally two R2 can be taken together with the atoms to which they are attached to form a 5-6 membered aryl or heteroaryl, a 3-8 membered saturated or partially saturated cycloalkyl, a 3-8 membered saturated or partially saturated heterocyclic group, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic group is optionally substituted by one or more groups selected from hydrogen, deuterium, alkyl, halogen, pentafluoride sulfur group, oxo, CN, CF3, OH, OCH3, OCH2CH3; and the hydrogen on R2 is optionally substituted by one or more groups selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1- 6-alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 cycloalkyl or heterocycloalkyl substitution;

[0179] M is arbitrarily and independently selected from

[0180] Z is independently selected from the group consisting of absent, C(R d1 )(R d2 ), O, NR d1 、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-、-N(R d7 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic groups, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z1 and Z2 is further optionally substituted by 1 to more substituents, wherein the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluorinated sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1- 3 alkyl, C 1-3 alkoxy;

[0181] Q represents any 3-20 membered cyclic structure, which can be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure can be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; and the hydrogen on the ring Q is optionally replaced by one or more selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, oxo, alkyl, alkenyl, alkynyl, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0182] Each R may be the same or different and is independently selected from hydrogen, deuterium, -CN, haloalkyl, haloalkoxy, deuterated alkyl, deuterated alkoxy, -OH, -SH and -NH2, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfamoyl, methylsulfonamido or -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute; and the hydrogen on R is further optionally substituted by 1 to more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 alkoxy;

[0183] R a and R bAny independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein, the C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by one or more radicals selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups substituted by saturated cycloalkyl or heterocyclic substituents; or R a and R b or R a and R2 or R a and R1 can also be connected together to form a 3-30 membered ring structure, wherein the ring structure can be a monocyclic, bicyclic, bridged or spirocyclic structure, and can contain 0 to multiple heteroatoms or unsaturated bonds; furthermore, R a The hydrogen on the alkoxy group is optionally replaced by one or more alkoxy groups selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 cycloalkyl or heterocycloalkyl substitution;

[0184] Every R d1 、R d2 、R d3 、Rd4 、R d5 、R d6 、R d7 may be the same or different and independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3- 10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein, the C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by one or more radicals selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups substituted by saturated cycloalkyl or heterocyclic substituents; or any R d1 、R d2 、R d3 、R d4 、R d5 、R d6 、R d7 Each other or / and R1 or R2 and the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, a 5-30 membered saturated or partially saturated heterocyclic group, and the hydrogen on the heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic alkyl is optionally selected from hydrogen, deuterium, halogen, pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 Cycloalkyl radical substitution; and at least one R d1 and R d2 Connected to form a 3-20 membered ring structure with the atoms to which they are attached;

[0185] The heteroatom represents any heteroatom or group independently selected from O, N, S, P, -P=O, S=O or SO2 and its isotope;

[0186] The halogen is arbitrarily and independently selected from F, Cl, Br, I and isotopes thereof;

[0187] m is an integer arbitrarily selected from 0, 1, 2, 3, and 4;

[0188] n is an integer arbitrarily selected from 0, 1, 2, 3, and 4.

[0189] In one embodiment of the present invention, the compound or its pharmaceutically acceptable salt, isotope-substituted product or isomer thereof has a structure of formula (IJ),

[0190] in,

[0191] Any represents a single bond or a double bond;

[0192] Z3 is independently selected from the group consisting of absence, a single bond, -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(Rd1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic groups, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z3 is further optionally substituted with one or more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluorinated sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 alkoxy;

[0193] X1 and X2 are independently selected from N or CR;

[0194] Y is independently selected from -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NRd5 )-、-S(=O)2N(R d6 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2-;

[0195] Each R1 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, -SH and -NH2, -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, amide, aminoacyl, sulfamoyl, sulfamoylamino, methylsulfonylamino or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute or M group; and the hydrogen on R1 is optionally replaced by 1 to more selected from H, deuterium, halogen, pentafluoride sulfur group, OCH3, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 or any two adjacent R1s together with the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, or a 5-30 membered saturated or partially saturated heterocyclic group, wherein the hydrogen atoms on the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group are optionally selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 The hydrogen on R1 is optionally replaced by one or more alkyl groups selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0196] Each R2 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, amino, hydroxyl, acyl, carboxyl, thiol, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10 Alkylamino, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamide, N,N-di(C 1-10 Alkyl)amino, C 1-10 Alkyloxy, C 1-10 Alkyl acyl, C 1-10 Alkyloxy, C 1-10 Alkylsulfonyl, C 1-10 Alkylsulfinyl, C 3-10 Cycloalkylamino, C3-10 heterocycloalkylamino, C 3-10 Cycloalkoxy, C 3-10 Heterocycloalkoxy, C 3-10 Cycloalkyl acyl, C 3-10 Cycloalkoxyacetyl, C 3-10 Cycloalkylsulfonyl and C 3-10 Cycloalkylsulfinyl, -YQ or M group; or optionally two R2 can be taken together with the atoms to which they are attached to form a 5-6 membered aryl or heteroaryl, a 3-8 membered saturated or partially saturated cycloalkyl, a 3-8 membered saturated or partially saturated heterocyclic group, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic group is optionally substituted by one or more groups selected from hydrogen, deuterium, alkyl, halogen, pentafluoride sulfur group, oxo, CN, CF3, OH, OCH3, OCH2CH3; and the hydrogen on R2 is optionally substituted by one or more groups selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 Substituted with cycloalkyl or heterocycloalkyl, -YQ or M groups;

[0197] M is arbitrarily and independently selected from

[0198] Z is independently selected from the group consisting of absent, C(R d1 )(R d2 ), O, NR d1 、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-、-N(R d7 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic groups, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z1 and Z2 is further optionally substituted by 1 to more substituents, wherein the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluorinated sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1- 3 alkyl, C 1-3 alkoxy;

[0199] Y is arbitrarily and independently selected from O, S or NR;

[0200] Q represents any 3-20 membered cyclic structure, which can be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure can be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; and the hydrogen on the ring Q is optionally replaced by one or more selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, oxo, alkyl, alkenyl, alkynyl, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0201] Each R may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, haloalkyl, haloalkoxy, deuterated alkyl, deuterated alkoxy, -OH, -SH and -NH2, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfamoyl, methylsulfonamido or -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute; and the hydrogen on R is further optionally substituted by 1 to more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 alkoxy;

[0202] R a and R b Any independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein, the C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by one or more radicals selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups substituted by saturated cycloalkyl or heterocyclic substituents; or R a and R b or R a and R2 or R a and R1 can also be connected together to form a 3-30 membered ring structure, wherein the ring structure can be a monocyclic, bicyclic, bridged or spirocyclic structure, and can contain 0 to multiple heteroatoms or unsaturated bonds; furthermore, R a The hydrogen on the alkoxy group is optionally replaced by one or more alkoxy groups selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 cycloalkyl or heterocycloalkyl substitution;

[0203] Every R d1 、R d2 、R d3 、R d4 、R d5 、R d6 、R d7 may be the same or different and independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3- 10 Cycloalkyl, C3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein, the C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by one or more radicals selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups substituted by saturated cycloalkyl or heterocyclic substituents; or any R d1 、R d2 、R d3 、R d4 、R d5 、R d6 、R d7 Each other or / and R1 or R2 and the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, a 5-30 membered saturated or partially saturated heterocyclic group, and the hydrogen on the heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic alkyl is optionally selected from hydrogen, deuterium, halogen, pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0204] The heteroatom represents any heteroatom or group independently selected from O, N, S, P, -P=O, S=O or SO2 and its isotope;

[0205] The halogen is arbitrarily and independently selected from F, Cl, Br, I and isotopes thereof;

[0206] m is an integer arbitrarily selected from 0, 1, 2, 3, and 4;

[0207] In one embodiment of the present invention, the compound or its pharmaceutically acceptable salt, isotope-substituted product or isomer thereof has a structure of formula (IK),

[0208] in,

[0209] Any represents a single bond or a double bond;

[0210] Z3 is independently selected from the group consisting of absence, a single bond, -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic groups, C 4-10Saturated or partially saturated heteroaryl; and the hydrogen on Z3 is further optionally substituted with one or more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluorinated sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 alkoxy;

[0211] X1 and X2 are independently selected from N or CR;

[0212] Y is independently selected from -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 ) -、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2-;

[0213] Each R1 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, -SH and -NH2, -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, amide, aminoacyl, sulfamoyl, sulfamoylamino, methylsulfonylamino or C 1-10 Alkoxy, C2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute or M group; and the hydrogen on R1 is optionally replaced by 1 to more selected from H, deuterium, halogen, pentafluoride sulfur group, OCH3, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 or any two adjacent R1s together with the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, or a 5-30 membered saturated or partially saturated heterocyclic group, wherein the hydrogen atoms on the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group are optionally selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 The hydrogen on R1 is optionally replaced by one or more alkyl groups selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0214] Each R2 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, amino, hydroxyl, acyl, carboxyl, thiol, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10 Alkylamino, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamide, N,N-di(C 1-10 Alkyl)amino, C 1-10 Alkyloxy, C 1-10 Alkyl acyl, C 1-10 Alkyloxy, C 1-10 Alkylsulfonyl, C 1-10 Alkylsulfinyl, C 3-10 Cycloalkylamino, C3-10 heterocycloalkylamino, C 3-10 Cycloalkoxy, C 3-10 Heterocycloalkoxy, C 3-10 Cycloalkyl acyl, C 3-10 Cycloalkoxyacetyl, C 3-10 Cycloalkylsulfonyl and C 3-10 Cycloalkylsulfinyl, -YQ or M group; or optionally two R2 can be taken together with the atoms to which they are attached to form a 5-6 membered aryl or heteroaryl, a 3-8 membered saturated or partially saturated cycloalkyl, a 3-8 membered saturated or partially saturated heterocyclic group, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic group is optionally substituted by one or more groups selected from hydrogen, deuterium, alkyl, halogen, pentafluoride sulfur group, oxo, CN, CF3, OH, OCH3, OCH2CH3; and the hydrogen on R2 is optionally substituted by one or more groups selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 Substituted with cycloalkyl or heterocycloalkyl, -YQ or M groups;

[0215] M is arbitrarily and independently selected from

[0216] Z is independently selected from the group consisting of absent, C(R d1 )(R d2 ), O, NR d1 、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(Rd1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-、-N(R d7 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic groups, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z1 and Z2 is further optionally substituted by 1 to more substituents, wherein the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluorinated sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1- 3 alkyl, C 1-3 alkoxy;

[0217] Y is arbitrarily and independently selected from O, S or NR;

[0218] Q represents any 3-20 membered cyclic structure, which can be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure can be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; and the hydrogen on the ring Q is optionally replaced by one or more selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, oxo, alkyl, alkenyl, alkynyl, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0219] Each R may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, haloalkyl, haloalkoxy, deuterated alkyl, deuterated alkoxy, -OH, -SH and -NH2, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfamoyl, methylsulfonamido or -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute; and the hydrogen on R is further optionally substituted with 1 to more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 alkoxy;

[0220] R a and R b Any independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein, the C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by one or more radicals selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups substituted by saturated cycloalkyl or heterocyclic substituents; or R a and R b or R a and R2 or R a and R1 can also be connected together to form a 3-30 membered ring structure, wherein the ring structure can be a monocyclic, bicyclic, bridged or spirocyclic structure, and can contain 0 to multiple heteroatoms or unsaturated bonds; furthermore, R a The hydrogen on the alkoxy group is optionally replaced by one or more alkoxy groups selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 cycloalkyl or heterocycloalkyl substitution;

[0221] Every R d1 、R d2 、R d3 、R d4 、R d5 、R d6 、R d7 may be the same or different and independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3- 10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein, the C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by one or more radicals selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups substituted by saturated cycloalkyl or heterocyclic substituents; or any R d1 、R d2 、R d3 、R d4 、R d5 、R d6 、R d7 Each other or / and R1 or R2 and the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, a 5-30 membered saturated or partially saturated heterocyclic group, and the hydrogen on the heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic alkyl is optionally selected from hydrogen, deuterium, halogen, pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0222] The heteroatom represents any heteroatom or group independently selected from O, N, S, P, -P=O, S=O or SO2 and its isotope;

[0223] The halogen is arbitrarily and independently selected from F, Cl, Br, I and isotopes thereof;

[0224] m is an integer arbitrarily selected from 0, 1, 2, 3, and 4.

[0225] In one embodiment of the present invention, the compound or its pharmaceutically acceptable salt, isotope-substituted product or isomer thereof has a structure of formula (IM):

[0226] in,

[0227] Y3 and Y4 are independently selected from -C(R d1 )(R d2 )-、O、-C(R d1 )(R d2 )C(R d1 )(R d2 )- or -C(=O)-;

[0228] Each R1 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, -SH and -NH2, -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, amide, aminoacyl, sulfamoyl, sulfamoylamino, methylsulfonylamino or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute or M group; and the hydrogen on R1 is optionally replaced by 1 to more selected from H, deuterium, halogen, pentafluoride sulfur group, OCH3, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 or any two adjacent R1s together with the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, or a 5-30 membered saturated or partially saturated heterocyclic group, wherein the hydrogen atoms on the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group are optionally selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 The hydrogen on R1 is optionally replaced by one or more alkyl groups selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0229] Each R2 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, amino, hydroxyl, mercapto, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10 Alkylamino, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamide, N,N-di(C 1-10 Alkyl)amino, C 1-10 Alkyloxy, C 1-10 Alkyl acyl, C 1-10 Alkyloxy, C 1-10 Alkylsulfonyl, C 1-10 Alkylsulfinyl, C 3-10 Cycloalkylamino, C3-10 heterocycloalkylamino, C 3-10 Cycloalkoxy, C 3-10 Heterocycloalkoxy, C 3-10 Cycloalkyl acyl, C 3-10 Cycloalkoxyacetyl, C 3-10 Cycloalkylsulfonyl and C 3-10 Cycloalkylsulfinyl, -YQ or M group; or optionally two R2 can be taken together with the atoms to which they are attached to form a 5-6 membered aryl or heteroaryl, a 3-8 membered saturated or partially saturated cycloalkyl, a 3-8 membered saturated or partially saturated heterocyclic group, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic group is optionally substituted by one or more groups selected from hydrogen, deuterium, alkyl, halogen, pentafluoride sulfur group, oxo, CN, CF3, OH, OCH3, OCH2CH3; and the hydrogen on R2 is optionally substituted by one or more groups selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6-alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 cycloalkyl or heterocycloalkyl substitution;

[0230] M is arbitrarily and independently selected from

[0231] Z is independently selected from the group consisting of absent, C(R d1 )(R d2 ),NR d1 、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-、-N(R d7 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic groups, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z is further optionally substituted with 1 to more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluorosulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 alkoxy;

[0232] Y is independently selected from -C(R d1 )(R d2 )-、-C(=Rd1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic groups, C 4-10 saturated or partially saturated heteroaryl;

[0233] Q represents any 3-20 membered cyclic structure, which can be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure can be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; and the hydrogen on the ring Q is optionally replaced by one or more selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, oxo, alkyl, alkenyl, alkynyl, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0234] Each R may be the same or different and is independently selected from hydrogen, deuterium, -CN, haloalkyl, haloalkoxy, deuterated alkyl, deuterated alkoxy, -OH, -SH and -NH2, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfamoyl, methylsulfonamido or -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute; and the hydrogen on R is further optionally substituted by 1 to more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 alkoxy;

[0235] R a and R b Any independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein, the C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by one or more radicals selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups substituted by saturated cycloalkyl or heterocyclic substituents; or R a and R b or R a and R2 or R a and R1 can also be connected together to form a 3-30 membered ring structure, wherein the ring structure can be a monocyclic, bicyclic, bridged or spirocyclic structure, and can contain 0 to multiple heteroatoms or unsaturated bonds; furthermore, R a The hydrogen on the alkoxy group is optionally replaced by one or more alkoxy groups selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 cycloalkyl or heterocycloalkyl substitution;

[0236] Every R d1 、R d2 、R d3 、R d4 、R d5 、R d6 、R d7 may be the same or different and independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3- 10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein, the C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by one or more radicals selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups substituted by saturated cycloalkyl or heterocyclic substituents; or any R d1 、R d2 、R d3 、R d4 、R d5 、R d6 、R d7 Each other or / and R1 or R2 and the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, a 5-30 membered saturated or partially saturated heterocyclic group, and the hydrogen on the heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic alkyl is optionally selected from hydrogen, deuterium, halogen, pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0237] The heteroatom represents any heteroatom or group independently selected from O, N, S, P, -P=O, S=O or SO2 and its isotope;

[0238] The halogen is arbitrarily and independently selected from F, Cl, Br, I and isotopes thereof;

[0239] m is an integer arbitrarily selected from 0, 1, 2 and 3;

[0240] n is an integer arbitrarily selected from 0, 1, 2, 3, and 4.

[0241] In one embodiment of the present invention, the compound or its pharmaceutically acceptable salt, isotope-substituted product or isomer thereof has a structure of formula (IN),

[0242] in,

[0243] Y3 and Y4 are independently selected from -C(R d1 )(R d2 )-、O、-C(R d1 )(R d2 )C(R d1 )(R d2 )- or -C(=O)-;

[0244] Each R1 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, -SH and -NH2, -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, amide, aminoacyl, sulfamoyl, sulfamoylamino, methylsulfonylamino or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute or M group; and the hydrogen on R1 is optionally replaced by 1 to more selected from H, deuterium, halogen, pentafluoride sulfur group, OCH3, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10or any two adjacent R1s together with the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, or a 5-30 membered saturated or partially saturated heterocyclic group, wherein the hydrogen atoms on the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group are optionally selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 The hydrogen on R1 is optionally replaced by one or more alkyl groups selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0245] Each R2 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, amino, hydroxyl, mercapto, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10 Alkylamino, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamide, N,N-di(C 1-10 Alkyl)amino, C 1-10 Alkyloxy, C 1-10 Alkyl acyl, C 1-10 Alkyloxy, C 1-10 Alkylsulfonyl, C 1-10 Alkylsulfinyl, C 3-10 Cycloalkylamino, C3-10 heterocycloalkylamino, C 3-10 Cycloalkoxy, C 3-10 Heterocycloalkoxy, C 3-10 Cycloalkyl acyl, C 3-10 Cycloalkoxyacetyl, C 3-10 Cycloalkylsulfonyl and C 3-10Cycloalkylsulfinyl, -YQ or M group; or optionally two R2 can be taken together with the atoms to which they are attached to form a 5-6 membered aryl or heteroaryl, a 3-8 membered saturated or partially saturated cycloalkyl, a 3-8 membered saturated or partially saturated heterocyclic group, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic group is optionally substituted by one or more groups selected from hydrogen, deuterium, alkyl, halogen, pentafluoride sulfur group, oxo, CN, CF3, OH, OCH3, OCH2CH3; and the hydrogen on R2 is optionally substituted by one or more groups selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1- 6-alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 cycloalkyl or heterocycloalkyl substitution;

[0246] M is arbitrarily and independently selected from

[0247] Z is independently selected from the group consisting of absent, C(R d1 )(R d2 ),NR d1 、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-、-N(R d7 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic groups, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z is further optionally substituted with 1 to more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluorosulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 alkoxy;

[0248] Y is independently selected from -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic groups, C 4-10 saturated or partially saturated heteroaryl;

[0249] Q represents any 3-20 membered cyclic structure, which can be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure can be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; and the hydrogen on the ring Q is optionally replaced by one or more selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, oxo, alkyl, alkenyl, alkynyl, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0250] Each R may be the same or different and is independently selected from hydrogen, deuterium, -CN, haloalkyl, haloalkoxy, deuterated alkyl, deuterated alkoxy, -OH, -SH and -NH2, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfamoyl, methylsulfonamido or -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute; and the hydrogen on R is further optionally substituted by 1 to more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 alkoxy;

[0251] R a and R b Any independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein, the C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by one or more radicals selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups substituted by saturated cycloalkyl or heterocyclic substituents; or R a and R b or R a and R2 or R a and R1 can also be connected together to form a 3-30 membered ring structure, wherein the ring structure can be a monocyclic, bicyclic, bridged or spirocyclic structure, and can contain 0 to multiple heteroatoms or unsaturated bonds; furthermore, R a The hydrogen on the alkoxy group is optionally replaced by one or more alkoxy groups selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 cycloalkyl or heterocycloalkyl substitution;

[0252] Every R d1 、R d2 、R d3 、R d4 、R d5 、R d6 、R d7 may be the same or different and independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3- 10 Cycloalkyl, C 3-10Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein, the C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by one or more radicals selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups substituted by saturated cycloalkyl or heterocyclic substituents; or any R d1 、R d2 、R d3 、R d4 、R d5 、R d6 、R d7 Each other or / and R1 or R2 and the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, a 5-30 membered saturated or partially saturated heterocyclic group, and the hydrogen on the heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic alkyl is optionally selected from hydrogen, deuterium, halogen, pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0253] The heteroatom represents any heteroatom or group independently selected from O, N, S, P, -P=O, S=O or SO2 and its isotope;

[0254] The halogen is arbitrarily and independently selected from F, Cl, Br, I and isotopes thereof;

[0255] m is an integer arbitrarily selected from 0, 1, 2 and 3;

[0256] n is an integer arbitrarily selected from 0, 1, 2, 3, and 4.

[0257] In one embodiment of the present invention, the compound or its pharmaceutically acceptable salt, isotope-substituted product or isomer thereof has the structure of formula (IO),

[0258] in,

[0259] Y3 and Y4 are independently selected from -C(R d1 )(R d2 )-、O、-C(R d1 )(R d2 )C(R d1 )(R d2 )- or -C(=O)-;

[0260] Each R1 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, -SH and -NH2, -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, amide, aminoacyl, sulfamoyl, sulfamoylamino, methylsulfonylamino or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute or M group; and the hydrogen on R1 is optionally replaced by 1 to more selected from H, deuterium, halogen, pentafluoride sulfur group, OCH3, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 or any two adjacent R1s together with the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, or a 5-30 membered saturated or partially saturated heterocyclic group, wherein the hydrogen atoms on the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group are optionally selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 The hydrogen on R1 is optionally replaced by one or more alkyl groups selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0261] Each R2 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, amino, hydroxyl, mercapto, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10 Alkylamino, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamide, N,N-di(C 1-10 Alkyl)amino, C 1-10 Alkyloxy, C 1-10 Alkyl acyl, C 1-10 Alkyloxy, C 1-10 Alkylsulfonyl, C 1-10 Alkylsulfinyl, C 3-10 Cycloalkylamino, C3-10 heterocycloalkylamino, C 3-10 Cycloalkoxy, C 3-10 Heterocycloalkoxy, C 3-10 Cycloalkyl acyl, C 3-10 Cycloalkoxyacetyl, C 3-10 Cycloalkylsulfonyl and C 3-10Cycloalkylsulfinyl, -YQ or M group; or optionally two R2 can be taken together with the atoms to which they are attached to form a 5-6 membered aryl or heteroaryl, a 3-8 membered saturated or partially saturated cycloalkyl, a 3-8 membered saturated or partially saturated heterocyclic group, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic group is optionally substituted by one or more groups selected from hydrogen, deuterium, alkyl, halogen, pentafluoride sulfur group, oxo, CN, CF3, OH, OCH3, OCH2CH3; and the hydrogen on R2 is optionally substituted by one or more groups selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1- 6-alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 cycloalkyl or heterocycloalkyl substitution;

[0262] M is arbitrarily and independently selected from

[0263] Z is independently selected from the group consisting of absent, C(R d1 )(R d2 ),NR d1 、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-、-N(R d7 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic groups, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z is further optionally substituted with 1 to more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluorosulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 alkoxy;

[0264] Y is independently selected from -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic groups, C 4-10 saturated or partially saturated heteroaryl;

[0265] Q represents any 3-20 membered cyclic structure, which can be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure can be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; and the hydrogen on the ring Q is optionally replaced by one or more selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, oxo, alkyl, alkenyl, alkynyl, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0266] Each R may be the same or different and is independently selected from hydrogen, deuterium, -CN, haloalkyl, haloalkoxy, deuterated alkyl, deuterated alkoxy, -OH, -SH and -NH2, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfamoyl, methylsulfonamido or -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute; and the hydrogen on R is further optionally substituted by 1 to more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 alkoxy;

[0267] R a and R b Any independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein, the C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by one or more radicals selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups substituted by saturated cycloalkyl or heterocyclic substituents; or R a and R b or R a and R2 or R a and R1 can also be connected together to form a 3-30 membered ring structure, wherein the ring structure can be a monocyclic, bicyclic, bridged or spirocyclic structure, and can contain 0 to multiple heteroatoms or unsaturated bonds; furthermore, R a The hydrogen on the alkoxy group is optionally replaced by one or more alkoxy groups selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 cycloalkyl or heterocycloalkyl substitution;

[0268] Every R d1 、R d2 、R d3 、R d4 、R d5 、R d6 、R d7 may be the same or different and independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3- 10 Cycloalkyl, C 3-10Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein, the C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by one or more radicals selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups substituted by saturated cycloalkyl or heterocyclic substituents; or any R d1 、R d2 、R d3 、R d4 、R d5 、R d6 、R d7 Each other or / and R1 or R2 and the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, a 5-30 membered saturated or partially saturated heterocyclic group, and the hydrogen on the heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic alkyl is optionally selected from hydrogen, deuterium, halogen, pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one to more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0269] The heteroatom represents any heteroatom or group independently selected from O, N, S, P, -P=O, S=O or SO2 and its isotope;

[0270] The halogen is arbitrarily and independently selected from F, Cl, Br, I and isotopes thereof;

[0271] m is an integer arbitrarily selected from 0, 1, 2 and 3;

[0272] n is an integer arbitrarily selected from 0, 1, 2, 3, and 4.

[0273] In one embodiment of the present invention, the compound or its pharmaceutically acceptable salt, isotope-substituted product or isomer thereof has a structure of formula (IP),

[0274] in,

[0275] Y3 and Y4 are independently selected from -C(R d1 )(R d2 )-、O、-C(R d1 )(R d2 )C(R d1 )(R d2 )- or -C(=O)-;

[0276] Each R1 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, -SH and -NH2, -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, amide, aminoacyl, sulfamoyl, sulfamoylamino, methylsulfonylamino or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute or M group; and the hydrogen on R1 is optionally replaced by 1 to more selected from H, deuterium, halogen, pentafluoride sulfur group, OCH3, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 or any two adjacent R1s together with the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, or a 5-30 membered saturated or partially saturated heterocyclic group, wherein the hydrogen atoms on the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group are optionally selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 The hydrogen on R1 is optionally replaced by one or more alkyl groups selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0277] Each R2 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, amino, hydroxyl, mercapto, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10 Alkylamino, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamide, N,N-di(C 1-10 Alkyl)amino, C 1-10 Alkyloxy, C 1-10 Alkyl acyl, C 1-10 Alkyloxy, C 1-10 Alkylsulfonyl, C 1-10 Alkylsulfinyl, C 3-10 Cycloalkylamino, C3-10 heterocycloalkylamino, C 3-10 Cycloalkoxy, C 3-10 Heterocycloalkoxy, C 3-10 Cycloalkyl acyl, C 3-10 Cycloalkoxyacetyl, C 3-10 Cycloalkylsulfonyl and C 3-10Cycloalkylsulfinyl, -YQ or M group; or optionally two R2 can be taken together with the atoms to which they are attached to form a 5-6 membered aryl or heteroaryl, a 3-8 membered saturated or partially saturated cycloalkyl, a 3-8 membered saturated or partially saturated heterocyclic group, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic group is optionally substituted by one or more groups selected from hydrogen, deuterium, alkyl, halogen, pentafluoride sulfur group, oxo, CN, CF3, OH, OCH3, OCH2CH3; and the hydrogen on R2 is optionally substituted by one or more groups selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1- 6-alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 cycloalkyl or heterocycloalkyl substitution;

[0278] M is arbitrarily and independently selected from

[0279] Z is independently selected from the group consisting of absent, C(R d1 )(R d2 ),NR d1 、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、- C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-、-N(R d7 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic groups, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z is further optionally substituted with 1 to more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluorosulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 alkoxy;

[0280] Y is independently selected from -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic groups, C 4-10 saturated or partially saturated heteroaryl;

[0281] Q represents any 3-20 membered cyclic structure, which can be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure can be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; and the hydrogen on the ring Q is optionally replaced by one or more selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, oxo, alkyl, alkenyl, alkynyl, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0282] Each R may be the same or different and is independently selected from hydrogen, deuterium, -CN, haloalkyl, haloalkoxy, deuterated alkyl, deuterated alkoxy, -OH, -SH and -NH2, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfamoyl, methylsulfonamido or -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocyclic alkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute; and the hydrogen on R is further optionally substituted by 1 to more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 alkoxy;

[0283] R a and R b Any independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein, the C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by one or more radicals selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups substituted by saturated cycloalkyl or heterocyclic substituents; or R a and R b or R a and R2 or R a and R1 can also be connected together to form a 3-30 membered ring structure, wherein the ring structure can be a monocyclic, bicyclic, bridged or spirocyclic structure, and can contain 0 to multiple heteroatoms or unsaturated bonds; furthermore, R a The hydrogen on the alkoxy group is optionally replaced by one or more alkoxy groups selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 cycloalkyl or heterocycloalkyl substitution;

[0284] Every R d1 、R d2 、R d3 、R d4 、R d5 、R d6 、R d7 may be the same or different and independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3- 10 Cycloalkyl, C 3-10Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein, the C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by one or more radicals selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups substituted by saturated cycloalkyl or heterocyclic substituents; or any R d1 、R d2 、R d3 、R d4 、R d5 、R d6 、R d7 Each other or / and R1 or R2 and the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, a 5-30 membered saturated or partially saturated heterocyclic group, and the hydrogen on the heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic alkyl is optionally selected from hydrogen, deuterium, halogen, pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups;

[0285] The heteroatom represents any heteroatom or group independently selected from O, N, S, P, -P=O, S=O or SO2 and its isotope;

[0286] The halogen is arbitrarily and independently selected from F, Cl, Br, I and isotopes thereof;

[0287] m is an integer arbitrarily selected from 0, 1, 2 and 3;

[0288] n is an integer arbitrarily selected from 0, 1, 2, 3, and 4.

[0289] In one embodiment of the present invention, the compound or its pharmaceutically acceptable salt, isotope-substituted product or isomer thereof has a structure of formula (III):

[0290] in,

[0291] X is selected from N or CR; R is selected from H, C 1-6 Alkyl, halogenated C 1-6 alkyl;

[0292] E is selected from O, S, NR e ; R e Selected from H, C 1-6 Alkyl, C 3-6 Cycloalkyl, halogenated C 1-6 alkyl;

[0293] Each R1 is the same or different and is independently selected from H, C 1-6 Alkyl, C 1-6 Alkoxy, S(O)2C 1-6 Alkyl, P(O)(C 1-6 Alkyl)2;

[0294] Each R2 is the same or different and is independently selected from H, P(O)(C 1-6 Alkyl) 2, -NH-Q; Q is selected from unsubstituted or optionally substituted by one, two or more R q Substituted following groups: 5-6 membered heterocyclic group; each R q the same or different, independently selected from H, halogen, C 1-6 Alkyl, halogenated C 1-6 alkyl;

[0295] R d1 、R d2 The same or different, independently selected from H, C 1-6 Alkyl, C 1-6 alkoxy;

[0296] R y1 、R y2 The same or different, independently selected from H, C 1-6 Alkyl, C 1-6 Alkoxy; or, R y1 、R y2and the atoms to which they are attached form a 5-12 membered heterocyclyl or a 5-10 membered heteroaryl;

[0297] m is selected from 0, 1, 2 or 3;

[0298] n is selected from 0, 1, 2, 3 or 4.

[0299] According to an embodiment of the present invention, R is selected from H, C 1-3 Alkyl, halogenated C 1-3 alkyl;

[0300] According to an embodiment of the present invention, R is selected from H, CH2CF3.

[0301] According to an embodiment of the present invention, R e Selected from H, C 3-6 Cycloalkyl, halogenated C 1-3 alkyl;

[0302] According to an embodiment of the present invention, R e Selected from cyclopropyl, CH2CF3.

[0303] According to an embodiment of the present invention, Selected from

[0304] According to an embodiment of the present invention, each R1 is the same or different and is independently selected from H, S(O)2C 1-3 Alkyl, P(O)(C 1-3 Alkyl)2;

[0305] According to an embodiment of the present invention, each R1 is the same or different and is independently selected from H, S(O)2CH3, P(O)(CH3)2.

[0306] According to an embodiment of the present invention, each R2 is the same or different and is independently selected from H, P(O)(C 1-3 Alkyl)2, -NH-Q; for example, H, P(O)(C 1-3 Alkyl)2, (like ), (like ).

[0307] According to an embodiment of the present invention, Q is selected from unsubstituted or optionally substituted with one, two or more R q Substituted: 6-membered heterocyclic group; for example, piperidinyl.

[0308] According to an embodiment of the present invention, each R q the same or different, independently selected from H, halogen, C 1-6 Alkyl; for example, H, F, methyl.

[0309] According to an embodiment of the present invention, each R2 is the same or different and is independently selected from H, P(O)(CH3)2, (For example ), (For example ), (For example ).

[0310] According to an embodiment of the present invention, R y1 、R y2 The same or different, independently selected from H, C 1-3 Alkoxy; for example, H, methoxy.

[0311] According to an embodiment of the present invention, R y1 、R y2 The atoms to which they are attached form a 5-7 membered heterocyclic group, a 12 membered heterocyclic group or a 5-6 membered heteroaryl group; for example, a furan ring, a dihydrofuran ring,

[0312] According to an embodiment of the present invention, Selected from

[0313] According to an embodiment of the present invention, Selected from

[0314] In some embodiments of the present invention, the above-mentioned compound or its pharmaceutically acceptable salt, or its corresponding isomer, isotope substitution, is a new compound selected from the structures disclosed in the examples in the text.

[0315] The present invention also provides a pharmaceutical composition comprising a therapeutically effective amount of at least one of the compound represented by formula (I), its pharmaceutically acceptable salts, solvates, enantiomers and isotope substitutions.

[0316] According to an embodiment of the present invention, the pharmaceutical composition is formulated for administration by a route selected from the group consisting of oral, parenteral, rectal, nasal, pulmonary, topical, buccal and sublingual, vaginal, parenteral, subcutaneous, intramuscular, intravenous, intradermal, intrathecal, and epidural.

[0317] According to an embodiment of the present invention, the pharmaceutical composition is preferably administered orally.

[0318] The oral dosage form is not particularly limited and may be any oral dosage form known in the art, preferably tablets, capsules, suspensions or oral solutions, etc.

[0319] The duration of administration of the pharmaceutical composition according to the present invention may depend on the severity of the disease, and is preferably at least 1 month, for example, 1, 2, 3, 4, 5 or 6 months, and may be lifelong depending on the disease condition.

[0320] According to an embodiment of the present invention, the pharmaceutical composition may further comprise a pharmaceutically acceptable excipient selected from at least one of the following excipients, including but not limited to a filler, a disintegrant, a binder, a lubricant, a surfactant, a flavoring agent, a wetting agent, a pH adjuster, a solubilizer or cosolvent, and an osmotic pressure regulator. Those skilled in the art can easily determine how to select the corresponding excipients and their corresponding amounts based on the requirements of the specific dosage form.

[0321] According to an embodiment of the present invention, the pharmaceutical composition may further contain one or more additional therapeutic agents.

[0322] Another object of the present invention is to provide the use of the above-mentioned compound in the preparation of a medicament for preventing and / or treating diseases associated with abnormalities in the P53 signaling pathway. Diseases associated with the P53 signaling pathway include, but are not limited to, various tumors such as lung cancer, intestinal cancer, pancreatic cancer, liver cancer, and breast cancer, as well as autoimmune diseases such as inflammatory bowel disease, and inflammatory or proliferative diseases such as psoriasis.

[0323] The present invention also provides the compound represented by formula (I), its pharmaceutically acceptable salts, solvates, enantiomers and isotopic substitutions, and the use of the pharmaceutical composition in preventing and / or treating diseases related to the P53 signaling pathway. The diseases related to the P53 signaling pathway have the definitions described above.

[0324] The present invention also provides a method for preventing and / or treating diseases related to the P53 signaling pathway, comprising administering to a patient a preventive or therapeutically effective amount of at least one of the compounds of formula (I), pharmaceutically acceptable salts, solvates, enantiomers, and isotopic substitutions thereof, or administering to a patient a preventive or therapeutically effective amount of the aforementioned pharmaceutical composition. The diseases related to the P53 signaling pathway are as defined above.

[0325] In some embodiments, the patient is a mammal, preferably a human.

[0326] Definition and Explanation:

[0327] C 1-10 Selected from C1, C2, C3, C4, C5, C6, C7, C8, C9 and C 10 ; C 2-10 Selected from C2, C3, C4, C5, C6, C7, C8, C9 and C 10 ; C 3-10Selected from C3, C4, C5, C6, C7, C8, C9 and C 10 ;

[0328] As used herein, the term "alkyl" is understood to mean a straight or branched chain saturated monovalent hydrocarbon radical having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, also referred to as "C 1-10 Alkyl". For example, "C 1-8 "Alkyl" means straight chain and branched chain alkyl groups having 1, 2, 3, 4, 5, 6, 7, or 8 carbon atoms, "C 1-6 The term "alkyl" refers to straight-chain and branched alkyl groups having 1, 2, 3, 4, 5 or 6 carbon atoms. The alkyl group is, for example, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, 2-methylbutyl, 1-methylbutyl, 1-ethylpropyl, 1,2-dimethylpropyl, neopentyl, 1,1-dimethylpropyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 2-ethylbutyl, 1-ethylbutyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 2,3-dimethylbutyl, 1,3-dimethylbutyl or 1,2-dimethylbutyl, or the like or isomers thereof. The term "alkylene" as used herein refers to a group of the formula -(CH2) n -a linear or branched divalent hydrocarbon group. Non-limiting examples include ethylene and propylene.

[0329] As used herein, the term "1 to a plurality of" means more than one, for example, 1, 2, 3, 4, 5 or more.

[0330] The term "aliphatic ring", "carbocycle" or "cycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon group, which may contain 3 to 20 carbon atoms, preferably 3 to 12 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12) carbon atoms, more preferably 3 to 6 carbon atoms. The carbocycle may be monocyclic or polycyclic, and may be a saturated cycloalkyl or may optionally contain one, two or more double bonds and / or triple bonds on its ring, thereby forming a so-called cycloalkenyl or cycloalkynyl group. In the case of a carbocycle having multiple rings, these rings may form spirocyclic, fused ring and bridged ring structures. For example, non-limiting examples of monocyclic carbocycles include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, cyclooctatetraenyl, and the like; and non-limiting examples of polycyclic carbocycles include decalinyl or isobornyl.

[0331] The term "aryl" or "aromatic ring" means: It should be understood that it preferably refers to a monovalent aromatic or partially aromatic monocyclic, bicyclic (such as fused, bridged, spiro) or tricyclic hydrocarbon ring having 6 to 20 carbon atoms, which can be a single aromatic ring or a polyaromatic ring fused together, preferably "C 6-14 Aryl". The term "C 6-14 "Aryl" is understood to mean preferably a monovalent aromatic or partially aromatic monocyclic, bicyclic or tricyclic hydrocarbon ring ("C 6-14 or a ring having 9 carbon atoms ("C9 aryl"), for example indanyl or indenyl, or a ring having 10 carbon atoms ("C 10 aryl) such as tetrahydronaphthyl, dihydronaphthyl or naphthyl, or a ring having 13 carbon atoms ("C 13 aryl), such as fluorenyl, or a ring having 14 carbon atoms ("C 14 aryl”), such as anthracenyl. When the C 6-20 When the aryl group is substituted, it may be monosubstituted or polysubstituted. Furthermore, there is no limitation on the position of substitution, and for example, substitution may be at the ortho, para or meta position.

[0332] The term "spirocyclic" refers to a ring system in which two rings share one ring atom, which may contain an aliphatic ring, a heterocyclic ring, an aromatic ring or a heteroaromatic ring as described above.

[0333] The term "paracyclic" refers to a ring system in which two rings share two ring atoms, and may contain an aliphatic ring, a heterocyclic ring, an aromatic ring or a heteroaromatic ring as described above.

[0334] The term "bridged ring" refers to a ring system in which two rings share three or more ring atoms, and may contain an aliphatic ring, a heterocyclic ring, an aromatic ring or a heteroaromatic ring as described above.

[0335] The term "heterocycle" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent containing 3 to 20 ring atoms, one or more of which is a heteroatom or atomic group selected from N, O, NH, S, S(O) or S(O)2, but excluding the ring portion of -OO-, -OS- or -SS-, and the remaining ring atoms are carbon. Preferably, it contains 3 to 12 ring atoms, 1-4 of which are heteroatoms (e.g., 1, 2, 3, and 4); more preferably, it contains 3 to 6 ring atoms (e.g., 3, 4, 5, 6). The heterocyclic group can be connected to the rest of the molecule through any one of the carbon atoms or a nitrogen atom (if present) or an oxygen or sulfur atom (particularly in the case of forming an onium salt). The heterocyclic group can include fused or bridged rings and / or spirocyclic rings. Non-limiting examples of monocyclic heterocyclic groups include azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothienyl, dihydroimidazolyl, dihydrofuranyl, dihydropyrazolyl, dihydropyrrolyl, dioxolyl, tetrahydropyranyl, pyrrolinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, dithianyl, trithianyl, homopiperazinyl, diazepanyl etc., preferably piperidinyl, pyrrolidinyl. Polycyclic heterocyclic groups include spirocyclic, fused ring and bridged heterocyclic groups, and can also be benzo-fused heterocyclic groups such as dihydroisoquinolinyl. The heterocyclic group can be bicyclic, and its non-limiting examples include hexahydrocyclopenta [c] pyrrole -2 (1H) - base, hexahydro pyrrolo [1,2-a] pyrazine -2 (1H) - base. The heterocyclyl group may also be partially unsaturated, i.e. it may contain one or more double bonds, non-limiting examples of which include dihydrofuranyl, dihydropyranyl, 2,5-dihydro-1H-pyrrolyl, 4H-[1,3,4]thiadiazinyl, 4,5-dihydrooxazolyl or 4H-[1,4]thiazinyl.

[0336] The heterocyclic group may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, sulfur pentafluoride, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxyl or carboxylate.

[0337] As used herein, the term "heteroaryl / heteroaromatic ring" refers to a heteroaromatic system comprising 1 to 4 heteroatoms, 5 to 20 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur, nitrogen and phosphorus. Heteroaryl is preferably 5 to 10 yuan (e.g., 5, 6, 7, 8, 9 or 10 yuan), more preferably 5 yuan or 6 yuan. Non-limiting examples of heteroaryl include, but are not limited to, thienyl, furyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, thia-4H-pyrazolyl, etc. and their benzo derivatives, such as benzofuranyl, benzothienyl, benzoxazolyl, benzisoxazolyl, benzimidazolyl, benzotriazolyl, indazolyl, indolyl, , isoindolyl, etc.; or pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, etc., and benzo derivatives thereof, such as quinolyl, quinazolinyl, isoquinolyl, etc.; or acinyl, indolizinyl, purinyl, etc. and benzo derivatives thereof; or cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl and / or phenoxazinyl, etc.

[0338] The heteroaryl group / heteroaromatic ring may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one, two or more groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, sulfur pentafluoride, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate.

[0339] Unless otherwise specified, heterocyclic groups, heteroaryls, or heteroaromatic rings include all possible isomeric forms thereof, such as positional isomers thereof. Thus, for some illustrative, non-limiting examples, substituted or bonded to other groups at one, two, or more positions of the 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 11-, 12-positions, etc. (if present) may include pyridin-2-yl, pyridin-2-ylene, pyridin-3-yl, pyridin-3-ylene, pyridin-4-ylene, and pyridin-4-ylene; thienyl or thienylene include thien-2-yl, thien-2-ylene, thien-3-ylene, and thien-3-ylene; pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, and pyrazol-5-yl.

[0340] The term "pharmaceutically acceptable" as used herein refers to those compounds, materials, compositions and / or dosage forms which, within the scope of sound medical judgment, are suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response or other problems or complications, commensurate with a reasonable benefit / risk ratio.

[0341] The term "pharmaceutically acceptable salt" refers to salts of the compounds of the present invention, prepared by reacting the compounds of the present invention with relatively nontoxic acids or bases. When the compounds of the present invention contain relatively acidic functional groups, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of base in neat solution or in a suitable inert solvent. Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino or magnesium salts, or similar salts. When the compounds of the present invention contain relatively basic functional groups, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of acid in neat solution or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include inorganic acid salts such as hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, bicarbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, bisulfate, hydroiodic acid, phosphorous acid, and the like; and organic acid salts such as acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, tartaric acid, and methanesulfonic acid; and salts of amino acids such as arginine, and organic acids such as glucuronic acid (see Berge et al., "Pharmaceutical Salts", Journal of Pharmaceutical Science 66: 1-19 (1977)). Certain specific compounds of the present invention contain both basic and acidic functional groups and can be converted into either base or acid addition salts.

[0342] Preferably, the neutral form of the compound is regenerated by contacting the salt with a base or acid in a conventional manner and isolating the parent compound. The parent form of the compound differs from its various salt forms in certain physical properties, such as solubility in polar solvents.

[0343] As used herein, "pharmaceutically acceptable salts" are derivatives of the compounds of the present invention, wherein the parent compound is modified by salification with an acid or alkali. Examples of pharmaceutically acceptable salts include, but are not limited to, inorganic or organic acid salts of bases such as amines, alkali metal or organic salts of acid radicals such as carboxylic acids, and the like. Pharmaceutically acceptable salts include conventional non-toxic salts such as sodium salts, potassium salts, amine salts, quaternary ammonium salts of the parent compound, and the like. Conventional non-toxic salts include, but are not limited to, those derived from inorganic and organic acids, inorganic and organic bases, wherein the inorganic or organic acid is selected from 2-acetoxybenzoic acid, 2-hydroxyethanesulfonic acid, acetic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, bicarbonate, carbonic acid, citric acid, edetic acid, ethanedisulfonic acid, ethanesulfonic acid, fumaric acid, glucoheptose, gluconic acid, glutamic acid, glycolic acid, hydrobromic acid, hydrochloric acid, hydroiodide, hydroxyl, hydroxynaphthalene The inorganic base and organic base described in the following examples are selected from sodium, potassium, magnesium, calcium, etc. or amines, diethylamine, triethylamine, ethanolamine, etc.

[0344] The pharmaceutically acceptable salts of the present invention can be synthesized from parent compounds containing acid radicals or bases by conventional chemical methods. Generally, such salts are prepared by reacting the free acid or base form of these compounds with a stoichiometric amount of an appropriate base or acid in water or an organic solvent, or a mixture of the two. Generally, non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred.

[0345] In addition to the form of salts, the compounds provided by the present invention also exist in prodrug form. The prodrugs of the compounds described herein easily undergo chemical changes under physiological conditions to be converted into the compounds of the present invention. In addition, prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an in vivo environment.

[0346] Some compounds of the present invention may exist in unsolvated or solvated forms, including hydrate forms. Generally speaking, solvated forms are comparable to unsolvated forms and are included within the scope of the present invention. Some compounds of the present invention may exist in polycrystalline or amorphous forms.

[0347] As used herein, the term "solvate" refers to an association formed between one or more solvent molecules and a compound of the present invention. Solvents that form solvates include, but are not limited to, water, isopropanol, ethanol, methanol, dimethyl sulfoxide, ethyl acetate, acetic acid, and aminoethanol. Thus, the term "hydrate" refers to an association formed when the solvent molecule is water.

[0348] Certain compounds of the present invention may have asymmetric carbon atoms (optical centers) or double bonds. Racemates, diastereomers, geometric isomers and individual isomers are all within the scope of the present invention.

[0349] The diagrammatic representations of racemic, ambiscalemic, scalemic, or enantiomerically pure compounds herein are adapted from Maehr, J. Chem. Ed. 1985, 62:114-120. Unless otherwise indicated, wedge-shaped and dashed bonds are used to represent the absolute configuration at a stereocenter. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, they are intended to include both E and Z geometric isomers unless otherwise specified. Likewise, all tautomeric forms are intended to be encompassed within the scope of this invention.

[0350] The compounds of the present invention may exist in specific geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis- and trans-isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, and racemic mixtures and other mixtures thereof, such as enantiomerically or diastereomerically enriched mixtures, all of which are within the scope of the present invention. Additional asymmetric carbon atoms may be present in substituents such as alkyl groups. All such isomers and mixtures thereof are encompassed within the scope of the present invention.

[0351] Optically active (R)- and (S)-isomers, as well as D and L isomers, can be prepared by chiral synthesis or chiral reagents or other conventional techniques. If one enantiomer of a compound of the present invention is desired, it can be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, wherein the resulting diastereomeric mixture is separated and the auxiliary group is cleaved to provide the pure desired enantiomer. Alternatively, when the molecule contains a basic functional group (such as an amino group) or an acidic functional group (such as a carboxyl group), a diastereomeric salt is formed with an appropriate optically active acid or base, and then the diastereoisomers are separated by fractional crystallization or chromatography as is known in the art, and then the pure enantiomer is recovered. In addition, the separation of enantiomers and diastereomers is typically accomplished by using chromatography, which employs a chiral stationary phase and is optionally combined with a chemical derivatization method (e.g., carbamate formation from an amine).

[0352] The compounds of the present invention may contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute the compound. For example, the compounds may be labeled with radioactive isotopes, such as tritium ( 3 H), iodine-125( 125 I) or C-14( 14C) All isotopic variations of the compounds of the present invention, whether radioactive or not, are encompassed within the scope of the present invention.

[0353] The term "pharmaceutically acceptable carrier" refers to any formulation or carrier medium that can deliver an effective amount of the active substance of the present invention, does not interfere with the biological activity of the active substance, and has no toxic side effects on the host or patient. Representative carriers include water, oils, vegetables and minerals, cream bases, lotion bases, ointment bases, etc. These bases include suspending agents, viscosity increasing agents, transdermal enhancers, etc. Their preparations are well known to those skilled in the art of cosmetics or topical medicine. For additional information about carriers, reference can be made to Remington: The Science and Practice of Pharmacy, 21st Ed., Lippincott, Williams & Wilkins (2005), the contents of which are incorporated herein by reference.

[0354] When any variable (e.g., R) occurs more than once in a compound's composition or structure, its definition at each occurrence is independent. Thus, for example, if a group is substituted with 0-2 Rs, the group may be optionally substituted with up to two Rs, with each occurrence of R being an independent choice. Furthermore, combinations of substituents and / or their variants are permissible only if such combinations result in stable compounds.

[0355] When a substituent's bond crosses two atoms in a ring, such substituent may be bonded to any atom in the ring. When a substituent is listed without specifying the atom through which it is bonded to a compound included in the general chemical formula but not specifically mentioned, such substituent may be bonded to any atom therein. Combinations of substituents and / or variants thereof are permissible only if such combinations result in stable compounds.

[0356] The term "halo" or "halogen" refers to fluorine, chlorine, bromine and iodine.

[0357] The present invention will now be further described by way of examples. The examples given below are for illustrative purposes only and are not intended to limit the scope of this invention. The compounds of the present invention can be prepared using many methods known in the art of organic synthesis. The examples of the present invention can be synthesized using the methods described below, as well as synthetic methods known in the art of synthetic organic chemistry, or by methods modified therefrom. Preferred methods include, but are not limited to, the methods described below.

[0358] Unless otherwise specified, all solvents used in the present invention are commercially available and do not require further purification when used. The reaction is usually carried out using anhydrous solvents under an inert atmosphere of nitrogen. Nuclear magnetic resonance spectra are measured on a Bruker-Avance-400 (400 MHz) spectrometer, and chemical shifts are reported in the form of δ (ppm). Mass spectrometry is performed using an Agilent 1200 series (plus 6110 / and 1956A) LC / MS or Shimadzu MS (DAD: SPD-M20A (LC)) and Shimadzu Micromass 2020 detector. The mass spectrometer is equipped with an electrospray ionization source (ESI) operating in positive and negative modes.

[0359] The abbreviations used are as follows: aq is aqueous solution; TLC is thin layer chromatography; RT is room temperature; MeOH is methanol; EtOH is ethanol; EtOAc is ethyl acetate; THF is tetrahydrofuran; equivalent is eq; CDI is carbonyldiimidazole; DCM is dichloromethane; PE is petroleum ether; DIAD is diisopropyl azodicarboxylate; DMF is N,N-dimethylformamide; DMSO is dimethyl sulfoxide; CBz is benzyloxycarbonyl; BOC is tert-butyl benzoate. Butylcarbonyl; HOAc is acetic acid; Ms is methanesulfonyl; NMP is N-methylpyrrolidone; DMAP is 4-(dimethylamino)pyridine; Boc2O is di-tert-butyl dicarbonate; TFA is trifluoroacetic acid; DIPEA is diisopropylethylamine; SOCl2 is thionyl chloride; CS2 is carbon disulfide; TsOH is 4-toluenesulfonic acid; MTBE is tert-butyl methyl ether; FA is formic acid; ACN is acetonitrile; i-PrOH is 2-propanol.

[0360] Compounds can be named manually or using The product is named after the manufacturer. If purchased commercially, the supplier's catalog name can also be used. TLC or LC-MS is usually used to determine whether the reaction is complete. DETAILED DESCRIPTION

[0361] In order to illustrate the present invention in more detail, the following examples are given, but the scope of the present invention is not limited thereto.

[0362] Example 1. Synthesis of (2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)dimethylphosphine oxide (Compound 1):

[0363] 1) Synthesis of 4-bromo-1-(phenylsulfonyl)-1H-indole

[0364] At 0°C, sodium hydride (918 mg, 22.95 mmol, 60% dispersion in kerosene) was added to a solution of 4-bromo-1H-indole (3.00 g, 15.30 mmol) in tetrahydrofuran (30 mL). After addition, stirring was continued at 0°C for 30 minutes, and then benzenesulfonyl chloride (4.06 g, 22.95 mmol) was added dropwise to the reaction mixture. The resulting reaction mixture was stirred at room temperature for 16 hours. After the reaction was completed, the reaction mixture was quenched with water (40 mL) and extracted with ethyl acetate (40 mL × 3). The combined organic layers were washed with brine (10 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 1) to give 4-bromo-1-(phenylsulfonyl)-1H-indole (4.65 g, 13.84 mmol, yield: 90.4%).

[0365] 1 H NMR (400MHz, CDCl3) δ7.95 (d, J = 8.4Hz, 1H), 7.88-7.86 (m, 2H), 7.63 (d, J = 3.6Hz, 1H), 7.55 (t, J = 7. 2Hz,1H),7.44(t,J=8.0Hz,2H),7.39(d,J=8.0Hz,1H),7.17(t,J=8.0Hz,1H),6.73(d,J=3.6Hz,1H).

[0366] 2) Synthesis of 4-bromo-2-iodo-1-(phenylsulfonyl)-1H-indole

[0367] To a solution of 4-bromo-1-(phenylsulfonyl)-1H-indole (2.00 g, 5.95 mmol) in tetrahydrofuran (20 mL) was added lithium diisopropylamide (9 mL, 17.85 mmol, 2.0 M in tetrahydrofuran) dropwise at -78°C. The mixture was stirred at -78°C for 30 minutes, followed by the addition of iodine (2.27 g, 8.93 mmol). The resulting reaction mixture was stirred at room temperature for 16 hours. Upon completion of the reaction, the resulting mixture was poured into a saturated chloride solution (30 mL) to quench the reaction and extracted with ethyl acetate (20 mL x 3). The combined organic layers were washed with saturated brine (10 mL x 3), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate=1 / 1) to give 4-bromo-2-iodo-1-(phenylsulfonyl)-1H-indole (876 mg, 1.90 mmol, yield: 31.8%).

[0368] 1H NMR(400MHz,DMSO-d6)δ8.19(d,J=8.4Hz,1H),7.91-7.89(m,2H),7.75(t,J=7.6Hz,1 H),7.64(t,J=8.0Hz,2H),7.50(d,J=7.6Hz,1H),7.23(t,J=8.0Hz,1H),7.13(s,1H).

[0369] 3) Synthesis of 4-bromo-2-iodo-1H-indole

[0370] Potassium carbonate (524 mg, 3.80 mmol) was added to a mixture of 4-bromo-2-iodo-1-(phenylsulfonyl)-1H-indole (876 mg, 1.90 mmol) in methanol (20 mL) and water (2 mL) at room temperature. The resulting reaction solution was stirred at 80°C for 5 hours. After completion of the reaction, the reaction mixture was concentrated and purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 1) to afford 4-bromo-2-iodo-1H-indole (426 mg, 1.32 mmol, yield: 69.8%).

[0371] 1 H NMR (400MHz, DMSO-d6) δ12.04(d,J=0.4Hz,1H),7.33(d,J=8.4Hz,1H),7.19(d,J=7.6Hz,1H),6.98(t,J=7.6Hz,1H),6.58(s,1H).

[0372] 4) Synthesis of 4-bromo-2-iodo-1-(2,2,2-trifluoroethyl)-1H-indole

[0373] To a solution of 4-bromo-2-iodo-1H-indole (426 mg, 1.32 mmol) in N,N-dimethylformamide (10 mL) at 0°C was added sodium hydride (79 mg, 1.98 mmol, 60% by weight dispersion in kerosene). The resulting reaction solution was stirred at 0°C for 30 minutes, followed by the addition of 2,2,2-trifluoroethyl trifluoromethanesulfonate (367 mg, 1.58 mmol). After the addition, the resulting solution was stirred at room temperature for 16 hours. Upon completion of the reaction, the solution was quenched with water (10 mL) and extracted with ethyl acetate (20 mL x 3). The combined organic phases were washed with saturated brine (10 mL x 3), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by reverse phase flash chromatography (chromatographic conditions: column: spherical C18, 20-40 μm, 40 g; mobile phase A: pure water containing 0.1% NH 3 ·H 2 O; mobile phase B: acetonitrile; flow rate: 40 mL / min; gradient: 40% B-95% B in 20 minutes; detector: 214 nm). When the mobile phase B content reached 82%, the fractions containing the product were collected and then concentrated under reduced pressure to give 4-bromo-2-iodo-1-(2,2,2-trifluoroethyl)-1H-indole (485 mg, 1.20 mmol, yield: 90.8%).

[0374] 1 H NMR (400MHz, DMSO-d6) δ7.69 (d, J = 8.4Hz, 1H), 7.31 (d, J = 7.6Hz, 1H), 7.11 (t, J = 8.4Hz, 1H), 6.85 (s, 1H), 5.23-5.16 (m, 2H).

[0375] 5) Synthesis of N-(3-(4-bromo-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-2-methoxy-4-(methylsulfonyl)aniline

[0376] To a solution of 4-bromo-2-iodo-1-(2,2,2,2-trifluoroethyl)-1H-indole (485 mg, 1.20 mmol) and 2-methyl-4-(methylsulfinyl)-N-(prop-2-yn-1-yl)aniline (574 mg, 2.40 mmol) in dimethyl sulfoxide (10 mL) was added diethylamine (876 mg, 12.00 mmol), cuprous iodide (46 mg, 0.24 mmol), and palladium tetrakistriphenylphosphine (139 mg, 0.12 mmol) at room temperature. The resulting reaction mixture was stirred at 25°C under nitrogen for 4 hours. After the reaction was complete, the reaction mixture was quenched with water (10 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic phases were washed with saturated brine (10 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 1) to give N-(3-(4-bromo-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-2-methoxy-4-(methylsulfonyl)aniline (480 mg, 0.93 mmol, yield: 77.6%).

[0377] 1 H NMR(400MHz, DMSO-d6)δ7.61(d,J=8.4Hz,1H),7.41-7.35(m,2H),7.26-7.19(m,2H),6.92(d,J=8.0Hz,1H ),6.76(s,1H),6.52(t,J=6.4Hz,1H),5.15-5.08(m,2H),4.39(d,J=6.0Hz,2H),3.90(s,3H),3.09(s,3H).

[0378] 6) Synthesis of (2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)dimethylphosphine oxide

[0379] At room temperature, potassium phosphate (54 mg, 0.25 mmol), palladium acetate (4 mg, 0.024 mmol) and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (12 mg, 0.021 mmol) were added to a solution of N-(3-(4-bromo-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)-2-methoxy-4-(methylsulfonyl)aniline (100 mg, 0.19 mmol) and dimethylphosphine oxide (20 mg, 0.25 mmol) in N,N-dimethylformamide (10 mL). After the addition was completed, the reaction solution was heated to 120°C and stirred for 5 hours under nitrogen protection. After the reaction was completed, the reaction solution was decompressed. The residue was concentrated. The residue was purified by reverse phase flash chromatography (chromatographic conditions: column: spherical C18, 20-40 μm, 40 g; mobile phase A: pure water containing 0.1% NH3·H2O; mobile phase B: acetonitrile; flow rate: 40 mL / min; gradient: 30% B-80% B in 20 minutes; detector: 254 nm). When the mobile phase B content reached 46%, the fraction containing the product was collected and then concentrated under reduced pressure to obtain 2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)dimethylphosphine oxide (Compound 1) (46.92 mg, 0.09 mmol, yield: 47.3%). LCMS m / z: 513 [M+H] + .

[0380] 1 H NMR (400MHz, DMSO-d6) δ7.78(d,J=8.4Hz,1H),7.54-7.49(m,1H),7.41-7.36(m,2H),7.26-7.23(m,2H),6.91(d,J=8.4Hz, 1H),6.51(t,J=6.0Hz,1H),5.18-5.12(m,2H),4.40(d,J=6.4Hz,2H),3.90(s,3H),3.09(s,3H),1.72(s,3H),1.69(s,3H).

[0381] Example 2. Synthesis of 1-cyclopropyl-N-((3S,4R)-3-fluoropiperidin-4-yl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1H-indole-4-amine or 1-cyclopropyl-N-((3R,4S)-3-fluoropiperidin-4-yl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1H-indole-4-amine (Compounds 2A and 2B):

[0382] 1) Synthesis of 1-cyclopropyl-2-iodo-4-nitro-1H-indole:

[0383] To a solution of 2-iodo-4-nitro-1H-indole (2.00 g, 6.94 mmol) in toluene (50 mL) was added copper acetate (1.26 g, 6.94 mmol), 4-dimethylaminopyridine (2.54 g, 20.82 mmol), and cyclopropylboronic acid (1.19 g, 13.88 mmol) at room temperature. After addition, the reaction mixture was purged with oxygen three times, maintaining an oxygen atmosphere. Sodium bis(trimethylsilyl)amide (6.94 mmol, 3.47 mL, 2 M) was then added. The reaction mixture was heated to 100°C and stirred for 16 hours. After the reaction was complete, the reaction mixture was quenched with saturated aqueous ammonium chloride (100 mL) and extracted with ethyl acetate (50 mL x 5). The combined organic layers were washed with saturated brine (50 mL x 3), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by reverse phase flash chromatography (chromatographic conditions: column: spherical C18, 20-40 μm, 330 g; mobile phase A: pure water containing 0.1% formic acid; mobile phase B: acetonitrile; flow rate: 120 mL / min; gradient: 5% B-95% B in 40 minutes; detector: 254 nm). When the mobile phase B content reached 80%, the fractions containing the product were collected and then concentrated under reduced pressure to give 1-cyclopropyl-2-iodo-4-nitro-1H-indole (1.03 g, 3.14 mmol, yield: 45.3%). LCMS m / z: 329 [M+H] + .

[0384] 2) Synthesis of 1-cyclopropyl-2-iodo-1H-indole-4-amine:

[0385] At room temperature, iron powder (2.02 g, 36.00 mmol) and ammonium chloride (1.91 g, 36.00 mmol) were added to a mixed solution of ethanol (20 mL) and water (2 mL) containing 1-cyclopropyl-2-iodo-4-nitro-1H-indole (1.18 g, 3.60 mmol). After the addition was complete, the reaction mixture was heated to 80°C and stirred for 1 hour. LCMS and TLC confirmed the completion of the reaction, and the reaction solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 3 / 1) to give 1-cyclopropyl-2-iodo-1H-indole-4-amine (900 mg, 3.02 mmol, yield: 83.9%). LCMS m / z: 299 [M+H] + .

[0386] 3) Synthesis of tert-butyl 4-((1-cyclopropyl-2-iodo-1H-indol-4-yl)amino)-3-fluoropiperidine-1-carboxylate:

[0387] At room temperature, tert-butyl 3-fluoro-4-oxopiperidine-1-carboxylate (3.28 g, 15.10 mmol) and sodium triacetoxyborohydride (1.60 g, 7.55 mmol) were added to a mixed solution of 1-cyclopropyl-2-iodo-1H-indol-4-amine (900 mg, 3.02 mmol) in 1,2-dichloroethane (5 mL) and acetic acid (15 mL). After the addition was complete, the reaction solution was heated to 40°C and stirred for 2 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 4 / 1) to give tert-butyl 4-((1-cyclopropyl-2-iodo-1H-indol-4-yl)amino)-3-fluoropiperidine-1-carboxylate (860 mg, 1.72 mmol, yield: 57.0%). LCMS m / z: 500 [M+H] + .

[0388] 4) Synthesis of tert-butyl 4-((1-cyclopropyl-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1H-indol-4-yl)amino)-3-fluoropiperidine-1-carboxylate:

[0389] To a solution of tert-butyl 4-((1-cyclopropyl-2-iodo-1H-indol-4-yl)amino)-3-fluoropiperidine-1-carboxylate (810 mg, 1.62 mmol) in dimethyl sulfoxide (10 mL) was added 2-methoxy-4-(methylsulfonyl)-N-(prop-2-yn-1-yl)aniline (774 mg, 3.24 mmol), diethylamine (1.18 g, 16.20 mmol), cuprous iodide (61 mg, 0.32 mmol), and tetrakistriphenylphosphine palladium (185 mg, 0.16 mmol) at room temperature. The mixture was stirred at 25°C for 16 hours. After the reaction was complete, the reaction solution was quenched with water (30 mL) and extracted with ethyl acetate (20 mL x 3). The combined organic layers were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by reverse phase flash chromatography (chromatographic conditions: column: spherical C18, 20-40 μm, 120 g; mobile phase A: aqueous solution containing 0.1% formic acid; mobile phase B: acetonitrile; flow rate: 80 mL / min; gradient: 5% B to 95% B over 35 minutes; detector: 254 nm). When the mobile phase B content reached 80%, the fractions containing the product were collected and then concentrated under reduced pressure to give tert-butyl 4-((1-cyclopropyl-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1H-indol-4-yl)amino)-3-fluoropiperidine-1-carboxylate (700 mg, 1.15 mmol, yield: 70.6%). LCMS m / z: 611 [M+H] + .

[0390] 5), Synthesis of tert-butyl (3R, 4S)-4-((1-cyclopropyl-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1H-indol-4-yl)amino)-3-fluoropiperidine-1-carboxylate and tert-butyl (3S, 4R)-4-((1-cyclopropyl-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1H-indol-4-yl)amino)-3-fluoropiperidine-1-carboxylate:

[0391] Tert-butyl 4-((1-cyclopropyl-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1H-indol-4-yl)amino)-3-fluoropiperidine-1-carboxylate (700 mg, 1.15 mmol) was purified by supercritical fluid chromatography (chromatographic conditions: system: Waters SFC 150; (250×25 mm, 10 μm; mobile phase A: Supercritical CO2; mobile phase B: MEOH (+0.1% 7.0 mol / l Ammonia in MeOH); A:B ratio: 55:45; flow rate: 100 mL / min; detection wavelength: 214 nm; column pressure: RT; column pressure: 100 bar) to obtain two isomers: C101-203-A-1 and C101-203-B:

[0392] C101-203-A-1: Peak 1: 2.676 min. (240 mg, 0.39 mmol, yield: 34.3%)

[0393] C101-203-B-9: Peak 2: 3.368 min. (270 mg, 0.44 mmol, yield: 38.6%).

[0394] 6) Synthesis of 1-cyclopropyl-N-((3R,4S)-3-fluoropiperidin-4-yl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1H-indole-4-amine or 1-cyclopropyl-N-((3S,4R)-3-fluoropiperidin-4-yl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1H-indole-4-amine (Compounds 2A and 2B)

[0395] At room temperature, 2,6-lutidine (106 mg, 0.99 mmol) and trimethylsilyl iodide (198 mg, 0.99 mmol) were added to a solution of C101-203-A-1 isomer (20 mg, 0.033 mmol) in dichloromethane (3 mL). After the addition, the reaction mixture was stirred at room temperature for 1 hour. After the reaction was complete, the reaction mixture was diluted with dichloromethane (50 mL), washed with saturated sodium sulfite (15 mL), and then washed with saturated brine (20 mL x 3). It was dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol=15 / 1) to give 1-cyclopropyl-N-((3S,4R)-3-fluoropiperidin-4-yl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1H-indol-4-amine or 1-cyclopropyl-N-((3R,4S)-3-fluoropiperidin-4-yl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1H-indol-4-amine (Compound 2A) (5.26 mg, 0.010 mmol, yield: 31.4%). LCMS m / z: 511 [M+H] + .

[0396] 1 H NMR (400MHz, CD3OD) δ7.50 (dd, J = 8.4Hz, 2.0Hz 1H), 7.31 (d, J = 1.6Hz 1H), 7.04 (t, J = 8.0Hz, 1H), 6.97 (d, J = 8.0Hz 1H),6.91(d,J=8.0Hz,1H),6.76(s,1H),6.33(d,J=7.6Hz,1H),4.90-4.78(m,1H),4.38(s,2H),3.97(s,3H),3.82-3.60( m,2H),3.19-3.15(m,1H),3.10-3.06(m,4H),3.03-2.89(m,1H),2.86-2.80(m,1H),1.96-1.84(m,2H),1.02-0.92(m,4H).

[0397] At room temperature, 2,6-lutidine (995 mg, 9.30 mmol) and trimethylsilyl iodide (1860 mg, 9.30 mmol) were added to a solution of C101-203-B-9 (192 mg, 0.31 mmol) in dichloromethane (10 mL). After the addition, the resulting reaction solution was stirred at room temperature for 2 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure. The residue was purified by reverse-phase flash chromatography (chromatographic conditions: column: spherical C18, 20-40 μm, 120 g; mobile phase A: pure water containing 0.1% NH3·H2O; mobile phase B: acetonitrile; flow rate: 80 mL / min; gradient: 5% B to 95% B over 40 minutes; detector: 254 nm) to obtain a crude product (136 mg). The crude product was further purified by preparative HPLC (chromatographic conditions: Waters 2762 / Qda; column: Sunfire C18, 19 × 250mm, 10um; mobile phase A: pure water containing 0.1% formic acid; mobile phase B: acetonitrile; flow rate: 20mL / min; gradient: 27%-27%; retention time: 7.4-9.5min in 16 minutes) to obtain 1-cyclopropyl-N-((3R,4S)-3-fluoropiperidin-4-yl)-2-(3-((2-methoxy-4-(methylsulfonyl)benzene) 1-(3-(2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1H-indol-4-amine or 1-cyclopropyl-N-((3S,4R)-3-fluoropiperidin-4-yl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)-1H-indol-4-amine (Compound 2B) (24.35 mg, 0.048 mmol, yield: 15.1%). LCMS m / z: 511 [M+H] + .

[0398] 1 H NMR (400MHz, CD3OD) δ7.46 (dd, J=8.4Hz, 2.0Hz 1H), 7.28 (d, J=2.0Hz 1H), 7.01 (t, J=8.0Hz, 1H), 6.92 (d, J=8.4Hz 1H),6.86(d,J=8.0Hz,1H),6.72(s,1H),6.29(d,J=7.6Hz,1H),4.70(s,1H),4.34(s,2H),3.92(s,3H),3.76- 3.65(m,1H),3.31-3.24(m,1H),3.10-3.03(m,5H),2.91-2.69(m,2H),1.89-1.72(m,2H),0.96-0.91(m,4H).

[0399] Example 3, Synthesis of (3S,4R)-3-fluoro-N-(2-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)benzo[b]thiophen-4-yl)piperidin-4-amine (Compound 3):

[0400] 1) Synthesis of 4-bromo-2-iodobenzo[b]thiophene:

[0401] To a solution of 4-bromobenzo[b]thiophene (5.00 g, 23.47 mmol) in tetrahydrofuran (50 mL) was added a solution of lithium diisopropylamide (35.21 mmol, 18 mL, 2 M) dropwise at -78°C. After the addition was complete, the resulting reaction solution was stirred at -78°C for 30 minutes, and then iodine (7.15 g, 28.16 mmol) was added to the mixed solution. After the addition was complete, the resulting mixed reaction solution was stirred at room temperature for 5 hours. After the reaction was complete, the reaction solution was poured into a saturated ammonium chloride solution (50 mL) to quench the reaction and extracted with ethyl acetate (50 mL x 3). The combined organic phases were washed with saturated brine (20 mL x 3), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by reverse phase flash chromatography (chromatographic conditions: column: spherical C18, 20-40 μm, 330 g; mobile phase A: pure water containing 0.1% NH3·H2O; mobile phase B: acetonitrile; flow rate: 120 mL / min; gradient: 40% B-100% B in 20 minutes; detector: 214 nm). When the mobile phase content reached 99%, the fractions containing the product were collected and then concentrated under reduced pressure to give 4-bromo-2-iodobenzo[B]thiophene (2.14 g, 6.31 mmol, yield: 26.8%).

[0402] 1H NMR (400MHz, DMSO-d6) δ8.02(d,J=8.0Hz,1H),7.71(d,J=0.8Hz,1H),7.61(dd,J=8.0Hz,0.8Hz,1H),7.29(t,J=8.0Hz,1H).

[0403] 2) Synthesis of tert-butyl (3-(4-bromobenzo[b]thiophen-2-yl)prop-2-yn-1-yl)(2-methoxy-4-(methylsulfonyl)phenyl)carbamate:

[0404] To a solution of 4-bromo-2-iodobenzo[b]thiophene (200 mg, 0.59 mmol) and tert-butyl (2-methoxy-4-(methylsulfonyl)phenyl)(prop-2-yn-1-yl)carbamate (400 mg, 1.18 mmol) in dimethyl sulfoxide (10 mL) was added diethylamine (431 mg, 5.90 mmol), cuprous iodide (23 mg, 0.12 mmol), and tetrakistriphenylphosphine palladium (69 mg, 0.059 mmol) at room temperature. After the addition was complete, the reaction mixture was stirred at 25°C under nitrogen for 2 hours. Upon completion of the reaction, the mixture was quenched with water (10 mL) and extracted with ethyl acetate (20 mL x 3). The combined organic phases were washed with saturated brine (10 mL x 3), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by reverse phase flash chromatography (chromatographic conditions: column: spherical C18, 20-40 μm, 80 g; mobile phase A: pure water containing 0.1% NH3·H2O; mobile phase B: acetonitrile; flow rate: 80 mL / min; gradient: 40% B to 100% B in 20 minutes; detector: 214 nm). When the mobile phase B content reached 98%, the fractions containing the product were collected and then concentrated under reduced pressure to give tert-butyl (3-(4-bromobenzo[b]thiophen-2-yl)prop-2-yn-1-yl)(2-methoxy-4-(methylsulfonyl)phenyl)carbamate (260 mg, 0.47 mmol, yield: 80.2%). LCMS m / z: 494 [M+H-56]. + .

[0405] 3) Synthesis of tert-butyl (3S, 4R)-4-((2-(3-((tert-butoxycarbonyl)(2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)benzo[b]thiophen-4-yl)amino)-3-fluoropiperidine-1-carboxylate:

[0406] To a solution of tert-butyl (3-(4-bromobenzo[b]thiophen-2-yl)prop-2-yn-1-yl)(2-methoxy-4-(methylsulfonyl)phenyl)carbamate (200 mg, 0.36 mmol) and tert-butyl (3S,4R)-4-amino-3-fluoropiperidine-1-carboxylate (78 mg, 0.36 mmol) in dioxane (10 mL) was added cesium carbonate (1.1 mL) at room temperature. 7g, 3.60mmol), methanesulfonic acid (2-dicyclohexylphosphino)-3,6-dimethoxy-2',4',6'-triisopropyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl) palladium(II) (36mg, 0.04mmol, 0.1equiv), and 2-dicyclohexylphosphino-2',6'-diisopropyloxy-1,1'-biphenyl (16mg, 0.04mmol). After the addition was complete, the resulting reaction solution was heated to 90°C and stirred for 2 hours under a nitrogen blanket. After the reaction was complete, the reaction solution was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography (chromatographic conditions: column: spherical C18, 20-40 μm, 80 g; mobile phase A: pure water containing 0.1% NH3·H2O; mobile phase B: acetonitrile; flow rate: 80 mL / min; gradient: 40% B to 100% B in 20 minutes; detector: 214 nm). When the mobile phase B content reached 95%, the fractions containing the product were collected and then concentrated under reduced pressure to give tert-butyl (3S,4R)-4-((2-(3-((tert-butoxycarbonyl)(2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)benzo[b]thiophen-4-yl)amino)-3-fluoropiperidine-1-carboxylate (120 mg, 0.17 mmol, yield: 48.0%). LCMS m / z: 688 [M+H]. + .

[0407] 4) Synthesis of (3S, 4R)-3-fluoro-N-(2-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)benzo[b]thiophen-4-yl)piperidin-4-amine (Compound 3):

[0408] To a solution of tert-butyl (3S,4R)-4-((2-(3-((tert-butoxycarbonyl)(2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)benzo[b]thiophen-4-yl)amino)-3-fluoropiperidine-1-carboxylate (50 mg, 0.072 mmol) in dichloromethane (10 mL) was added 2,6-lutidine (225 mg, 2.10 mmol) and iodotrimethylsilane (420 mg, 2.10 mmol). After the addition was complete, the reaction mixture was stirred at room temperature for 1 hour. After the reaction was complete, the reaction mixture was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography (chromatographic conditions: column: spherical C18, 20-40 μm, 40 g; mobile phase A: pure water containing 0.1% NH3·H2O; mobile phase B: acetonitrile; flow rate: 40 mL / min; gradient: 40% B to 95% B in 20 minutes; detector: 214 nm). When the mobile phase B content reached 76%, the fractions containing the product were collected, and then reduced pressure and concentrated to give (3S,4R)-3-fluoro-N-(2-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)benzo[b]thiophen-4-yl)piperidin-4-amine (Compound 3) (12.57 mg, 0.026 mmol, yield: 35.4%). LCMS m / z: 488 [M+H] + .

[0409] 1 H NMR (400MHz, DMSO-d6) δ8.04(s,1H),7.41(d,J=8.4Hz,1H),7.25(s,1H),7.16(t,J=8.0Hz,1H) ,7.06(d,J=7.6Hz,1H),6.84(d,J=8.4Hz,1H),6.54(d,J=7.6Hz,1H),6.48(t,J=6.0Hz,1H),5. 82(d,J=8.0Hz,1H),4.76-4.64(m,1H),4.34(d,J=6.0Hz,2H),3.90(s,3H),3.73-3.63(m,1H), 3.14-3.11(m,4H),2.99-2.96(m,1H),2.89-2.67(m,1H),2.62-2.55(m,1H),1.82-1.60(m,2H).

[0410] Example 4. Synthesis of (S)-(4-((3-(4-((6,6-dimethylpiperidin-3-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide (Compound 4):

[0411] 1) Synthesis of (4-amino-3-methoxyphenyl) dimethylphosphine oxide:

[0412] To a solution of 4-bromo-2-methoxyaniline (5.00 g, 24.75 mmol) and dimethylphosphine oxide (2.51 g, 32.18 mmol) in N,N-dimethylformamide (50 mL) was added potassium phosphate (6.89 g, 32.18 mmol), palladium acetate (412 mg, 2.48 mmol), and 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (1.44 g, 2.48 mmol) at room temperature. After the addition was complete, the resulting reaction solution was stirred at 150°C under nitrogen for 5 hours. After the reaction was complete, the reaction solution was quenched with water (50 mL) and extracted with acetate (50 mL x 5). The combined organic layers were washed with saturated ammonium chloride solution (50 mL x 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography (chromatographic conditions: column: spherical C18, 20-40 μm, 330 g; mobile phase A: pure water containing 0.1% NH3·H2O; mobile phase B: acetonitrile; flow rate: 150 mL / min; gradient: 20% B-95% B in 20 minutes; detector: 214 nm). When the mobile phase B content reached 31%, the fractions containing the product were collected and then concentrated under reduced pressure to give (4-amino-3-methoxyphenyl)dimethylphosphine oxide (1.90 g, 9.55 mmol, yield: 38.5%), LCMS m / z: 200 [M+H] + .

[0413] 2) Synthesis of tert-butyl (4-(dimethylphosphoryl)-2-methoxyphenyl)carbamate:

[0414] At room temperature, triethylamine (2.89 g, 28.65 mmol), 4-dimethylaminopyridine (1.17 g, 9.55 mmol), and di-tert-butyl dicarbonate (2.08 g, 9.55 mmol) were added to a solution of (4-amino-3-methoxyphenyl)dimethylphosphine oxide (1.90 g, 9.55 mmol) in dichloromethane (20 mL). After the addition was complete, the resulting reaction solution was stirred at room temperature for 16 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 1) to give tert-butyl (4-(dimethylphosphoryl)-2-methoxyphenyl)carbamate (630 mg, 2.11 mmol, yield: 22.0%). LCMS m / z: 300 [M+H] + .

[0415] 3) Synthesis of tert-butyl (4-(dimethylphosphoryl)-2-methoxyphenyl) (prop-2-yn-1-yl)carbamate:

[0416] To a solution of tert-butyl (4-(dimethylphosphoryl)-2-methoxyphenyl)carbamate (200 mg, 0.67 mmol) in N,N-dimethylformamide (5 mL) was added cesium carbonate (655 mg, 2.01 mmol) and 3-bromoprop-1-yne (95 mg, 0.80 mmol). After the addition was complete, the reaction mixture was heated to 80°C and stirred for 3 hours. Upon completion of the reaction, the resulting mixture was filtered and concentrated under reduced pressure. The residue was purified by reverse-phase flash chromatography (chromatographic conditions: column: spherical C18, 20-40 μm, 120 g; mobile phase A: pure water containing 0.1% NH3·H2O; mobile phase B: acetonitrile; flow rate: 80 mL / min; gradient: 5% B to 95% B over 20 minutes; detector: 254 nm). Fractions containing the product were collected when the mobile phase B content reached 53%, and then concentrated under reduced pressure to provide tert-butyl (4-(dimethylphosphoryl)-2-methoxyphenyl)(prop-2-yn-1-yl)carbamate (180 mg, 0.53 mmol, yield: 80.0%). LCMS m / z: 338 [M+H] + .

[0417] 4) Synthesis of tert-butyl (3-(4-bromo-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)(4-(dimethylphosphoryl)-2-methoxyphenyl)carbamate:

[0418] To a solution of tert-butyl (4-(dimethylphosphoryl)-2-methoxyphenyl)(prop-2-yn-1-yl)carbamate (168 mg, 0.50 mmol) and 4-bromo-2-iodo-1-(2,2,2-trifluoroethyl)-1H-indole (202 mg, 0.50 mmol) in dimethyl sulfoxide (3 mL) was added triethylamine (253 mg, 2.50 mmol), cuprous iodide (10 mg, 0.052 mmol), and tetrakistriphenylphosphine palladium (35 mg, 0.03 mmol) at room temperature. After the addition was complete, the reaction solution was stirred at 25°C under nitrogen for 2 hours. After the reaction was complete, the reaction solution was quenched with water (3 mL) and extracted with ethyl acetate (10 mL × 3). The combined organic phase was washed with saturated brine (10 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography (chromatographic conditions: column: spherical C18, 20-40 μm, 120 g; mobile phase A: pure water containing 0.1% NH3·H2O; mobile phase B: acetonitrile; flow rate: 80 mL / min; gradient: 40% B-100% B in 20 minutes; detector: 214 nm). When the mobile phase B content reached 82%, the fractions containing the product were collected and then concentrated under reduced pressure to give tert-butyl (3-(4-bromo-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)(4-(dimethylphosphoryl)-2-methoxyphenyl)carbamate (260 mg, 0.42 mmol, yield: 85.2%). LCMS m / z: 613 [M+H] + .

[0419] 5) Synthesis of tert-butyl (S)-(4-(dimethylphosphoryl)-2-methoxyphenyl)(3-(4-((6,6-dimethylpiperidin-3-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)carbamate:

[0420] At room temperature, to a solution of tert-butyl (3-(4-bromo-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)(4-(dimethylphosphoryl)-2-methoxyphenyl)carbamate (210 mg, 0.34 mmol) and (S)-6,6-dimethylpiperidin-3-amine hydrochloride (61 mg, 0.37 mmol) in dioxane (5 mL) was added. Cesium carbonate (1.11 g, 3.40 mmol), methanesulfonic acid (2-dicyclohexylphosphine)-3,6-dimethoxy-2',4',6'-triisopropyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl) palladium(II) (27 mg, 0.03 mmol), and 2-dicyclohexylphosphine-2',6'-diisopropyloxy-1,1'-biphenyl (14 mg, 0.03 mmol). After the addition was complete, the resulting reaction solution was stirred at 90°C under nitrogen for 2 hours. The reaction solution was filtered and concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography (chromatographic conditions: column: spherical C18, 20-40 μm, 120 g; mobile phase A: pure water containing 0.1% formic acid; mobile phase B: acetonitrile; flow rate: 80 mL / min; gradient: 40% B to 100% B in 20 minutes; detector: 214 nm). When the mobile phase B content reached 51%, the fractions containing the product were collected and then concentrated under reduced pressure to give tert-butyl (S)-(4-(dimethylphosphoryl)-2-methoxyphenyl)(3-(4-((6,6-dimethylpiperidin-3-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)carbamate (60 mg, 0.09 mmol, yield: 26.5%). LCMS m / z: 661 [M+H] + .

[0421] 6) Synthesis of (S)-(4-((3-(4-((6,6-dimethylpiperidin-3-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide (Compound 4):

[0422] To a solution of tert-butyl (S)-(4-(dimethylphosphoryl)-2-methoxyphenyl)(3-(4-((6,6-dimethylpiperidin-3-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)carbamate (60 mg, 0.09 mmol) in dichloromethane (5 mL) was added 2,6-lutidine (289 mg, 2.70 mmol) and iodotrimethylsilane (540 mg, 2.70 mmol). After the addition was complete, the reaction solution was stirred at room temperature for 1 hour. After the reaction was completed, the reaction solution was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography (chromatographic conditions: column: spherical C18, 20-40 μm, 40 g; mobile phase A: pure water containing 0.1% NH3·H2O; mobile phase B: acetonitrile; flow rate: 40 mL / min; gradient: 40% B to 95% B in 20 minutes; detector: 214 nm). When the mobile phase B content reached 73%, the fractions containing the product were collected and then concentrated under reduced pressure to give (S)-(4-((3-(4-((6,6-dimethylpiperidin-3-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-3-methoxyphenyl)dimethylphosphine oxide (Compound 4) (14.42 mg, 0.026 mmol, yield: 28.3%). LCMS m / z: 561 [M+H] + .

[0423] 1 H NMR (400MHz, DMSO-d6) δ7.23-7.18(m,1H),7.15-7.12(m,1H),7.05(s,1H),7.00(t,J=8.0Hz,1H),6.84 (dd,J=8.4Hz,3.2Hz,1H),6.69(d,J=8.4Hz,1H),6.17(d,J=8.0Hz,1H),6.03(t,J=6.4Hz,1H),5.49(d, J=8.0Hz,1H),4.93-4.86(m,2H),4.31(d,J=6.4Hz,2H),3.85(s,3H),3.43-3.35(m,2H),3.00-2.98(m, 1H),2.62-2.56(m,1H),1.83-1.80(m,1H),1.66-1.52(m,8H),1.42-1.36(m,1H),1.10(d,J=8.4Hz,6H).

[0424] 19 F NMR(400MHz,DMSO-d6)δ-69.18; 31 P NMR (400 MHz, DMSO-d6) δ 31.94.

[0425] Example 5. Synthesis of N-((3S,4R)-3-fluoropiperidin-4-yl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)benzo[d]oxazol-4-amine (Compound 5):

[0426] 1) Synthesis of tert-butyl (3S, 4R)-4-(benzo[d]oxazol-4-ylamino)-3-fluoropiperidine-1-carboxylate

[0427] To a solution of 4-bromobenzo[d]oxazole (500 mg, 2.53 mmol) and tert-butyl (3S,4R)-4-amino-3-fluoropiperidine-1-carboxylate (663 mg, 3.04 mmol) in dioxane (30 mL) at room temperature were added cesium carbonate (8.25 g, 25.30 mmol), methanesulfonic acid (2-dicyclohexylphosphino)-3,6-dimethoxy-2',4',6'-triisopropyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) (227 mg, 0.25 mmol), and 2-dicyclohexylphosphino-2',6'-diisopropyloxy-1,1'-biphenyl (117 mg, 0.25 mmol). The resulting reaction mixture was heated at 90°C under nitrogen and stirred for 3 hours. The slurry was then concentrated under reduced pressure. The residue was purified by reverse-phase flash chromatography (chromatographic conditions: column: spherical C18, 20-40 μm, 120 g; mobile phase A: pure water containing 0.1% NH3·H2O; mobile phase B: acetonitrile; flow rate: 80 mL / min; gradient: 30% B to 95% B over 20 minutes; detector: 214 nm). Fractions containing the product were collected when the mobile phase B content reached 63%, and then concentrated under reduced pressure to provide tert-butyl (3S,4R)-4-(benzo[d]oxazol-4-ylamino)-3-fluoropiperidine-1-carboxylate (200 mg, 0.60 mmol, yield: 23.6%). LCMS m / z: 336 [M+H] + .

[0428] 2) Synthesis of tert-butyl (3S, 4R)-3-fluoro-4-((2-iodobenzo[d]oxazol-4-yl)amino)piperidine-1-carboxylate:

[0429] To a solution of tert-butyl (3S,4R)-4-(benzo[d]oxazol-4-ylamino)-3-fluoropiperidine-1-carboxylate (200 mg, 0.60 mmol) in N,N-dimethylformamide (10 mL) was added a solution of 1,1,1,2,2,3,3,4,4-nonafluoro-4-iodobutane (415 mg, 1.20 mmol) and sodium tert-butoxide (173 mg, 1.80 mmol) in N,N-dimethylformamide (10 mL) at room temperature. The resulting mixed reaction solution was stirred at room temperature for 30 minutes. The resulting mixed reaction solution was quenched with saturated ammonium chloride solution (20 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic phases were washed with saturated ammonium chloride (20 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography (chromatographic conditions: column: spherical C18, 20-40 μm, 120 g; mobile phase A: pure water containing 0.1% NH3·H2O; mobile phase B: acetonitrile; flow rate: 80 mL / min; gradient: 30% B to 95% B in 20 minutes; detector: 214 nm). When the mobile phase B content reached 76%, the fractions containing the product were collected and concentrated under reduced pressure to give tert-butyl (3S,4R)-3-fluoro-4-((2-iodobenzo[d]oxazol-4-yl)amino)piperidine-1-carboxylate (150 mg, 0.33 mmol, yield: 54.5%). LCMS m / z: 462 [M+H] + .

[0430] 3) Synthesis of tert-butyl (3S,4R)-4-((2-(3-((tert-butoxycarbonyl)(2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)benzo[d]oxazol-4-yl)amino)-3-fluoropiperidine-1-carboxylate:

[0431] To a solution of tert-butyl (3S,4R)-3-fluoro-4-((2-iodobenzo[d]oxazol-4-yl)amino)piperidine-1-carboxylate (50 mg, 1.11 mmol) and tert-butyl (2-methoxy-4-(methylsulfonyl)phenyl)(prop-2-yn-1-yl)carbamate (75 mg, 0.22 mmol) in triethylamine (10 mL) was added cuprous iodide (4 mg, 0.02 mmol) and bistriphenylphosphine palladium dichloride (8 mg, 0.011 mmol) at room temperature. The resulting mixed reaction solution was stirred at 30°C under nitrogen for 3 hours. The mixed reaction solution was quenched with water (5 mL) and extracted with ethyl acetate (10 mL × 3). The combined organic phase was washed with saturated brine (10 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography (chromatographic conditions: column: spherical C18, 20-40 μm, 120 g; mobile phase A: 0.1% NH3·H2O in water; mobile phase B: acetonitrile; flow rate: 80 mL / min; gradient: 30% B to 95% B in 20 minutes; detector: 214 nm). When the mobile phase B content reached 68%, the fractions containing the product were collected and concentrated under reduced pressure to give tert-butyl (3S,4R)-4-((2-(3-((tert-butoxycarbonyl)(2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)benzo[d]oxazol-4-yl)amino)-3-fluoropiperidine-1-carboxylate (30 mg, 0.04 mmol, yield: 41.1%). LCMS m / z: 673 [M+H] + .

[0432] 4) Synthesis of N-((3S,4R)-3-fluoropiperidin-4-yl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)benzo[d]oxazol-4-amine (Compound 5):

[0433] To a solution of tert-butyl (3S,4R)-4-((2-(3-((tert-butoxycarbonyl)(2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)benzo[d]oxazol-4-yl)amino)-3-fluoropiperidine-1-carboxylate (30 mg, 0.045 mmol) in dichloromethane (7 mL) was added 2,6-lutidine (128 mg, 1.20 mmol) and iodotrimethylsilane (240 mg, 1.20 mmol). The resulting reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography (chromatographic conditions: column: spherical C18, 20-40 μm, 40 g; mobile phase: pure water containing 0.1% NH3·H2O; mobile phase B: acetonitrile; flow rate: 40 mL / min; gradient: 40% B to 95% B in 20 minutes; detector: 214 nm). Fractions containing the product were collected when the mobile phase B content reached 47%, and then concentrated under reduced pressure to give N-((3S,4R)-3-fluoropiperidin-4-yl)-2-(3-((2-methoxy-4-(methylsulfonyl)phenyl)amino)prop-1-yn-1-yl)benzo[d]oxazol-4-amine (Compound 5) (6.49 mg, 0.014 mmol, yield: 30.7%). LCMS m / z: 473 [M+H] + .

[0434] 1 H NMR(400MHz, DMSO-d6)δ7.43(d,J=8.0Hz,1H),7.27(s,1H),7.19(t,J=8.0Hz,1H), 6.88-6.81(m,2H),6.66(d,J=8.0Hz,1H),6.59(t,J=5.6Hz,1H),5.71(d,J=8.8Hz,1 H),4.75-4.62(m,1H),4.42(d,J=6.0Hz,2H),4.05-3.9(m,1H),3.91(s,3H),3.17- 3.12(m,1H),3.09(s,3H),2.97-2.94(m,1H),2.82-2.58(m,3H),1.67-1.63(m,2H).

[0435] 19 F NMR(400MHz,DMSO-d6)δ-203.696

[0436] Example 6. Synthesis of (7-((3-((4-((3S,4R)-3-fluoropiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-2,3-dihydrobenzofuran-4-yl)dimethylphosphine oxide (Compound 6)

[0437] 1) Synthesis of tert-butyl (4-bromo-2,3-dihydrobenzofuran-7-yl)carbamate

[0438] A solution of 4-bromo-2,3-dihydrobenzofuran-7-amine (576 mg, 2.69 mmol) and di-tert-butyl dicarbonate (1.47 g, 6.73 mmol) in tetrahydrofuran (10 mL) was heated at 70°C and stirred for 16 hours. The mixed reaction solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 8 / 1) to give tert-butyl (4-bromo-2,3-dihydrobenzofuran-7-yl)carbamate (880 mg, crude product). LCMS m / z: 301 [M+H-56+41]. + .

[0439] 2) Synthesis of (7-amino-2,3-dihydrobenzofuran-4-yl)dimethylphosphine oxide

[0440] To a solution of tert-butyl (4-bromo-2,3-dihydrobenzofuran-7-yl)carbamate (830 mg, 2.64 mmol) and dimethylphosphine oxide (412 mg, 5.28 mmol) in N,N-dimethylformamide (10 mL) at room temperature were added potassium phosphate (1.68 g, 7.92 mmol), 4,5-bis(diphenylphosphino-9,9-dimethylxanthene) (151 mg, 0.26 mmol), and palladium acetate (43 mg, 0.26 mmol). The resulting reaction mixture was heated at 120°C under nitrogen and stirred for 16 hours. The reaction mixture was diluted with water (100 mL) and extracted with ethyl acetate (100 mL x 2). The combined organic phases were concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography (chromatographic conditions: column: spherical C18, 20-40 μm, 120 g; mobile phase A: pure water containing 0.1% formic acid; mobile phase B: acetonitrile; flow rate: 85 mL / min; gradient: 5% B-95% B in 30 minutes; detector: 254 nm). When the mobile phase B content reached 43%, the fractions containing the product were collected and concentrated under reduced pressure to give (7-amino-2,3-dihydrobenzofuran-4-yl)dimethylphosphine oxide (760 mg, crude product), LCMS m / z: 212 [M+H] + .

[0441] 3) Synthesis of tert-butyl (4-(dimethylphosphoryl)-2,3-dihydrobenzofuran-7-yl)carbamate

[0442] A solution of (7-amino-2,3-dihydrobenzofuran-4-yl)dimethylphosphine oxide (660 mg, 3.13 mmol) and di-tert-butyl dicarbonate (1.71 g, 7.83 mmol) in tetrahydrofuran (10 mL) was heated at 70° C. and stirred for 16 hours. The mixed reaction solution was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography (chromatographic conditions: column: spherical C18, 20-40 μm, 120 g; mobile phase A: pure water containing 0.1% formic acid; mobile phase B: acetonitrile; flow rate: 85 mL / min; gradient: 5% B-95% B in 30 minutes; detector: 254 nm). When the mobile phase B content reached 45%, the product fractions were collected and concentrated under reduced pressure to give tert-butyl (4-(dimethylphosphoryl)-2,3-dihydrobenzofuran-7-yl)carbamate (110 mg, 0.35 mmol, yield: 11.3%), LCMS m / z: 312 [M+H] + .

[0443] 4) Synthesis of tert-butyl (4-(dimethylphosphoryl)-2,3-dihydrobenzofuran-7-yl)(prop-2-yn-1-yl)carbamate

[0444] To a solution of tert-butyl (4-(dimethylphosphoryl)-2,3-dihydrobenzofuran-7-yl)carbamate (70 mg, 0.23 mmol) in N,N-dimethylformamide (5 mL) at room temperature was added 3-bromoprop-1-yne (137 mg, 1.15 mmol) and cesium carbonate (375 mg, 1.15 mmol). The resulting mixed reaction solution was heated at 80°C and stirred under nitrogen for 3 hours. The mixed reaction solution was quenched with water (50 mL) and extracted with ethyl acetate (20 mL x 3). The combined organic layers were concentrated under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane / methanol=20 / 1) to give tert-butyl (4-(dimethylphosphoryl)-2,3-dihydrobenzofuran-7-yl)(prop-2-yn-1-yl)carbamate (30 mg, 0.086 mmol, yield: 38.1%), LCMS m / z: 350 [M+H] + .

[0445] 6) Synthesis of tert-butyl (3-(4-bromo-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)propyl-2-yn-1-yl)(4-(dimethylphosphoryl)-2,3-dihydrobenzofuran-7-yl)carbamate

[0446] To a solution of tert-butyl (4-(dimethylphosphinoyl)-2,3-dihydrobenzofuran-7-yl)(prop-2-yn-1-yl)carbamate (100 mg, 0.29 mmol) and 4-bromo-2-iodo-1-(2,2,2-trifluoroethyl)-1H-indole (141 mg, 0.35 mmol) in dimethyl sulfoxide (2 mL) was added triethylamine (88 mg, 0.87 mmol), cuprous iodide (6 mg, 0.03 mmol), and tetrakis(triphenylphosphine)palladium (35 mg, 0.03 mmol) at room temperature. The resulting mixed reaction solution was heated at 30°C and stirred under nitrogen for 16 hours. The mixed reaction solution was quenched by adding water (50 mL) and extracted with ethyl acetate (20 mL x 2). The combined organic phases were concentrated under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane / methanol=10 / 1) to give tert-butyl (3-(4-bromo-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)propyl-2-yn-1-yl)(4-(dimethylphosphoryl)-2,3-dihydrobenzofuran-7-yl)carbamate (54 mg, 0.086 mmol, yield: 30.1%), LCMS m / z: 627 [M+H] + .

[0447] 7) Synthesis of tert-butyl (3S,4R)-4-((2-(3-((tert-butoxycarbonyl)(4-(dimethylphosphoryl)-2,3-dihydrobenzofuran-7-yl)amino)propyl-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)-3-fluoropiperidine-1-carboxylate

[0448] To a solution of tert-butyl (3-(4-bromo-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)propyl-2-yn-1-yl)(4-(dimethylphosphoryl)-2,3-dihydrobenzofuran-7-yl)carbamate (40 mg, 0.064 mmol) and tert-butyl (3S,4R)-4-amino-3-fluoropiperidine-1-carboxylate (17 mg, 0.077 mmol) in 1,4-dioxane (2 mL) was added cesium carbonate (62 mg, 0.19 mmol), Ruphos (3 mg, 0.006 mmol), and Brettphos Pd G3 (5 mg, 0.006 mmol) at room temperature. The resulting mixed reaction solution was heated at 90°C under nitrogen protection and stirred for 4 hours. The mixed reaction solution was concentrated under reduced pressure. The residue was purified by preparative thin layer chromatography (dichloromethane / methanol=20 / 1) to give tert-butyl (3S,4R)-4-((2-(3-((tert-butoxycarbonyl)(4-(dimethylphosphoryl)-2,3-dihydrobenzofuran-7-yl)amino)propyl-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)-3-fluoropiperidine-1-carboxylate (40 mg, 0.052 mmol, yield: 81.9%), LCMS m / z: 763 [M+H] + .

[0449] 8) Synthesis of (7-((3-((4-((3S,4R)-3-fluoropiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-2,3-dihydrobenzofuran-4-yl)dimethylphosphine oxide

[0450] At room temperature, trimethylsilyl iodide (156 mg, 0.78 mmol) was added to a solution of tert-butyl (3S,4R)-4-((2-(3-((tert-butoxycarbonyl)(4-(dimethylphosphoryl)-2,3-dihydrobenzofuran-7-yl)amino)propyl-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)-3-fluoropiperidine-1-carboxylate (20 mg, 0.036 mmol) and 2,6-lutidine (83 mg, 0.78 mmol) in dichloromethane (2 mL). The resulting mixed reaction solution was stirred at room temperature for 1 hour. The resulting mixed reaction solution was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography (chromatographic conditions: column: spherical C18, 20-40 μm, 40 g; mobile phase A: pure water containing 0.1% NH3·H2O; mobile phase B: acetonitrile; flow rate: 40 mL / min; gradient: 5% B-95% B in 30 minutes; detector: 214 nm). When the mobile phase B content reached 48%, the fractions containing the product were collected and concentrated under reduced pressure to obtain the crude product. The crude product was purified by preparative thin layer chromatography (dichloromethane / methanol = 20 / 1) to give (7-((3-((4-((3S,4R)-3-fluoropiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino)-2,3-dihydrobenzofuran-4-yl)dimethylphosphine oxide (3.05 mg, 0.005 mmol, yield: 20.6%), LCMS m / z: 563 [M+H] + .

[0451] 1 H NMR(400MHz,CD3OD)7.14-7.06(m,2H),6.90(s,1H),6.82-6.73(m,2H),6.37(d, J=8.0Hz,1H),4.94(s,1H),4.77-4.70(m,2H),4.64(t,J=8.8Hz,2H),4.34(s,2H ),3.88-3.76(m,1H),3.46-3.39(m,2H),3.23-3.19(m,1H),3.13-2.94(m,1H),2 .91-2.83(m,1H),2.04-1.95(m,1H),1.93-1.88(m,2H),1.75(d,J=13.2Hz,6H).

[0452] 19 F NMR(377MHz,CD3OD)δ-71.76,-206.61.

[0453] 31 P NMR (162 MHz, CD3OD) δ 41.10.

[0454] Example 7. Synthesis of N-((3S,4R)-3-fluoropiperidin-4-yl)-2-((4-(methylsulfonyl)-2,3-dihydrobenzofuran-7-yl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine (Compound 7)

[0455] 1) Synthesis of 4-bromo-2,3-dihydrobenzofuran-7-amine

[0456] A solution of 2,3-dihydrobenzofuran-7-amine (2.50 g, 18.52 mmol) and N-bromosuccinimide (3.63 g, 20.37 mmol) in N,N-dimethylformamide (30 mL) was stirred at room temperature for 16 hours. The mixed reaction solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 10 / 1) to give 4-bromo-2,3-dihydrobenzofuran-7-amine (2.64 g, 12.34 mmol, yield: 66.6%), LCMS m / z: 216 [M+H] + .

[0457] 2) Synthesis of 4-(methylsulfonyl)-2,3-dihydrobenzofuran-7-amine

[0458] At room temperature, L-proline (269 mg, 2.34 mmol) and cuprous iodide (445 mg, 2.34 mmol) were added to a solution of 2-bromo-2,3-dihydrobenzofuran-7-amine (500 mg, 2.34 mmol) and sodium NaSO2Me methylsulfinate (358 mg, 3.51 mmol) in dimethyl sulfoxide (5 mL). The resulting mixed reaction solution was heated at 110°C and stirred for 16 hours under nitrogen protection. The mixed reaction solution was decompressed and the solvent was removed. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 1) to give 4-(methylsulfonyl)-2,3-dihydrobenzofuran-7-amine (250 mg, 1.17 mmol, yield: 50.2%), LCMS m / z: 214 [M+H] + .

[0459] 3) Synthesis of tert-butyl (4-(methylsulfonyl)-2,3-dihydrobenzofuran-7-yl)carbamate

[0460] A solution of 4-(methylsulfonyl)-2,3-dihydrobenzofuran-7-amine (200 mg, 0.94 mmol) and di-tert-butyl dicarbonate (615 mg, 2.82 mmol) in 14-dioxane (5 mL) was heated at 110° C. and stirred for 16 hours. The mixed reaction solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 1) to give tert-butyl (4-(methylsulfonyl)-2,3-dihydrobenzofuran-7-yl)carbamate (120 mg, 0.38 mmol, yield: 40.8%), LCMS m / z: 299 [M+H-56+41]. + .

[0461] 3) Synthesis of tert-butyl (4-(methylsulfonyl)-2,3-dihydrobenzofuran-7-yl)(prop-2-yn-1-yl)carbamate

[0462] At 0°C, sodium hydride (60% by mass dispersed in mineral oil, 77 mg, 1.92 mmol) was added to a solution of tert-butyl (4-(methylsulfonyl)-2,3-dihydrobenzofuran-7-yl)carbamate (150 mg, 0.48 mmol) in tetrahydrofuran (5 mL). The resulting mixed reaction solution was stirred at 0°C for 30 minutes, and then 3-bromo-1-alkyne (286 mg, 2.40 mmol) was slowly added at 0°C. The resulting mixed reaction solution was protected by nitrogen and heated to 70°C with stirring for 16 hours. The mixed reaction solution was quenched with saturated aqueous ammonium chloride (50 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic phases were washed with saturated brine (50 mL × 3). The combined organic phases were concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 2 / 1) to give tert-butyl (4-(methylsulfonyl)-2,3-dihydrobenzofuran-7-yl)(prop-2-yn-1-yl)carbamate (100 mg, 0.285 mmol, yield: 59.5%), LCMS m / z: 296 [M+H-56] + .

[0463] 3) Synthesis of tert-butyl (3-(4-bromo-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)propyl-2-yn-1-yl)(4-(methylsulfonyl)-2,3-dihydrobenzofuran-7-yl)carbamate

[0464] At room temperature, triethylamine (86 mg, 0.855 mmol, 3.0 equivalents) and cuprous iodide (6 mg, 0.03 mmol) and tetrakis(triphenylphosphine)palladium (35 mg, 0.03 mol) were added to a solution of tert-butyl (4-(methylsulfonyl)-2,3-dihydrobenzofuran-7-yl)(prop-2-yn-1-yl)carbamate (100 mg, 0.285 mmol) and 4-bromo-2-iodo-1-(2,2,2-trifluoroethyl)-1H-indole (138 mg, 0.342 mmol) in dimethyl sulfoxide (5 mL). The resulting mixed reaction solution was heated at 30°C under nitrogen protection and stirred for 5 hours. The mixed reaction solution was quenched with saturated ammonium chloride (50 mL) and extracted with ethyl acetate (20 mL × 2). The combined organic phases were washed with saturated brine (50 mL × 3). The combined organic phases were concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 1) to give a crude product. The crude product was purified by reverse phase flash chromatography (chromatographic conditions: column: spherical C18, 20-40 μm, 40 g; mobile phase A: pure water containing 0.1% formic acid; mobile phase B: acetonitrile; flow rate: 40 mL / min; gradient: 5% B-95% B in 30 minutes; detector: 214 nm). When the mobile phase B content reached 52%, the fractions containing the desired product were collected and concentrated under reduced pressure to give tert-butyl (3-(4-bromo-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)propyl-2-yn-1-yl)(4-(methylsulfonyl)-2,3-dihydrobenzofuran-7-yl)carbamate (50 mg, 0.080 mmol, yield: 27.9%), LCMS m / z: 650 [M+23]. + ,

[0465] 5) Synthesis of tert-butyl (3S,4R)-4-((2-(3-((tert-butoxycarbonyl)(4-(methylsulfonyl)-2,3-dihydrobenzofuran-7-yl)amino)propyl-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)-3-fluoropiperidine-1-carboxylate

[0466] To a solution of tert-butyl (3-(4-bromo-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)propyl-2-yn-1-yl)(4-(methylsulfonyl)-2,3-dihydrobenzofuran-7-yl)carbamate (50 mg, 0.080 mmol) and tert-butyl (3S,4R)-4-amino-3-fluoropiperidine-1-carboxylate (35 mg, 0.16 mmol) in 1,4-dioxane (2 mL) was added C cesium carbonate (52 mg, 0.16 mmol), Ruphos (7 mg, 0.016 mmol), and Brettphos Pd G3 (7 mg, 0.008 mmol) at room temperature. The resulting mixed reaction solution was heated at 90°C under nitrogen protection and stirred for 3 hours. The mixed reaction solution was concentrated under reduced pressure. The residue was purified by preparative thin layer chromatography (petroleum ether / ethyl acetate = 1 / 2) to give tert-butyl (3S,4R)-4-((2-(3-((tert-butoxycarbonyl)(4-(methylsulfonyl)-2,3-dihydrobenzofuran-7-yl)amino)propyl-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)-3-fluoropiperidine-1-carboxylate (50 mg, 0.065 mmol, yield: 81.9%), LCMS m / z: 765 [M+H] + .

[0467] 6) Synthesis of N-((3S,4R)-3-fluoropiperidin-4-yl)-2-((4-(methylsulfonyl)-2,3-dihydrobenzofuran-7-yl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indole-4-amine

[0468] To a solution of tert-butyl (3S,4R)-4-((2-(3-((tert-butoxycarbonyl)(4-(methylsulfonyl)-2,3-dihydrobenzofuran-7-yl)amino)propyl-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)-3-fluoropiperidine-1-carboxylate (50 mg, 0.065 mmol) and 2,6-lutidine (139 mg, 1.30 mmol) in dichloromethane (3 mL) was added trimethylsilyl iodide (260 mg, 1.30 mmol). The resulting mixed reaction solution was stirred at room temperature for 2 hours. The resulting mixed reaction solution was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography (chromatographic conditions: column: spherical C18, 20-40 μm, 40 g; mobile phase A: pure water containing 0.1% NH3·H2O; mobile phase B: acetonitrile; flow rate: 40 mL / min; gradient: 5% B-95% B in 30 minutes; detector: 214 nm). When the mobile phase B content reached 61%, the fractions containing the product were collected and concentrated under reduced pressure to give N-((3S,4R)-3-fluoropiperidin-4-yl)-2-((4-(methylsulfonyl)-2,3-dihydrobenzofuran-7-yl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine (10.01 mg, 0.018 mmol, yield: 27.1%), LCMS m / z: 565 [M+H] + ;

[0469] 1 H NMR (400MHz, DMSO-d6)7.23(d,J=8.4Hz,1H),7.19(s,1H),7.01(t,J=8.0Hz,1H),6.79(d,J=8.8Hz,1H),6.74(d ,J=8.4Hz,1H),6.40(t,J=6.0Hz,1H),6.26(d,J=8.0Hz,1H),5.53(d,J=8.8Hz,1H),4.95-4.93(m,2H),4.82-4.6 9(m,1H),4.64(t,J=8.8Hz,2H),4.33(d,J=6.4Hz,2H),3.76-3.63(m,1H),3.46(t,J=8.8Hz,2H),3.21-3.15(m,1 H),3.06(s,3H),3.03-3.00(m,1H),2.91-2.78(m,1H),2.68-2.62(m,1H),1.82-1.72(m,1H),1.68-1.65(m,1H).

[0470] 19F NMR(377MHz,DMSO-d6)δ-69.16,-202.80.

[0471] Example 8. Synthesis of N-((3S,4R)-3-fluoropiperidin-4-yl)-2-(3-(((4-(methylsulfonyl)benzofuran-7-yl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine (Compound 8)

[0472] 1) Synthesis of tert-butyl (4-(methylsulfonyl)benzofuran-7-yl)carbamate

[0473] To a solution of tert-butyl 4-(methylsulfonyl)-2,3-dihydrobenzofuran-7-yl)carbamate (280 mg, 0.89 mmol) in carbon tetrachloride (10 mL) at room temperature were added N-bromosuccinimide (191 mg, 1.07 mmol) and azobisisobutyronitrile (3 mg, 0.02 mmol). The resulting mixed reaction solution was heated at 85°C and stirred for 1 hour. The mixed reaction solution was diluted with dichloromethane (10 mL) and washed with saturated sodium bicarbonate aqueous solution (10 mL) and saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1 / 1) to give tert-butyl (4-(methylsulfonyl)benzofuran-7-yl)carbamate (100 mg, 0.32 mmol, yield: 36.0%), LCMS m / z: 297 [M+H-56+41]. + .

[0474] 2) Synthesis of tert-butyl (4-(methylsulfonyl)benzofuran-7-yl)(prop-2-yn-1-yl)carbamate

[0475] At room temperature, to a solution of N, N-dimethylformamide (8 mL) dissolved with tert-butyl (4- (methylsulfonyl) benzofuran-7-yl) carbamate (80 mg, 0.26 mmol), 3-bromoprop-1-yne (92 mg, 0.77 mmol) and cesium carbonate (252 mg, 0.77 mmol) were added. The mixed reaction solution was heated at 80 ° C and stirred for 2 hours. The mixed reaction solution was quenched with water (10 mL) and extracted with ethyl acetate (10 mL × 3). The combined organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 2 / 1) to give tert-butyl 4- (methylsulfonyl) benzofuran-7-yl) (prop-2-yn-1-yl) carbamate (120 mg, crude product), LCMS m / z: 335 [M + H-56 + 41]+ .

[0476] 3) Synthesis of tert-butyl (3-(4-bromo-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)(4-(methylsulfonyl)benzofuran-7-yl)carbamate

[0477] To a solution of tert-butyl (4-(methylsulfonyl)benzofuran-7-yl)(prop-2-yn-1-yl)carbamate (100 mg, 0.29 mmol) and 4-bromo-2-iodo-1-(2,2,2-trifluoroethyl)-1H-indole (139 mg, 0.34 mmol) in dimethyl sulfoxide (10 mL) was added triethylamine (87 mg, 0.86 mmol), cuprous iodide (5 mg, 0.03 mmol) and tetrakis(triphenylphosphine)palladium (33 mg, 0.03 mmol) at room temperature. The mixed reaction solution was heated at 30°C under nitrogen protection and stirred for 2 hours. The mixed reaction solution was quenched by adding water (10 mL) and extracted with ethyl acetate (10 mL × 3). The combined organic phase was washed with saturated brine (5 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 2 / 1) to give tert-butyl (3-(4-bromo-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)(4-(methylsulfonyl)benzofuran-7-yl)carbamate (180 mg, crude product). LCMS: m / z: 627 [M+H] + .

[0478] 4) Synthesis of tert-butyl (3S,4R)-4-((2-(3-((tert-butoxycarbonyl)(4-(methylsulfonyl)benzofuran-7-yl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)-3-fluoropiperidine-1-carboxylate

[0479] To a solution of tert-butyl (3-(4-bromo-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)(4-(methylsulfonyl)benzofuran-7-yl)carbamate (160 mg, 0.26 mmol) and tert-butyl (3S,4R)-4-amino-3-fluoropiperidine-1-carboxylate (61 mg, 0.28 mmol) in 1,4-dioxane (10 mL) was added cesium carbonate (834 mg, 2.56 mmol), Ruphos (12 mg, 0.03 mmol), and Brettphos Pd G3 (23 mg, 0.03 mmol) at room temperature. The mixed reaction solution was heated at 90°C under nitrogen protection and stirred for 2 hours. The mixed reaction solution was filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 2 / 1) to give tert-butyl (3S,4R)-4-((2-(3-((tert-butoxycarbonyl)(4-(methylsulfonyl)benzofuran-7-yl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)-3-fluoropiperidine-1-carboxylate (100 mg, 0.13 mmol, yield: 51.3%), LCMS m / z: 763 [M+H] + .

[0480] 5) Synthesis of N-((3S,4R)-3-fluoropiperidin-4-yl)-2-(3-(((4-(methylsulfonyl)benzofuran-7-yl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indole-4-amine

[0481] To a solution of tert-butyl (3S,4R)-4-((2-(3-((tert-butoxycarbonyl)(4-(methylsulfonyl)benzofuran-7-yl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)-3-fluoropiperidine-1-carboxylate (100 mg, 0.13 mmol) in dichloromethane (10 mL) at 0°C was added 2,6-lutidine (421 mg, 3.93 mmol) and iodotrimethylsilane (786 mg, 3.93 mol). The reaction mixture was stirred at room temperature for 1 hour. The resulting reaction mixture was concentrated under reduced pressure. The residue was purified by preparative HPLC using the following conditions: Column: Spherical C18, 20-40 μm, 80 g; Mobile phase A: Pure water containing 0.1% NH3·H2O; Mobile phase B: Acetonitrile; Flow rate: 40 mL / min; Gradient: 5% B to 60% B over 12 minutes; Detector: 254 nm. Fractions containing the desired product were collected at 47.5% B and concentrated under reduced pressure to yield N-((3S,4R)-3-fluoropiperidin-4-yl)-2-(3-(((4-(methylsulfonyl)benzofuran-7-yl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-amine (32.18 mg, 0.06 mmol, 43.6% yield); LCMS m / z: 563 [M+H]. + .

[0482] 1 H NMR (400MHz, DMSO-d6)8.19(d,J=2.0Hz,1H),7.61(d,J=8.4Hz,1H),7.39(t,J=6.0Hz,1H),7.20(s,1H ),7.16(d,J=2.0Hz,1H),7.00(t,J=8.0Hz,1H),6.87(d,J=8.4Hz,1H),6.72(d,J=8.0Hz,1H),6.25(d, J=8.0Hz,1H),5.51-5.48(m,1H),4.96-4.90(m,2H),4.77-4.65(m,1H),4.48(d,J=6.4Hz,2H),3.72-3 .61(m,1H),3.11(s,3H),2.99-2.95(m,1H),2.83-2.70(m,1H),2.63-2.57(m,2H),1.74-1.62(m,2H).

[0483] Example 9. Synthesis of (7-((3-(4-(((3S,4R)-3-fluoropiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino]benzofuran-4-yl)dimethylphosphine oxide (Compound 9)

[0484] 1) Synthesis of tert-butyl (4-(dimethylphosphoryl)benzofuran-7-yl)carbamate

[0485] At room temperature, NBS (232 mg, 1.30 mmol) and AIBN (3 mg, 0.02 mmol) were added to a solution of tert-butyl (4-(dimethylphosphoryl)-2,3-dihydrobenzofuran-7-yl)carbamate (270 mg, 0.87 mmol) in carbon tetrachloride (30 mL). The mixed reaction solution was heated at 85 ° C and stirred for 1 hour. The mixed reaction solution was diluted with dichloromethane (10 mL), washed with saturated sodium bicarbonate (20 mL) and saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane / methanol = 20 / 1) to give tert-butyl (4-(dimethylphosphoryl)benzofuran-7-yl)carbamate (180 mg, 0.58 mmol, yield: 67.2%), LCMS m / z: 310 [M+H] + .

[0486] 2. Synthesis of tert-butyl (4-(dimethylphosphoryl)benzofuran-7-yl)(prop-2-yn-1-yl)carbamate

[0487] To a solution of tert-butyl (4-(dimethylphosphoryl)benzofuran-7-yl)carbamate (160 mg, 0.52 mmol) in N,N-dimethylformamide (20 mL) was added 3-bromoprop-1-yne (185 mg, 1.55 mmol) and Cs2CO3 (506 mg, 1.55 mmol) at room temperature. The resulting mixed reaction solution was heated at 80°C and stirred for 2 hours. The mixed reaction solution was quenched with water (20 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (dichloromethane / methanol=20 / 1) to give tert-butyl (4-(dimethylphosphoryl)benzofuran-7-yl)(prop-2-yn-1-yl)carbamate (160 mg, 0.46 mmol, yield: 89.3%), LCMS m / z: 348 [M+H] + .

[0488] 3. Synthesis of tert-butyl (3-(4-bromo-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)(4-(dimethylphosphoryl)benzofuran-7-yl)carbamate

[0489] To a solution of 4-(dimethylphosphoryl)benzofuran-7-yl)(prop-2-yn-1-yl)benzofuraldehyde-7-yl(prop-2-ethyn-1-yl)carbamate (140 mg, 0.40 mmol) and 4-bromo-2-iodo-1-(2,2,2-trifluoroethyl)-1H-indole (196 mg, 0.48 mmol) in dimethyl sulfoxide (10 mL) was added triethylamine (122 mg, 1.21 mmol), cuprous iodide (8 mg, 0.04 mmol), and tetrakis(triphenylphosphine)palladium (47 mg, 0.04 mmol) at room temperature. The resulting mixed reaction solution was heated at 30°C under nitrogen and stirred for 2 hours. The mixed reaction solution was quenched with water (20 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic phases were washed with saturated brine (10 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane / methanol=20 / 1) to give tert-butyl (3-(4-bromo-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)(4-(dimethylphosphoryl)benzofuran-7-yl)carbamate (210 mg, 0.34 mmol, yield: 83.7%), LCMS m / z: 625 [M+H + .

[0490] 4) Synthesis of tert-butyl (3S,4R)-4-((2-(3-((tert-butoxycarbonyl)(4-(dimethylphosphoryl)benzofuran-7-yl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-yl)amino)-3-fluoropiperidine-1-carboxylate

[0491] To a solution of tert-butyl (3-(4-bromo-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)(4-(dimethylphosphoryl)benzofuran-7-yl)carbamate (190 mg, 0.30 mmol) and tert-butyl (3S,4R)-4-amino-3-fluoropiperidine-1-carboxylate (73 mg, 0.34 mmol) in 1,4-dioxane (20 mL) was added cesium carbonate (994 mg, 3.05 mmol), Ruphos (14 mg, 0.03 mmol), and Brettphos Pd G3 (28 mg, 0.03 mmol) at room temperature. The mixed reaction solution was heated at 90°C under nitrogen protection and stirred for 2 hours. The mixed reaction solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane / methanol=20 / 1) to give tert-butyl (3S,4R)-4-((2-(3-((tert-butoxycarbonyl))(4-(dimethylphosphoryl)benzofuran-7-yl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-ylamino)-3-fluoropiperidine-1-carboxylate (135 mg, 0.18 mmol, yield: 58.2%), LCMS m / z: 761 [M+H]. + .

[0492] 5) Synthesis of (7-((3-(4-(((3S,4R)-3-fluoropiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino]benzofuran-4-yl)dimethylphosphine oxide

[0493] To a solution of tert-butyl (3S,4R)-4-((2-(3-((tert-butoxycarbonyl))(4-(dimethylphosphoryl)benzofuran-7-yl)amino)prop-1-yn-1-yl)-1-(2,2,2-trifluoroethyl)-1H-indol-4-ylamino)-3-fluoropiperidine-1-carboxylate (135 mg, 0.18 mmol) in dichloromethane (15 mL) was added 2,6-lutidine (569 mg, 5.32 mmol) and iodotrimethylsilane (1.064 g, 5.32 mmol) at 0°C. The resulting mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: column: spherical C18, 20-40 μm, 80 g; mobile phase A: water (0.1% NH3·H2O); mobile phase B: acetonitrile; flow rate: 40 mL / min; gradient: 5% B to 60% B over 12 minutes; detector: 254 nm. At 47.5% B, fractions containing the product were collected and concentrated under reduced pressure to yield (7-((3-(4-(((3S,4R)-3-fluoropiperidin-4-yl)amino)-1-(2,2,2-trifluoroethyl)-1H-indol-2-yl)prop-2-yn-1-yl)amino]benzofuran-4-yl)dimethylphosphine oxide (20.13 mg, 0.04 mmol, yield: 20.2%), LCMS m / z: 561 [M+H]. + .

[0494] 1 H NMR (400MHz, DMSO-d6) δ8.06(d,J=2.0Hz,1H),7.44(dd,J=12.0Hz,8.0Hz,1H),7.24(d,J=2.0Hz,1H),7.18(s,1H),7. 00(t,J=8.0Hz,1H),6.88(t,J=6.0Hz,1H),6.82-6.79(m,1H),6.72(d,J=8.4Hz,1H),6.24(d,J=7.6Hz,1H),5.48(d,J =8.8Hz,1H),4.94-4.87(m,2H),4.76-4.63(m,1H),4.43(d,J=6.4Hz,2H),3.70-3.61(m,1H),3.13-3.07(m,1H),2.98 -2.94(m,1H),2.82-2.67(m,1H),2.61-2.55(m,1H),1.73-1.69(m,1H),1.67(s,3H),1.64(s,3H),1.60-1.56(m,1H)..

[0495] 19F NMR(377MHz,DMSO-d6)δ-69.23,-202.48.

[0496] 31 P NMR (162 MHz, DMSO-d6) δ 30.90.

[0497] Example 10, Synthesis of (3S,4R)-3-fluoro-1-methyl-N-(2-(3-((4-(methylsulfonyl)-2H-spiro[benzofuran-3,1'-cyclopropane]-7-yl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)piperidin-4-amine (Compound 10):

[0498] To a solution of (3S,4R)-3-fluoro-N-(2-(3-((4-(methylsulfonyl)-2H-spiro[benzofuran-3,1'-cyclopropane]-7-yl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)piperidin-4-amine (70 mg, 0.12 mmol) in methanol (5 mL) was added TEA (48 mg, 0.48 mmol), MgSO (86 mg, 0.72 mmol), para.HCHO (14 mg, 0.48 mmol), and NaBHCN (30 mg, 0.48 mmol) at 0°C and stirred for 2 hours. LCMS showed the reaction was complete, and the reaction mixture was concentrated under reduced pressure. The residue was purified by pre-HPLC (chromatographic conditions: Waters 3767 / QDA, column: SunFire SunFire C18, 19*250 mm, 10 um; mobile phase A: 0.1% NH4CO3 / H2O, mobile phase B: acetylacetone; flow rate: 20 mL / min; gradient: 42% to 45%; retention time: 6.3-7.1 min, 17 min) to give (3S,4R)-3-fluoro-1-methyl-N-(2-(3-((4-(methylsulfonyl)-2H-spiro[benzofuran-3,1'-cyclopropane]-7-yl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)piperidin-4-amine (19.17 mg, 0.031 mmol, yield: 25.8%). LCMS m / z:622[M+H] + .

[0499] 1H NMR (400MHz, DMSO-d6) δ7.27(t,J=7.6Hz,2H),7.21(d,J=8.0Hz,1H),6.79(dd,J=7.6,5.2Hz,2H),6.45(t, J=6.0Hz,1H),5.16(d,J=8.4Hz,1H),4.79(d,J=49.2Hz,1H),4.48-4.30(m,4H),3.82(q,J=11.2Hz,2H),3.6 5(d,J=28.0Hz,1H),3.12-2.97(m,4H),2.79(d,J=10.0Hz,1H),2.29(t,J=15.2Hz,1H),2.17(d,J=9.6Hz,3H ),2.08(t,J=11.2Hz,1H),1.94(dd,J=22.5,11.6Hz,1H),1.71(d,J=11.2Hz,1H),1.65(s,2H),0.94(s,2H). 19 F NMR(377MHz,DMSO-d6)δ-63.063,-199.274.

[0500] Example 11, Synthesis of (3S,4R)-3-fluoro-N-(2-(3-((4-(methylsulfonyl)-2H-spiro[benzofuran-3,1'-cyclopropane]-7-yl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)piperidin-4-amine (Compound 11):

[0501] 1) Synthesis of 4-(methylsulfonyl)-2H-spiro[benzofuran-3,1'-cyclopropane]-7-amine:

[0502] 4-Iodo-2H-spiro[benzofuran-3,1'-cyclopropane]-7-amine (620 mg, 2.16 mmol), CH3S2Ona (1.10 g, 10.80 mmol), L-proline (248 mg, 2.16 mmol), and CuI (410 mg, 2.16 mmol) were dissolved in DMF (20 mL) and heated at 130°C with stirring for 16 hours. LCMS indicated the reaction was complete. H2O (20 mL) was added to the reaction mixture, and the mixture was extracted with EA (10 mL x 3). The combined organic phases were washed with saturated brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (DCM:MeOH=10:1, 254 nm) to give 4-(methylsulfonyl)-2H-spiro[benzofuran-3,1'-cyclopropane]-7-amine (320 mg, 1.34 mmol, yield: 61.9%), LCMS m / z: 240 [M+H] + .

[0503] 2) Synthesis of 4-(methylsulfonyl)-N-(prop-2-yn-1-yl)-2H-spiro[benzofuran-3,1'-cyclopropane]-7-amine

[0504] A solution of (4-(methylsulfonyl)-2H-spiro[benzofuran-3,1'-cyclopropane]-7-amine (270 mg, 1.13 mmol), 3-bromo-1-propyne (673 mg, 5.65 mmol) and K2CO3 (172 mg, 1.24 mmol) in DMF (15 mL) was heated at 75°C and stirred for 2 hours. LCMS showed 44% of the product. H2O (10 mL) was added to the reaction mixture to dilute it and extract it with EA (10 mL×3). The combined organic layers were washed with saturated brine (20 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (DCM:MeOH=10: 1,254 nm) was purified to give 4-(methylsulfonyl)-N-(prop-2-yn-1-yl)-2H-spiro[benzofuran-3,1′-cyclopropane]-7-amine (210 mg, 0.76 mmol, yield: 67.1%), LCMS m / z: 278 [M+H] + .

[0505] 3) Synthesis of N-(3-(7-bromo-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)-4-(methylsulfonyl)-2H-spiro[benzofuran-3,1'-cyclopropane]-7-amine

[0506] To a solution of 4-(methylsulfonyl)-N-(prop-2-yn-1-yl)-2H-spiro[benzofuran-3,1'-cyclopropane]-7-amine (210 mg, 0.76 mmol) and 7-bromo-2-iodo-3-(2,2,2-trifluoroethyl)benzothiophene (383 mg, 0.91 mmol) in DMSO (5 mL) was added CuI (14 mg, 0.076 mmol), Pd(PPh3)4 (88 mg, 0.076 mmol), and TEA (231 mg, 2.28 mmol) at room temperature. The mixture was stirred at 25°C for 16 hours. LCMS indicated the reaction was complete. H2O (15 mL) was added to the reaction mixture, and the mixture was extracted with EA (15 mL x 3). The combined organic layers were washed with saturated brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (DCM:MeOH=10:1, 254 nm) to give N-(3-(7-bromo-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)-4-(methylsulfonyl)-2H-spiro[benzofuran-3,1'-cyclopropane]-7-amine (200 mg, 0.35 mmol, yield: 46.2%), LCMS m / z: 570 [M+H] + .

[0507] 4) Synthesis of tert-butyl (3S,4R)-3-fluoro-4-((2-(3-((4-(methylsulfonyl)-2H-spiro[benzofuran-3,1'-cyclopropane]-7-yl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)amino)piperidine-1-carboxylate

[0508] To a solution of N-(3-(7-bromo-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-2-yl)prop-2-yn-1-yl)-4-(methylsulfonyl)-2H-spiro[benzofuran-3,1'-cyclopropane]-7-amine (330 mg, 0.58 mmol) and tert-butyl (3S,4R)-4-amino-3-fluoropiperidine-1-carboxylate (252 mg, 1.16 mmol) in 1,4-dioxane (5.0 mL) were added Ruphos (54 mg, 0.116 mmol), Brettphos Pd G3 (105 mg, 0.116 mmol), and Cs2CO3 (943 mg, 1.74 mmol) at room temperature, and the mixture was heated at 100°C with stirring for 2 hours. LCMS showed that the reaction was complete. H2O (5 mL) was added to the reaction mixture and extracted with EA (5 mL x 3). The combined organic phases were washed with saturated brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (DCM:MeOH = 10:1, 254 nm) to give tert-butyl (3S,4R)-3-fluoro-4-((2-(3-((4-(methylsulfonyl)-2H-spiro[benzofuran-3,1'-cyclopropane]-7-yl)amino)prop-1-yn-1-yl)-3-(2,2,2-trifluoroethyl)benzo[b]thiophen-7-yl)amino)piperidine-1-carboxylate (200 mg, 0.28 mmol, yield: 48.7%), LCMS m / z: 652 [M+H-56]. + .

[0509] 5) Synthesis of (3S,4R)-3-fluoro-N-(2-(3-((4-(methylsulfonyl)-2H-spiro[benzofuran-3,...

Claims

1. A compound represented by formula (I), a pharmaceutically acceptable salt, solvate, enantiomer or isotope-substituted product thereof, in, Ring B arbitrarily represents a 3-20 membered cyclic structure, which may be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure may be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring, or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; Z3 is independently selected from the group consisting of absence, a single bond, -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic group, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z3 is further optionally substituted with 1 to more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluorosulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 Alkoxy; X1, X2 are independently selected from N or CR; Each R1 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, -SH and -NH2, -COOH, amide or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamide, methylsulfonylamino or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute or M group; and the hydrogen on R1 is optionally replaced by 1 to more selected from H, deuterium, halogen, pentafluoride sulfur, OCH3, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 or any two adjacent R1s together with the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, or a 5-30 membered saturated or partially saturated heterocyclic group, and the hydrogen atoms on the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group are optionally selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 The hydrogen on R1 is optionally replaced by one or more selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; Each R2 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, amino, hydroxyl, mercapto, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10 Alkylamino, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamide, N,N-di(C 1-10 Alkyl)amino, C 1-10 Alkyloxy, C 1-10 Alkyl acyl, C 1-10 Alkyloxy, C 1-10 Alkylsulfonyl, C 1-10 Alkylsulfinyl, C 3-10 Cycloalkylamino, C3-10 heterocycloalkylamino, C 3-10 Cycloalkoxy, C 3-10 Heterocycloalkoxy, C 3-10 Cycloalkyl acyl, C 3-10 Cycloalkoxyacetyl, C 3-10 Cycloalkylsulfonyl and C 3-10 Cycloalkylsulfinyl, -YQ or M group; or optionally two R2 can form a 5-6 membered aryl or heteroaryl group together with the atoms to which they are attached, a 3-8 membered saturated or partially saturated cycloalkyl group, a 3-8 membered saturated or partially saturated heterocyclic group, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic group is optionally substituted by one or more groups selected from hydrogen, deuterium, alkyl, halogen, pentafluoride sulfur group, oxo, CN, CF3, OH, OCH3, OCH2CH3; and the hydrogen on R2 is optionally substituted by one or more groups selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 Cycloalkyl or heterocycloalkyl substitution; M is arbitrarily and independently selected from Z is independently selected from the group consisting of absent, C(R d1 )(R d2 ), O, NR d1 ,-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-、-N(R d7 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic group, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z1 and Z2 is further optionally substituted by 1 to more substituents, wherein the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluorosulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1- 3 alkyl, C 1-3 Alkoxy; Y is arbitrarily and independently selected from O, S or NR; Q arbitrarily represents a 3-20 membered cyclic structure, which may be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure may be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; and the hydrogen on the ring Q is optionally preferably replaced by one or more selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, alkyl, alkenyl, alkynyl, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; Each R may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, haloalkyl, haloalkoxy, deuterated alkyl, deuterated alkoxy, -OH, -SH and -NH2, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfamoyl, methylsulfonamido or -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2- 10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute; and the hydrogen on R is further optionally substituted by 1 to more substituents, the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 Alkoxy; R a and R b Any independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein said C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by 1 to more than one selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups are substituted by saturated cycloalkyl or heterocyclic substituents; or R a and R b or R a and R2 or R a and R1 can also be connected to form a 3-30 membered cyclic structure, wherein the cyclic structure can be a monocyclic, bicyclic, bridged or spirocyclic structure, and can contain 0 to more heteroatoms or unsaturated bonds; furthermore, R a The hydrogen on the 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1- 6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 Cycloalkyl or heterocycloalkyl substitution; Every R d1 , R d2 , R d3 , R d4 , R d5 , R d6 , R d7 may be the same or different and are independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein said C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by 1 to more than one selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups are substituted by saturated cycloalkyl or heterocyclic substituents; or any R d1 , R d2 , R d3 , R d4 , R d5 , R d6 , R d7 The heteroaryl, saturated or partially saturated cycloalkyl, or saturated or partially saturated heterocyclic group may be formed by themselves or / and R1 or R2 and the atoms to which they are attached, and the hydrogen on the heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group may be selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; The hetero represents any heteroatom or group independently selected from O, N, S, P, -P=O, S=O or SO2 and isotopes thereof; The halogen is arbitrarily and independently selected from F, Cl, Br, I and isotopes thereof; m is an integer arbitrarily selected from 0, 1, 2, 3, and 4; n is an integer arbitrarily selected from 0, 1, 2, 3, 4 and 5. The premise is that when ring B is When any two R and / or R1 are connected, they form a 7-30 membered macrocyclic structure or a condensed ring structure together with the atoms on the ring.

2. The compound according to claim 1, or a pharmaceutically acceptable salt, solvate, enantiomer or isotope thereof, characterized in that: It has the structure of formula (IA), in, Y, Y1, Y2, Y3, Y4, and Y5 are each independently selected from the group consisting of absence, a single bond, -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、N、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-、-N(R d7 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic group, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Y, Y1, Y2, Y3, Y4, Y5 is further optionally substituted with 1 to more substituents, wherein the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluorosulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 Alkoxy; Ring B arbitrarily represents a 3-20 membered cyclic structure, which may be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure may be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring, or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; Z3 is independently selected from the group consisting of absence, a single bond, -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic group, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z3 is further optionally substituted with 1 to more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluorosulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 Alkoxy; X1 is independently selected from N or CR; Each R1 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, -SH and -NH2, -COOH, amide or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamide, methylsulfonylamino or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute or M group; and the hydrogen on R1 is optionally replaced by 1 to more selected from H, deuterium, halogen, pentafluoride sulfur, OCH3, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 or any two adjacent R1s together with the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, or a 5-30 membered saturated or partially saturated heterocyclic group, and the hydrogen atoms on the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group are optionally selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 The hydrogen on R1 is optionally replaced by one or more selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; Each R2 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, amino, hydroxyl, mercapto, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10 Alkylamino, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamide, N,N-di(C 1-10 Alkyl)amino, C 1-10 Alkyloxy, C 1-10 Alkyl acyl, C 1-10 Alkyloxy, C 1-10 Alkylsulfonyl, C 1-10 Alkylsulfinyl, C 3-10 Cycloalkylamino, C3-10 heterocycloalkylamino, C 3-10 Cycloalkoxy, C 3-10 Heterocycloalkoxy, C 3-10 Cycloalkyl acyl, C 3-10 Cycloalkoxyacetyl, C 3-10 Cycloalkylsulfonyl and C 3-10 a cycloalkylsulfinyl group, a -YQ group or an M group; or or optionally two R2 can form a 5-6 membered aryl or heteroaryl group together with the atoms to which they are attached, a 3-8 membered saturated or partially saturated cycloalkyl group, a 3-8 membered saturated or partially saturated heterocyclic group, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic group is optionally substituted by one or more groups selected from hydrogen, deuterium, alkyl, halogen, pentafluoride sulfur group, oxo, CN, CF3, OH, OCH3, OCH2CH3; and the hydrogen on R2 is optionally substituted by one or more groups selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 Cycloalkyl or heterocycloalkyl substitution; M is arbitrarily and independently selected from Z is independently selected from the group consisting of absent, C(R d1 )(R d2 ), O, NR d1 ,-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-、-N(R d7 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic group, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z1 and Z2 is further optionally substituted by 1 to more substituents, wherein the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluorosulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1- 3 alkyl, C 1-3 Alkoxy; Q arbitrarily represents a 3-20 membered cyclic structure, which may be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure may be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; and the hydrogen on the ring Q is optionally preferably replaced by one or more selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, alkyl, alkenyl, alkynyl, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; Each R may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, haloalkyl, haloalkoxy, deuterated alkyl, deuterated alkoxy, -OH, -SH and -NH2, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfamoyl, methylsulfonamido or -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2- 10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute; and the hydrogen on R is further optionally substituted by 1 to more substituents, the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 Alkoxy; R a and R b Any independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein said C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by 1 to more than one selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups are substituted by saturated cycloalkyl or heterocyclic substituents; or R a and R b or R a and R2 or R a and R1 can also be connected to form a 3-30 membered cyclic structure, wherein the cyclic structure can be a monocyclic, bicyclic, bridged or spirocyclic structure, and can contain 0 to more heteroatoms or unsaturated bonds; furthermore, R a The hydrogen on the 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1- 6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 Cycloalkyl or heterocycloalkyl substitution; Every R d1 , R d2 , R d3 , R d4 , R d5 , R d6 , R d7 may be the same or different and are independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein said C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by 1 to more than one selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups are substituted by saturated cycloalkyl or heterocyclic substituents; or any R d1 , R d2 , R d3 , R d4 , R d5 , R d6 , R d7 The heteroaryl, saturated or partially saturated cycloalkyl, or saturated or partially saturated heterocyclic group may be formed by themselves or / and R1 or R2 and the atoms to which they are attached, and the hydrogen on the heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group may be selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; The heteroatom represents any heteroatom or group independently selected from O, N, S, P, -P=O, S=O or SO2 and isotopes thereof; The halogen is arbitrarily and independently selected from F, Cl, Br, I and isotopes thereof; m is an integer arbitrarily selected from 0, 1, 2, 3, and 4; n is an integer arbitrarily selected from 0, 1, 2, 3, 4 and 5.

3. The compound according to claim 1 or 2, or a pharmaceutically acceptable salt, solvate, enantiomer or isotope substituted product thereof, characterized in that: It has the structure of formula (IB), in, Y, Y1, Y2, Y3, Y4, and Y5 are each independently selected from -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic group, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Y, Y1, Y2, Y3, Y4, Y5 is further optionally substituted with 1 to more substituents, wherein the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluorosulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 Alkoxy; Z3 is independently selected from the group consisting of absence, a single bond, -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic group, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z3 is further optionally substituted with 1 to more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluorosulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 Alkoxy; X is independently selected from O, S, N (R d4 )、-C(R d1 )(R d2 )-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aryl, or -C(R d1 )=C(R d1 )-; X1 is independently selected from N or CR; Each R1 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, -SH and -NH2, -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, amide, sulfamoyl, sulfonamide, methylsulfonylamino or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute or M group; and the hydrogen on R1 is optionally replaced by 1 to more selected from H, deuterium, halogen, pentafluoride sulfur, OCH3, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 or any two adjacent R1s together with the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, or a 5-30 membered saturated or partially saturated heterocyclic group, and the hydrogen atoms on the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group are optionally selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 The hydrogen on R1 is optionally replaced by one or more selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; Each R2 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, amino, hydroxyl, mercapto, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10 Alkylamino, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamide, N,N-di(C 1-10 Alkyl)amino, C 1-10 Alkyloxy, C 1-10 Alkyl acyl, C 1-10 Alkyloxy, C 1-10 Alkylsulfonyl, C 1-10 Alkylsulfinyl, C 3-10 Cycloalkylamino, C3-10 heterocycloalkylamino, C 3-10 Cycloalkoxy, C 3-10 Heterocycloalkoxy, C 3-10 Cycloalkyl acyl, C 3-10 Cycloalkoxyacetyl, C 3-10 Cycloalkylsulfonyl and C 3-10 Cycloalkylsulfinyl, -YQ or M group; or optionally two R2 can form a 5-6 membered aryl or heteroaryl group together with the atoms to which they are attached, a 3-8 membered saturated or partially saturated cycloalkyl group, a 3-8 membered saturated or partially saturated heterocyclic group, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic group is optionally substituted by one or more groups selected from hydrogen, deuterium, alkyl, halogen, pentafluoride sulfur group, oxo, CN, CF3, OH, OCH3, OCH2CH3; and the hydrogen on R2 is optionally substituted by one or more groups selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 Cycloalkyl or heterocycloalkyl substitution; M is arbitrarily and independently selected from Z is independently selected from the group consisting of absent, C(R d1 )(R d2 ), O, NR d1 ,-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-、-N(R d7 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic group, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z1 and Z2 is further optionally substituted by 1 to more substituents, wherein the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluorosulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1- 3 alkyl, C 1-3 Alkoxy; Q arbitrarily represents a 3-20 membered cyclic structure, which may be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure may be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; and the hydrogen on the ring Q is optionally preferably replaced by one or more selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, alkyl, alkenyl, alkynyl, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; Each R may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, haloalkyl, haloalkoxy, deuterated alkyl, deuterated alkoxy, -OH, -SH and -NH2, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfamoyl, methylsulfonamido or -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2- 10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute; and the hydrogen on R is further optionally substituted by 1 to more substituents, the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 Alkoxy; R a and R b Any independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein said C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by 1 to more than one selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups are substituted by saturated cycloalkyl or heterocyclic substituents; or R a and R b or R a and R2 or R a and R1 can also be connected to form a 3-30 membered cyclic structure, wherein the cyclic structure can be a monocyclic, bicyclic, bridged or spirocyclic structure, and can contain 0 to more heteroatoms or unsaturated bonds; furthermore, R a The hydrogen on the 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1- 6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 Cycloalkyl or heterocycloalkyl substitution; Every R d1 , R d2 , R d3 , R d4 , R d5 , R d6 , R d7 may be the same or different and are independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein said C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by 1 to more than one selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups are substituted by saturated cycloalkyl or heterocyclic substituents; or any R d1 , R d2 , R d3 , R d4 , R d5 , R d6 , R d7 Together with each other or / and R1 or R2 and the atoms to which they are attached, they form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, a 5-30 membered saturated or partially saturated heteroaryl The hydrogen on the heteroaryl, saturated or partially saturated cycloalkyl, or heterocycloalkyl is optionally selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; The heteroatom represents any heteroatom or group independently selected from O, N, S, P, -P=O, S=O or SO2 and isotopes thereof; The halogen is arbitrarily and independently selected from F, Cl, Br, I and isotopes thereof; m is an integer arbitrarily selected from 0, 1, 2, 3, and 4; n is an integer arbitrarily selected from 0, 1, 2, 3, and 4.

4. The compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt, solvate, enantiomer or isotope thereof, characterized in that: It has the structure of formula (IC): in, Y, Y1, Y2, Y3, Y4, and Y5 are each independently selected from -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic group, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Y, Y1, Y2, Y3, Y4, Y5 is further optionally substituted with 1 to more substituents, wherein the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluorosulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 Alkoxy; Z3 is independently selected from the group consisting of absence, a single bond, -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic group, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z3 is further optionally substituted with 1 to more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluorosulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 Alkoxy; X is independently selected from N or -CR-; X1 is independently selected from N or CR; Each R1 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, -SH and -NH2, -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, amide, sulfamoyl, sulfonamide, methylsulfonylamino or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute or M group; and the hydrogen on R1 is optionally replaced by 1 to more selected from H, deuterium, halogen, pentafluoride sulfur, OCH3, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Substituents of heterocyclic groups; or any two adjacent R1 and The atoms attached to them together form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, or a 5-30 membered saturated or partially saturated heterocyclic group, and the hydrogen on the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group is optionally selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 The hydrogen on R1 is optionally replaced by one or more selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; Each R2 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, amino, hydroxyl, mercapto, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10 Alkylamino, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamide, N,N-di(C 1-10 Alkyl)amino, C 1-10 Alkyloxy, C 1-10 Alkyl acyl, C 1-10 Alkyloxy, C 1-10 Alkylsulfonyl, C 1-10 Alkylsulfinyl, C 3-10 Cycloalkylamino, C3-10 heterocycloalkylamino, C 3-10 Cycloalkoxy, C 3-10 Heterocycloalkoxy, C 3-10 Cycloalkyl acyl, C 3-10 Cycloalkoxyacetyl, C 3-10 Cycloalkylsulfonyl and C 3-10 Cycloalkylsulfinyl, -YQ or M group; or optionally two R2 can form a 5-6 membered aryl or heteroaryl group together with the atoms to which they are attached, a 3-8 membered saturated or partially saturated cycloalkyl group, a 3-8 membered saturated or partially saturated heterocyclic group, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic group is optionally substituted by one or more groups selected from hydrogen, deuterium, alkyl, halogen, pentafluoride sulfur group, oxo, CN, CF3, OH, OCH3, OCH2CH3; and the hydrogen on R2 is optionally substituted by one or more groups selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 Cycloalkyl or heterocycloalkyl substitution; M is arbitrarily and independently selected from Z is independently selected from the group consisting of absent, C(R d1 )(R d2 ), O, NR d1 ,-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-、-N(R d7 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic group, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z1 and Z2 is further optionally substituted by 1 to more substituents, wherein the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluorosulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1- 3 alkyl, C 1-3 Alkoxy; Q arbitrarily represents a 3-20 membered cyclic structure, which may be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure may be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; and the hydrogen on the ring Q is optionally preferably replaced by one or more selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, alkyl, alkenyl, alkynyl, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; Each R may be the same or different and is independently selected from hydrogen, deuterium, -CN, haloalkyl, haloalkoxy, deuterated alkyl, deuterated alkoxy, -OH, -SH and -NH2, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamido, methylsulfonylamino or -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute; and the hydrogen on R is further optionally substituted by 1 to more substituents, the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 Alkoxy; R a and R b Any independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein said C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by 1 to more than one selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups are substituted by saturated cycloalkyl or heterocyclic substituents; or R a and R b or R a and R2 or R a and R1 can also be connected to form a 3-30 membered cyclic structure, wherein the cyclic structure can be a monocyclic, bicyclic, bridged or spirocyclic structure, and can contain 0 to more heteroatoms or unsaturated bonds; furthermore, R a The hydrogen on the 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1- 6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 Cycloalkyl or heterocycloalkyl substitution; Every R d1 , R d2 , R d3 , R d4 , R d5 , R d6 , R d7 may be the same or different and are independently selected from hydrogen, deuterium, halogen, Sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein said C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by 1 to more than one selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups are substituted by saturated cycloalkyl or heterocyclic substituents; or any R d1 , R d2 , R d3 , R d4 , R d5 , R d6 , R d7 The heteroaryl, saturated or partially saturated cycloalkyl, or saturated or partially saturated heterocyclic group may be formed by themselves or / and R1 or R2 and the atoms to which they are attached, and the hydrogen on the heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group may be selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; The hetero represents any heteroatom or group independently selected from O, N, S, P, -P=O, S=O or SO2 and isotopes thereof; The halogen is arbitrarily and independently selected from F, Cl, Br, I and isotopes thereof; m is an integer arbitrarily selected from 0, 1, 2, 3, and 4; n is an integer arbitrarily selected from 0, 1, 2, 3, and 4.

5. The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt, solvate, enantiomer or isotope thereof, characterized in that: It has the structure of formula (ID): in, Y1, Y2, Y3, Y4, and Y5 are each independently selected from -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic group, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Y1, Y2, Y3, Y4, and Y5 is further optionally substituted with one or more substituents, wherein the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluorosulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 Alkoxy; X is independently selected from N or -CR-; X1 is independently selected from N or CR; Each R1 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, -SH and -NH2, -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, amide, sulfamoyl, sulfonamide, methylsulfonylamino or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute or M group; and the hydrogen on R1 is optionally replaced by 1 to more selected from H, deuterium, halogen, pentafluoride sulfur, OCH3, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 or any two adjacent R1s together with the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, or a 5-30 membered saturated or partially saturated heterocyclic group, and the hydrogen atoms on the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group are optionally selected from hydrogen, deuterium, halogen, sulfur pentafluoride, Base, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 The hydrogen on R1 is optionally replaced by one or more selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; Each R2 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, amino, hydroxyl, mercapto, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10 Alkylamino, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamide, N,N-di(C 1-10 Alkyl)amino, C 1-10 Alkyloxy, C 1-10 Alkyl acyl, C 1-10 Alkyloxy, C 1-10 Alkylsulfonyl, C 1-10 Alkylsulfinyl, C 3-10 Cycloalkylamino, C3-10 heterocycloalkylamino, C 3-10 Cycloalkoxy, C 3-10 Heterocycloalkoxy, C 3-10 Cycloalkyl acyl, C 3-10 Cycloalkoxyacetyl, C 3-10 Cycloalkylsulfonyl and C 3-10 Cycloalkylsulfinyl, -YQ or M group; or optionally two R2 can form a 5-6 membered aryl or heteroaryl group together with the atoms to which they are attached, a 3-8 membered saturated or partially saturated cycloalkyl group, a 3-8 membered saturated or partially saturated heterocyclic group, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic group is optionally substituted by one or more groups selected from hydrogen, deuterium, alkyl, halogen, pentafluoride sulfur group, oxo, CN, CF3, OH, OCH3, OCH2CH3; and the hydrogen on R2 is optionally substituted by one or more groups selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 Cycloalkyl or heterocycloalkyl substitution; M is arbitrarily and independently selected from Z is independently selected from the group consisting of absent, C(R d1 )(R d2 ), O, NR d1 ,-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-、-N(R d7 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic group, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z1 and Z2 is further optionally substituted by 1 to more substituents, wherein the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluorosulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1- 3 alkyl, C 1-3 Alkoxy; Q arbitrarily represents a 3-20 membered cyclic structure, which may be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure may be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; and the hydrogen on the ring Q is optionally preferably replaced by one or more selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, alkyl, alkenyl, alkynyl, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; Each R may be the same or different and is independently selected from hydrogen, deuterium, -CN, haloalkyl, haloalkoxy, deuterated alkyl, deuterated alkoxy, -OH, -SH and -NH2, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamido, methylsulfonylamino or -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute; and the hydrogen on R is further optionally substituted by 1 to more substituents, the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 Alkoxy; R a and R b Any independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein said C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by 1 to more than one selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups are substituted by saturated cycloalkyl or heterocyclic substituents; or R a and R b or R a and R2 or R a and R1 can also be connected to form a 3-30 membered cyclic structure, wherein the cyclic structure can be a monocyclic, bicyclic, bridged or spirocyclic structure, and can contain 0 to more heteroatoms or unsaturated bonds; furthermore, R a The hydrogen on the 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1- 6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 Cycloalkyl or heterocycloalkyl substitution; Every R d1 , R d2 , R d3 , R d4 , R d5 , R d6 , R d7 may be the same or different and are independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein said C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by 1 to more than one selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups are substituted by saturated cycloalkyl or heterocyclic substituents; or any R d1 , R d2 , R d3 , R d4 , R d5 , R d6 , R d7 The heteroaryl, saturated or partially saturated cycloalkyl, or saturated or partially saturated heterocyclic group may be formed by themselves or / and R1 or R2 and the atoms to which they are attached, and the hydrogen on the heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group may be selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; The heteroatom represents any heteroatom or group independently selected from O, N, S, P, -P=O, S=O or SO2 and isotopes thereof; The halogen is arbitrarily and independently selected from F, Cl, Br, I and isotopes thereof; m is an integer arbitrarily selected from 0, 1, 2, 3, and 4; n is an integer arbitrarily selected from 0, 1, 2, 3, and 4.

6. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt, solvate, enantiomer or isotope thereof, characterized in that: It has the structure of formula (IE): in, Y1, Y2, Y3, Y4, and Y5 are each independently selected from -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic group, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Y1, Y2, Y3, Y4, and Y5 is further optionally substituted with one or more substituents, wherein the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluorosulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 Alkoxy; X is independently selected from N or -CR-; X1 is independently selected from N or CR; Each R1 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, -SH and -NH2, -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, amide, aminesulfonamido, methylsulfonylamino or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute or M group; and the hydrogen on R1 is optionally replaced by 1 to more selected from H, deuterium, halogen, pentafluoride sulfur, OCH3, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 or any two adjacent R1s together with the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, or a 5-30 membered saturated or partially saturated heterocyclic group, and the hydrogen atoms on the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group are optionally selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially Saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 The hydrogen on R1 is optionally replaced by one or more selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; Each R2 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, amino, hydroxyl, mercapto, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10 Alkylamino, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamide, N,N-di(C 1-10 Alkyl)amino, C 1-10 Alkyloxy, C 1-10 Alkyl acyl, C 1-10 Alkyloxy, C 1-10 Alkylsulfonyl, C 1-10 Alkylsulfinyl, C 3-10 Cycloalkylamino, C3-10 heterocycloalkylamino, C 3-10 Cycloalkoxy, C 3-10 Heterocycloalkoxy, C 3-10 Cycloalkyl acyl, C 3-10 Cycloalkoxyacetyl, C 3-10 Cycloalkylsulfonyl and C 3-10 Cycloalkylsulfinyl, -YQ or M group; or optionally two R2 can form a 5-6 membered aryl or heteroaryl group together with the atoms to which they are attached, a 3-8 membered saturated or partially saturated cycloalkyl group, a 3-8 membered saturated or partially saturated heterocyclic group, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic group is optionally substituted by one or more groups selected from hydrogen, deuterium, alkyl, halogen, pentafluoride sulfur group, oxo, CN, CF3, OH, OCH3, OCH2CH3; and the hydrogen on R2 is optionally substituted by one or more groups selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 Cycloalkyl or heterocycloalkyl substitution; M is arbitrarily and independently selected from Z is independently selected from the group consisting of absent, C(R d1 )(R d2 ), O, NR d1 ,-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-、-N(R d7 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic group, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z1 and Z2 is further optionally substituted by 1 to more substituents, wherein the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluorosulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1- 3 alkyl, C 1-3 Alkoxy; Q arbitrarily represents a 3-20 membered cyclic structure, which may be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure may be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; and the hydrogen on the ring Q is optionally preferably replaced by one or more selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, alkyl, alkenyl, alkynyl, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; Each R may be the same or different and is independently selected from hydrogen, deuterium, -CN, haloalkyl, haloalkoxy, deuterated alkyl, deuterated alkoxy, -OH, -SH and -NH2, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamido, methylsulfonylamino or -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute; and the hydrogen on R is further optionally substituted by 1 to more substituents, the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 Alkoxy; R a and R b Any independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein said C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by 1 to more than one selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups are substituted by saturated cycloalkyl or heterocyclic substituents; or R a and R b or R a and R2 or R a and R1 can also be connected to form a 3-30 membered cyclic structure, wherein the cyclic structure can be a monocyclic, bicyclic, bridged or spirocyclic structure, and can contain 0 to more heteroatoms or unsaturated bonds; furthermore, R a The hydrogen on the 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1- 6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 Cycloalkyl or heterocycloalkyl substitution; Every R d1 , R d2 , R d3 , R d4 , R d5 , R d6 , R d7 may be the same or different and are independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein said C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkane Base, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by 1 to more than one selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups are substituted by saturated cycloalkyl or heterocyclic substituents; or any R d1 , R d2 , R d3 , R d4 , R d5 , R d6 , R d7 The heteroaryl, saturated or partially saturated cycloalkyl, or saturated or partially saturated heterocyclic group may be formed by themselves or / and R1 or R2 and the atoms to which they are attached, and the hydrogen on the heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group may be selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; The heteroatom represents any heteroatom or group independently selected from O, N, S, P, -P=O, S=O or SO2 and isotopes thereof; The halogen is arbitrarily and independently selected from F, Cl, Br, I and isotopes thereof; m is an integer arbitrarily selected from 0, 1, 2, 3, and 4; n is an integer arbitrarily selected from 0, 1, 2, 3, and 4.

7. The compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt, solvate, enantiomer or isotope thereof, characterized in that: It has the structure of formula (IF): in, Y, Y1, Y2, Y3, Y4, and Y5 are each independently selected from -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic group, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Y1, Y2, Y3, Y4, and Y5 is further optionally substituted with one or more substituents, wherein the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluorosulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 Alkoxy; Ring C represents any 3-20 membered cyclic structure, which may be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure may be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; and the hydrogen on ring Q is optionally replaced by one or more selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, alkyl, alkenyl, alkynyl, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; X is independently selected from N or -CR-; X1 is independently selected from N or CR; Each R1 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, -SH and -NH2, -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, amide, aminoacyl, sulfamoyl, sulfonamide, methylsulfonylamino or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute or M group; and the hydrogen on R1 is optionally replaced by 1 to more selected from H, deuterium, halogen, pentafluoride sulfur, OCH3, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 or any two adjacent R1s together with the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, or a 5-30 membered saturated or partially saturated heterocyclic group, and the hydrogen atoms on the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group are optionally selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 The hydrogen on R1 is optionally replaced by one or more selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; Each R2 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, amino, hydroxyl, mercapto, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10 Alkylamino, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamide, N,N-di(C 1-10 Alkyl)amino, C 1-10 Alkyloxy, C 1-10 Alkyl acyl, C 1-10 Alkyloxy, C 1-10 Alkylsulfonyl, C 1-10 Alkylsulfinyl, C 3-10 Cycloalkylamino, C3-10 heterocycloalkylamino, C 3-10 Cycloalkoxy, C 3-10 Heterocycloalkoxy, C 3-10 Cycloalkyl acyl, C 3-10 Cycloalkoxyacetyl, C 3-10 Cycloalkylsulfonyl and C 3-10 Cycloalkylsulfinyl, -YQ or M group; or optionally two R2 can form a 5-6 membered aryl or heteroaryl group together with the atoms to which they are attached, a 3-8 membered saturated or partially saturated cycloalkyl group, a 3-8 membered saturated or partially saturated heterocyclic group, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic group is optionally substituted by one or more groups selected from hydrogen, deuterium, alkyl, halogen, pentafluoride sulfur group, oxo, CN, CF3, OH, OCH3, OCH2CH3; and the hydrogen on R2 is optionally substituted by one or more groups selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 Cycloalkyl or heterocycloalkyl substitution; M is arbitrarily and independently selected from Z is independently selected from the group consisting of absent, C(R d1 )(R d2 ), O, NR d1 ,-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-、-N(R d7 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic group, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z1 and Z2 is further optionally substituted by 1 to more substituents, wherein the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluorosulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1- 3 alkyl, C 1-3 Alkoxy; Q arbitrarily represents a 3-20 membered cyclic structure, which may be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure may be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; and the hydrogen on the ring Q is optionally preferably replaced by one or more selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, alkyl, alkenyl, alkynyl, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; Each R may be the same or different and is independently selected from hydrogen, deuterium, -CN, haloalkyl, haloalkoxy, deuterated alkyl, deuterated alkoxy, -OH, -SH and -NH2, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamido, methylsulfonylamino or -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute; and the hydrogen on R is further optionally substituted by 1 to more substituents, the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 Alkoxy; R a and R b Any independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein said C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by 1 to more than one selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups are substituted by saturated cycloalkyl or heterocyclic substituents; or R a and R b or R a and R2 or R a and R1 can also be connected to form a 3-30 membered cyclic structure, wherein the cyclic structure can be a monocyclic, bicyclic, bridged or spirocyclic structure, and can contain 0 to more heteroatoms or unsaturated bonds; furthermore, R a The hydrogen on the 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1- 6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 Cycloalkyl or heterocycloalkyl substitution; Every R d1 , R d2 , R d3 , R d4 , R d5 , R d6 , R d7 may be the same or different and are independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein said C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by 1 to more than one selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups are substituted by saturated cycloalkyl or heterocyclic substituents; or any R d1 , R d2 , R d3 , R d4 , R d5 , R d6 , R d7 The heteroaryl, saturated or partially saturated cycloalkyl, or saturated or partially saturated heterocyclic group may be formed by themselves or / and R1 or R2 and the atoms to which they are attached, and the hydrogen on the heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group may be selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; The heteroatom represents any heteroatom or group independently selected from O, N, S, P, -P=O, S=O or SO2 and isotopes thereof; The halogen is arbitrarily and independently selected from F, Cl, Br, I and isotopes thereof; m is an integer arbitrarily selected from 0, 1, 2, 3, and 4; n is an integer arbitrarily selected from 0, 1, 2, 3, and 4.

8. The compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt, solvate, enantiomer or isotope thereof, characterized in that: It has the structure of formula (IG): in, Y, Y1, Y2, Y3, Y4, and Y5 are each independently selected from -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic group, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Y1, Y2, Y3, Y4, and Y5 is further optionally substituted with one or more substituents, wherein the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluorosulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 Alkoxy; Ring C represents any 3-20 membered cyclic structure, which may be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure may be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; and the hydrogen on ring Q is optionally replaced by one or more selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, alkyl, alkenyl, alkynyl, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; X1 is independently selected from N or CR; Each R1 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, -SH and -NH2, -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, amide, aminoacyl, sulfamoyl, sulfonamide, methylsulfonylamino or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute or M group; and the hydrogen on R1 is optionally replaced by 1 to more selected from H, deuterium, halogen, pentafluoride sulfur, OCH3, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 or any two adjacent R1s together with the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, or a 5-30 membered saturated or partially saturated heterocyclic group, and the hydrogen atoms on the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group are optionally selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 The hydrogen on R1 is optionally replaced by one or more selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; Each R2 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, amino, hydroxyl, mercapto, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10 Alkylamino, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamide, N,N-di(C 1-10 Alkyl)amino, C 1-10 Alkyloxy, C 1-10 Alkyl acyl, C 1-10 Alkyloxy, C 1-10 Alkylsulfonyl, C 1-10 Alkylsulfinyl, C 3-10 Cycloalkylamino, C3-10 heterocycloalkylamino, C 3-10 Cycloalkoxy, C 3-10 Heterocycloalkoxy, C 3-10 Cycloalkyl acyl, C 3-10 Cycloalkoxyacetyl, C 3-10 Cycloalkylsulfonyl and C 3-10 Cycloalkylsulfinyl, -YQ or M group; or optionally two R2 can form a 5-6 membered aryl or heteroaryl group together with the atoms to which they are attached, a 3-8 membered saturated or partially saturated cycloalkyl group, a 3-8 membered saturated or partially saturated heterocyclic group, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic group is optionally substituted by one or more groups selected from hydrogen, deuterium, alkyl, halogen, pentafluoride sulfur group, oxo, CN, CF3, OH, OCH3, OCH2CH3; and the hydrogen on R2 is optionally substituted by one or more groups selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 Cycloalkyl or heterocycloalkyl substitution; M is arbitrarily and independently selected from Z is independently selected from the group consisting of absent, C(R d1 )(R d2 ), O, NR d1 ,-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-、-N(R d7 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic group, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z1 and Z2 is further optionally substituted by 1 to more substituents, wherein the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluorosulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1- 3 alkyl, C 1-3 Alkoxy; Q arbitrarily represents a 3-20 membered cyclic structure, which may be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure may be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; and the hydrogen on the ring Q is optionally preferably replaced by one or more selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, alkyl, alkenyl, alkynyl, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; Each R may be the same or different and is independently selected from hydrogen, deuterium, -CN, haloalkyl, haloalkoxy, deuterated alkyl, deuterated alkoxy, -OH, -SH and -NH2, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamido, methylsulfonylamino or -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute; and the hydrogen on R is further optionally substituted by 1 to more substituents, the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 Alkoxy; R a and R b Any independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein said C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cyclic hydrocarbons C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by 1 to more than one selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups are substituted by saturated cycloalkyl or heterocyclic substituents; or R a and R b or R a and R2 or R a and R1 can also be connected to form a 3-30 membered cyclic structure, wherein the cyclic structure can be a monocyclic, bicyclic, bridged or spirocyclic structure, and can contain 0 to more heteroatoms or unsaturated bonds; furthermore, R a The hydrogen on the 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1- 6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 Cycloalkyl or heterocycloalkyl substitution; Every R d1 , R d2 , R d3 , R d4 , R d5 , R d6 , R d7 may be the same or different and are independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein said C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by 1 to more than one selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups are substituted by saturated cycloalkyl or heterocyclic substituents; or any R d1 , R d2 , R d3 , R d4 , R d5 , R d6 , R d7 The heteroaryl, saturated or partially saturated cycloalkyl, or saturated or partially saturated heterocyclic group may be formed by themselves or / and R1 or R2 and the atoms to which they are attached, and the hydrogen on the heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group may be selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; The heteroatom represents any heteroatom or group independently selected from O, N, S, P, -P=O, S=O or SO2 and isotopes thereof; The halogen is arbitrarily and independently selected from F, Cl, Br, I and isotopes thereof; m is an integer arbitrarily selected from 0, 1, 2, 3, and 4; n is an integer arbitrarily selected from 0, 1, 2, 3, and 4.

9. The compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt, solvate, enantiomer or isotope thereof, characterized in that: It has the structure of formula (IH): in, Y is independently selected from -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic group, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Y is further optionally substituted with 1 to more substituents, wherein the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluorosulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 Alkoxy; X is independently selected from N or -CR-; X1 is independently selected from N or CR; Each R1 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, -SH and -NH2, -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, Amide, aminoacyl, sulfamoyl, sulfonamide, methylsulfonylamino or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute or M group; and the hydrogen on R1 is optionally replaced by 1 to more selected from H, deuterium, halogen, pentafluoride sulfur, OCH3, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 or any two adjacent R1s together with the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, or a 5-30 membered saturated or partially saturated heterocyclic group, and the hydrogen atoms on the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group are optionally selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 The hydrogen on R1 is optionally replaced by one or more selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; Each R2 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, amino, hydroxyl, mercapto, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10 Alkylamino, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamide, N,N-di(C 1-10 Alkyl)amino, C 1-10 Alkyloxy, C 1-10 Alkyl acyl, C 1-10 Alkyloxy, C 1-10 Alkylsulfonyl, C 1-10 Alkylsulfinyl, C 3-10 Cycloalkylamino, C3-10 heterocycloalkylamino, C 3-10 Cycloalkoxy, C 3-10 Heterocycloalkoxy, C 3-10 Cycloalkyl acyl, C 3-10 Cycloalkoxyacetyl, C 3-10 Cycloalkylsulfonyl and C 3-10 Cycloalkylsulfinyl, -YQ or M group; or optionally two R2 can form a 5-6 membered aryl or heteroaryl group together with the atoms to which they are attached, a 3-8 membered saturated or partially saturated cycloalkyl group, a 3-8 membered saturated or partially saturated heterocyclic group, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic group is optionally substituted by one or more groups selected from hydrogen, deuterium, alkyl, halogen, pentafluoride sulfur group, oxo, CN, CF3, OH, OCH3, OCH2CH3; and the hydrogen on R2 is optionally substituted by one or more groups selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 Cycloalkyl or heterocycloalkyl substitution; M is arbitrarily and independently selected from Z is independently selected from the group consisting of absent, C(R d1 )(R d2 ), O, NR d1 ,-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-、-N(R d7 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic group, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z1 and Z2 is further optionally substituted by 1 to more substituents, wherein the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluorosulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1- 3 alkyl, C 1-3 Alkoxy; Q arbitrarily represents a 3-20 membered cyclic structure, which may be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure may be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; and the hydrogen on the ring Q is optionally preferably replaced by one or more selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, alkyl, alkenyl, alkynyl, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; Each R may be the same or different and is independently selected from hydrogen, deuterium, -CN, haloalkyl, haloalkoxy, deuterated alkyl, deuterated alkoxy, -OH, -SH and -NH2, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamido, methylsulfonylamino or -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute; and the hydrogen on R is further optionally substituted by 1 to more substituents, the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 Alkoxy; R a and R b Any independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein said C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by 1 to 2 or more selected from hydrogen, deuterium, halogen fluorinated sulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups are substituted by saturated cycloalkyl or heterocyclic substituents; or R a and R b or R a and R2 or R a and R1 can also be connected to form a 3-30 membered cyclic structure, wherein the cyclic structure can be a monocyclic, bicyclic, bridged or spirocyclic structure, and can contain 0 to more heteroatoms or unsaturated bonds; furthermore, R a The hydrogen on the 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1- 6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 Cycloalkyl or heterocycloalkyl substitution; Every R d1 , R d2 , R d3 , R d4 , R d5 , R d6 , R d7 may be the same or different and are independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein said C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by 1 to more than one selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups are substituted by saturated cycloalkyl or heterocyclic substituents; or any R d1 , R d2 , R d3 , R d4 , R d5 , R d6 , R d7 The heteroaryl, saturated or partially saturated cycloalkyl, or saturated or partially saturated heterocyclic group may be formed by themselves or / and R1 or R2 and the atoms to which they are attached, and the hydrogen on the heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group may be selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 Cycloalkyl radical substitution; and at least one R d1 and R d2 Connected to the atoms to which they are attached to form a 3-20 membered ring structure; The heteroatom represents any heteroatom or group independently selected from O, N, S, P, -P=O, S=O or SO2 and isotopes thereof; The halogen is arbitrarily and independently selected from F, Cl, Br, I and isotopes thereof; m is an integer arbitrarily selected from 0, 1, 2, 3, and 4; n is an integer arbitrarily selected from 0, 1, 2, 3, and 4; Preferably, the compound, its pharmaceutically acceptable salt, solvate, enantiomer or isotope substituted product has the structure of formula (II): in, Y is independently selected from -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic group, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Y is further optionally substituted with 1 to more substituents, wherein the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluorosulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 Alkoxy; X1 is independently selected from N or CR; Each R1 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, -SH and -NH2, -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, amide, aminoacyl, sulfamoyl, sulfonamide, methylsulfonylamino or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute or M group; and the hydrogen on R1 is optionally Preferably, 1 to 2 are selected from H, deuterium, halogen, sulfur pentafluoride, OCH3, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 or any two adjacent R1s together with the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, or a 5-30 membered saturated or partially saturated heterocyclic group, and the hydrogen atoms on the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group are optionally selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 The hydrogen on R1 is optionally replaced by one or more selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; Each R2 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, amino, hydroxyl, mercapto, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10 Alkylamino, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamide, N,N-di(C 1-10 Alkyl)amino, C 1-10 Alkyloxy, C 1-10 Alkyl acyl, C 1-10 Alkyloxy, C 1-10 Alkylsulfonyl, C 1-10 Alkylsulfinyl, C 3-10 Cycloalkylamino, C3-10 heterocycloalkylamino, C 3-10 Cycloalkoxy, C 3-10 Heterocycloalkoxy, C 3-10 Cycloalkyl acyl, C 3-10 Cycloalkoxyacetyl, C 3-10 Cycloalkylsulfonyl and C 3-10 Cycloalkylsulfinyl, -YQ or M group; or optionally two R2 can form a 5-6 membered aryl or heteroaryl group together with the atoms to which they are attached, a 3-8 membered saturated or partially saturated cycloalkyl group, a 3-8 membered saturated or partially saturated heterocyclic group, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic group is optionally substituted by one or more groups selected from hydrogen, deuterium, alkyl, halogen, pentafluoride sulfur group, oxo, CN, CF3, OH, OCH3, OCH2CH3; and the hydrogen on R2 is optionally substituted by one or more groups selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 Cycloalkyl or heterocycloalkyl substitution; M is arbitrarily and independently selected from Z is independently selected from the group consisting of absent, C(R d1 )(R d2 ), O, NR d1 ,-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-、-N(R d7 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic group, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z1 and Z2 is further optionally substituted by 1 to more substituents, wherein the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluorosulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1- 3 alkyl, C 1-3 Alkoxy; Q arbitrarily represents a 3-20 membered cyclic structure, which may be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure may be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; and the hydrogen on the ring Q is optionally preferably replaced by one or more selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, alkyl, alkenyl, alkynyl, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; Each R may be the same or different and is independently selected from hydrogen, deuterium, -CN, haloalkyl, haloalkoxy, deuterated alkyl, deuterated alkoxy, -OH, -SH and -NH2, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamido, methylsulfonylamino or -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute; and the hydrogen on R is further optionally substituted by 1 to more substituents, the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 Alkoxy; R a and R b Any independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein said C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by 1 to more than one selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups are substituted by saturated cycloalkyl or heterocyclic substituents; or R a and R b or R a and R2 or R a and R1 can also be connected to form a 3-30 membered cyclic structure, wherein the cyclic structure can be a monocyclic, bicyclic, bridged or spirocyclic structure, and can contain 0 to more heteroatoms or unsaturated bonds; furthermore, R a The hydrogen atoms on the is selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1- 6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 Cycloalkyl or heterocycloalkyl substitution; Every R d1 , R d2 , R d3 , R d4 , R d5 , R d6 , R d7 may be the same or different and are independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein said C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by 1 to more than one selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups are substituted by saturated cycloalkyl or heterocyclic substituents; or any R d1 , R d2 , R d3 , R d4 , R d5 , R d6 , R d7 The heteroaryl, saturated or partially saturated cycloalkyl, or saturated or partially saturated heterocyclic group may be formed by themselves or / and R1 or R2 and the atoms to which they are attached, and the hydrogen on the heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group may be selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 Cycloalkyl radical substitution; and at least one R d1 and R d2 Connected to the atoms to which they are attached to form a 3-20 membered ring structure; The heteroatom represents any heteroatom or group independently selected from O, N, S, P, -P=O, S=O or SO2 and isotopes thereof; The halogen is arbitrarily and independently selected from F, Cl, Br, I and isotopes thereof; m is an integer arbitrarily selected from 0, 1, 2, 3, and 4; n is an integer arbitrarily selected from 0, 1, 2, 3, and 4; Preferably, the compound, its pharmaceutically acceptable salt, solvate, enantiomer or isotope substituted product has the structure of formula (IJ): in, Any represents a single bond or a double bond; Z3 is independently selected from the group consisting of absence, a single bond, -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic group, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z3 is further optionally substituted with 1 to more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluorosulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 Alkoxy; X1, X2 are independently selected from N or CR; Y is independently selected from -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-、-O-、-S-、-C(=O)O-、-OC(=O)-、-C(=O)-、-C(=S)-、-S(=O)–、-S(=O)2-; Each R1 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, -SH and -NH2, -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, amide, aminoacyl, sulfamoyl, sulfonamide, methylsulfonylamino or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute or M group; and the hydrogen on R1 is optionally Preferably, 1 to 2 are selected from H, deuterium, halogen, sulfur pentafluoride, OCH3, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 or any two adjacent R1s together with the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, or a 5-30 membered saturated or partially saturated heterocyclic group, and the hydrogen atoms on the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group are optionally selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 The hydrogen on R1 is optionally replaced by one or more selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; Each R2 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, amino, hydroxyl, acyl, carboxyl, thiol, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10 Alkylamino, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamide, N,N-di(C 1-10 Alkyl)amino, C 1-10 Alkyloxy, C 1-10 Alkyl acyl, C 1-10 Alkyloxy, C 1-10 Alkylsulfonyl, C 1-10 Alkylsulfinyl, C 3-10 Cycloalkylamino, C3-10 heterocycloalkylamino, C 3-10 Cycloalkoxy, C 3-10 Heterocycloalkoxy, C 3-10 Cycloalkyl acyl, C 3-10 Cycloalkoxyacetyl, C 3-10 Cycloalkylsulfonyl and C 3-10 Cycloalkylsulfinyl, -YQ or M group; or optionally two R2 can form a 5-6 membered aryl or heteroaryl group together with the atoms to which they are attached, a 3-8 membered saturated or partially saturated cycloalkyl group, a 3-8 membered saturated or partially saturated heterocyclic group, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic group is optionally substituted by one or more groups selected from hydrogen, deuterium, alkyl, halogen, pentafluoride sulfur group, oxo, CN, CF3, OH, OCH3, OCH2CH3; and the hydrogen on R2 is optionally substituted by one or more groups selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, -CN, -OH, CF3, C 1-6 Alkyl, C 1- 6-alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 Substituted with cycloalkyl or heterocycloalkyl, -YQ or M groups; M is arbitrarily and independently selected from Z is independently selected from the group consisting of absent, C(R d1 )(R d2 ), O, NR d1 ,-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-、-N(R d7 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic group, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z1 and Z2 is further optionally substituted by 1 to more substituents, wherein the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluorosulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1- 3 alkyl, C 1-3 Alkoxy; Y is arbitrarily and independently selected from O, S or NR; Q arbitrarily represents a 3-20 membered cyclic structure, which may be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure may be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; and the hydrogen on the ring Q is optionally preferably replaced by one or more selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, alkyl, alkenyl, alkynyl, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; Each R may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, haloalkyl, haloalkoxy, deuterated alkyl, deuterated alkoxy, -OH, -SH and -NH2, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfamoyl, methylsulfonamido or -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2- 10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute; and the hydrogen on R is further optionally substituted by 1 to more substituents, the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 Alkoxy; R a and R b Any independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein said C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by 1 to more than one selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups are substituted by saturated cycloalkyl or heterocyclic substituents; or R a and R b or R a and R2 or R a and R1 can also be connected together to form a 3-30 membered ring structure, wherein the ring structure can be a single ring, A bicyclic, bridged or spirocyclic structure, and may contain 0 or more heteroatoms or unsaturated bonds; furthermore, R a The hydrogen on the 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1- 6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 Cycloalkyl or heterocycloalkyl substitution; Every R d1 , R d2 , R d3 , R d4 , R d5 , R d6 , R d7 may be the same or different and are independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein said C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by 1 to more than one selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups are substituted by saturated cycloalkyl or heterocyclic substituents; or any R d1 , R d2 , R d3 , R d4 , R d5 , R d6 , R d7 The heteroaryl, saturated or partially saturated cycloalkyl, or saturated or partially saturated heterocyclic group may be formed by themselves or / and R1 or R2 and the atoms to which they are attached, and the hydrogen on the heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group may be selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; The heteroatom represents any heteroatom or group independently selected from O, N, S, P, -P=O, S=O or SO2 and isotopes thereof; The halogen is arbitrarily and independently selected from F, Cl, Br, I and isotopes thereof; m is an integer arbitrarily selected from 0, 1, 2, 3, and 4.

10. The compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt, solvate, enantiomer or isotope thereof, characterized in that: It has the structure of formula (IK): in, Any represents a single bond or a double bond; Z3 is independently selected from the group consisting of absence, a single bond, -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic group, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z3 is further optionally substituted with 1 to more substituents, the substituents being arbitrarily selected from hydrogen, deuterium, halogen, pentafluorosulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 Alkoxy; X1, X2 are independently selected from N or CR; Y is independently selected from -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-、-O-、-S-、-C(=O)O-、-OC(=O)-、-C(=O)-、-C(=S)-、-S(=O)–、-S(=O)2-; Each R1 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, -SH and -NH2, -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, amide, aminoacyl, sulfamoyl, sulfonamide, methylsulfonylamino or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 ring Alkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute or M group; and the hydrogen on R1 is optionally replaced by 1 to more selected from H, deuterium, halogen, pentafluoride sulfur, OCH3, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 or any two adjacent R1s together with the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, or a 5-30 membered saturated or partially saturated heterocyclic group, and the hydrogen atoms on the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group are optionally selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 The hydrogen on R1 is optionally replaced by one or more selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; Each R2 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, amino, hydroxyl, acyl, carboxyl, thiol, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10 Alkylamino, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamide, N,N-di(C 1-10 Alkyl)amino, C 1-10 Alkyloxy, C 1-10 Alkyl acyl, C 1-10 Alkyloxy, C 1-10 Alkylsulfonyl, C 1-10 Alkylsulfinyl, C 3-10 Cycloalkylamino, C3-10 heterocycloalkylamino, C 3-10 Cycloalkoxy, C 3-10 Heterocycloalkoxy, C 3-10 Cycloalkyl acyl, C 3-10 Cycloalkoxyacetyl, C 3-10 Cycloalkylsulfonyl and C 3-10 Cycloalkylsulfinyl, -YQ or M group; or optionally two R2 can form a 5-6 membered aryl or heteroaryl group together with the atoms to which they are attached, a 3-8 membered saturated or partially saturated cycloalkyl group, a 3-8 membered saturated or partially saturated heterocyclic group, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic group is optionally substituted by one or more groups selected from hydrogen, deuterium, alkyl, halogen, pentafluoride sulfur group, oxo, CN, CF3, OH, OCH3, OCH2CH3; and the hydrogen on R2 is optionally substituted by one or more groups selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, -CN, -OH, CF3, C 1-6 Alkyl, C 1- 6-alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 Substituted with cycloalkyl or heterocycloalkyl, -YQ or M groups; M is arbitrarily and independently selected from Z is independently selected from the group consisting of absent, C(R d1 )(R d2 ), O, NR d1 ,-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-、-N(R d7 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic group, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z1 and Z2 is further optionally substituted by 1 to more substituents, wherein the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluorosulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1- 3 alkyl, C 1-3 Alkoxy; Y is arbitrarily and independently selected from O, S or NR; Q arbitrarily represents a 3-20 membered cyclic structure, which may be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure may be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; and the hydrogen on the ring Q is optionally preferably replaced by one or more selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, alkyl, alkenyl, alkynyl, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; Each R may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, haloalkyl, haloalkoxy, deuterated alkyl, deuterated alkoxy, -OH, -SH and -NH2, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfamoyl, methylsulfonamido or -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2- 10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute; and the hydrogen on R is further optionally substituted by 1 to more substituents, the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 Alkoxy; R a and R b Any independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein said C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by 1 to more than one selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 A saturated or partially substituted group is substituted by a substituent of a saturated cycloalkyl or heterocyclic group; or R a and R b or R a and R2 or R a and R1 can also be connected to form a 3-30 membered cyclic structure, wherein the cyclic structure can be a monocyclic, bicyclic, bridged or spirocyclic structure, and can contain 0 to more heteroatoms or unsaturated bonds; furthermore, R a The hydrogen on the 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1- 6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 Cycloalkyl or heterocycloalkyl substitution; Every R d1 , R d2 , R d3 , R d4 , R d5 , R d6 , R d7 may be the same or different and are independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein said C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by 1 to more than one selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups are substituted by saturated cycloalkyl or heterocyclic substituents; or any R d1 , R d2 , R d3 , R d4 , R d5 , R d6 , R d7 The heteroaryl, saturated or partially saturated cycloalkyl, or saturated or partially saturated heterocyclic group may be formed by themselves or / and R1 or R2 and the atoms to which they are attached, and the hydrogen on the heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group may be selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; The heteroatom represents any heteroatom or group independently selected from O, N, S, P, -P=O, S=O or SO2 and isotopes thereof; The halogen is arbitrarily and independently selected from F, Cl, Br, I and isotopes thereof; m is an integer arbitrarily selected from 0, 1, 2, 3, and 4; Preferably, the compound, its pharmaceutically acceptable salt, solvate, enantiomer or isotope substituted product has the structure of formula (IL): in, X1 is independently selected from N or CR; Each R1 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, -SH and -NH2, -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamide, methylsulfonylamino or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute or M group; and the hydrogen on R1 is optionally replaced by 1 to more selected from H, deuterium, halogen, pentafluoride sulfur, OCH3, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3- 10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1- 10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 or any two adjacent R1s together with the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, or a 5-30 membered saturated or partially saturated heterocyclic group, and the hydrogen atoms on the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group are optionally selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 The hydrogen on R1 is optionally replaced by one or more selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; Each R2 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, amino, hydroxyl, mercapto, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10 Alkylamino, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamide, N,N-di(C 1-10 Alkyl)amino, C 1-10 Alkyloxy, C 1-10 Alkyl acyl, C 1-10 Alkyloxy, C 1-10 Alkylsulfonyl, C 1-10 Alkylsulfinyl, C 3-10 Cycloalkylamino, C3-10 heterocycloalkylamino, C 3-10 Cycloalkoxy, C 3-10 Heterocycloalkoxy, C 3-10 Cycloalkyl acyl, C 3-10 Cycloalkoxyacetyl, C 3-10 Cycloalkylsulfonyl and C 3-10 Cycloalkylsulfinyl, -YQ or M group; or optionally two R2 can form a 5-6 membered aryl or heteroaryl group together with the atoms to which they are attached, a 3-8 membered saturated or partially saturated cycloalkyl group, a 3-8 membered saturated or partially saturated heterocyclic group, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic group is optionally substituted by one or more groups selected from hydrogen, deuterium, alkyl, halogen, pentafluoride sulfur group, oxo, CN, CF3, OH, OCH3, OCH2CH3; and the hydrogen on R2 is optionally substituted by one or more groups selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 Substituted with cycloalkyl or heterocycloalkyl, -YQ or M groups; M is arbitrarily and independently selected from Z is independently selected from the group consisting of absent, C(R d1 )(R d2 ), O, NR d1 ,-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-、-N(R d7 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic group, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z1 and Z2 is further optionally substituted by 1 to more substituents, wherein the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluorosulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1- 3 alkyl, C 1-3 Alkoxy; Y is arbitrarily and independently selected from O, S or NR; Q arbitrarily represents a 3-20 membered cyclic structure, which may be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure may be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; and the hydrogen on the ring Q is optionally preferably replaced by one or more selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, alkyl, alkenyl, alkynyl, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; Each R may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, haloalkyl, haloalkoxy, deuterated alkyl, deuterated alkoxy, -OH, -SH and -NH2, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfamoyl, methylsulfonamido or -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2- 10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute; and the hydrogen on R is further optionally substituted by 1 to more substituents, the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 Alkoxy; Every R d1 , R d2 , R d3 , R d4 , R d5 , R d6 , R d7 may be the same or different and are independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein said C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by 1 to more than one selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups are substituted by saturated cycloalkyl or heterocyclic substituents; or any R d1 , R d2 , R d3 , R d4 , R d5 , R d6 , R d7 The heteroaryl, saturated or partially saturated cycloalkyl, or saturated or partially saturated heterocyclic group may be formed by themselves or / and R1 or R2 and the atoms to which they are attached, and the hydrogen on the heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group may be selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; The heteroatom represents any heteroatom or group independently selected from O, N, S, P, -P=O, S=O or SO2 and isotopes thereof; The halogen is arbitrarily and independently selected from F, Cl, Br, I and isotopes thereof; m is an integer arbitrarily selected from 0, 1, 2, 3, and 4; n is an integer arbitrarily selected from 0, 1, 2, 3, 4 and 5; Preferably, the compound, its pharmaceutically acceptable salt, solvate, enantiomer or isotope substituted product has the structure of formula (IM): in, Y3 and Y4 are independently selected from -C(R d1 )(R d2 )-、O、-C(R d1 )(R d2 )C(R d1 )(R d2 )- or -C(=O)-; Each R1 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, -SH and -NH2, -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, amide, aminoacyl, sulfamoyl, sulfonamide, methylsulfonylamino or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute or M group; and the hydrogen on R1 is optionally replaced by 1 to more selected from H, deuterium, halogen, pentafluoride sulfur, OCH3, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 or any two adjacent R1s together with the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, or a 5-30 membered saturated or partially saturated heterocyclic group, and the hydrogen atoms on the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group are optionally selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 The hydrogen on R1 is optionally replaced by one or more selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; Each R2 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, amino, hydroxyl, mercapto, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10 Alkylamino, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamide, N,N-di(C 1-10 Alkyl)amino, C 1-10 Alkyloxy, C 1-10 Alkyl acyl, C 1-10 Alkyloxy, C 1-10 Alkylsulfonyl, C 1-10 Alkylsulfinyl, C 3-10 Cycloalkylamino, C3-10 heterocycloalkylamino, C 3-10 Cycloalkoxy, C 3-10 Heterocycloalkoxy, C 3-10 Cycloalkyl acyl, C 3-10 Cycloalkoxyacetyl, C 3-10 Cycloalkylsulfonyl and C 3-10 Cycloalkylsulfinyl, -YQ or M group; or optionally two R2 can form a 5-6 membered aryl or heteroaryl group together with the atoms to which they are attached, a 3-8 membered saturated or partially saturated cycloalkyl group, a 3-8 membered saturated or partially saturated heterocyclic group, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic group is optionally substituted by one or more groups selected from hydrogen, deuterium, alkyl, halogen, pentafluoride sulfur group, oxo, CN, CF3, OH, OCH3, OCH2CH3; and the hydrogen on R2 is optionally substituted by one or more groups selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 Cycloalkyl or heterocycloalkyl substitution; M is arbitrarily and independently selected from Z is independently selected from the group consisting of absent, C(R d1 )(R d2 ), NR d1 ,-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-、-N(R d7 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic group, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z is further optionally substituted with 1 to more substituents, wherein the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluorosulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1- 3 alkyl, C 1-3 Alkoxy; Y is independently selected from -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、 -C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic group, C 4-10 saturated or partially saturated heteroaryl; Q arbitrarily represents a 3-20 membered cyclic structure, which may be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure may be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; and the hydrogen on the ring Q is optionally preferably replaced by one or more selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, alkyl, alkenyl, alkynyl, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; Each R may be the same or different and is independently selected from hydrogen, deuterium, -CN, haloalkyl, haloalkoxy, deuterated alkyl, deuterated alkoxy, -OH, -SH and -NH2, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamido, methylsulfonylamino or -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute; and the hydrogen on R is further optionally substituted by 1 to more substituents, the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 Alkoxy; R a and R b Any independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein said C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by 1 to more than one selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups are substituted by saturated cycloalkyl or heterocyclic substituents; or R a and R b or R a and R2 or R a and R1 can also be connected to form a 3-30 membered cyclic structure, wherein the cyclic structure can be a monocyclic, bicyclic, bridged or spirocyclic structure, and can contain 0 to more heteroatoms or unsaturated bonds; furthermore, R a The hydrogen on the 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1- 6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 Cycloalkyl or heterocycloalkyl substitution; Every R d1 , R d2 , R d3 , R d4 , R d5 , R d6 , R d7 may be the same or different and are independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein said C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by 1 to more than one selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups are substituted by saturated cycloalkyl or heterocyclic substituents; or any R d1 , R d2 , R d3 , R d4 , R d5 , R d6 , R d7 The heteroaryl, saturated or partially saturated cycloalkyl, or saturated or partially saturated heterocyclic group may be formed by themselves or / and R1 or R2 and the atoms to which they are attached, and the hydrogen on the heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group may be selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; The heteroatom represents any heteroatom or group independently selected from O, N, S, P, -P=O, S=O or SO2 and isotopes thereof; The halogen is arbitrarily and independently selected from F, Cl, Br, I and isotopes thereof; m is an integer arbitrarily selected from 0, 1, 2 and 3; n is an integer arbitrarily selected from 0, 1, 2, 3, and 4.

11. The compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt, solvate, enantiomer or isotope thereof, characterized in that: It has the structure of formula (IN): in, Y3 and Y4 are independently selected from -C(R d1 )(R d2 )-、O、-C(R d1 )(R d2 )C(R d1 )(R d2 )- or -C(=O)-; Each R1 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, -SH and -NH2, -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, amide, aminoacyl, sulfamoyl, sulfonamide, methylsulfonylamino or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute or M group; and the hydrogen on R1 is optionally replaced by 1 to more selected from H, deuterium, halogen, pentafluoride sulfur, OCH3, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 or any two adjacent R1s together with the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, or a 5-30 membered saturated or partially saturated heterocyclic group, and the hydrogen atoms on the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group are optionally selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 The hydrogen on R1 is optionally replaced by one or more selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; Each R2 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, amino, hydroxyl, mercapto, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10 Alkylamino, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamide, N,N-di(C 1-10 Alkyl)amino, C 1-10 Alkyloxy, C 1-10 Alkyl acyl, C 1-10 Alkyloxy, C 1-10 Alkylsulfonyl, C 1-10 Alkylsulfinyl, C 3-10 Cycloalkylamino, C3-10 heterocycloalkylamino, C 3-10 Cycloalkoxy, C 3-10 Heterocycloalkoxy, C 3-10 Cycloalkyl acyl, C 3-10 Cycloalkoxyacetyl, C 3-10 Cycloalkylsulfonyl and C 3-10 Cycloalkylsulfinyl, -YQ or M group; or optionally two R2 can form a 5-6 membered aryl or heteroaryl group together with the atoms to which they are attached, a 3-8 membered saturated or partially saturated cycloalkyl group, a 3-8 membered saturated or partially saturated heterocyclic group, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic group is optionally substituted by one or more groups selected from hydrogen, deuterium, alkyl, halogen, pentafluoride sulfur group, oxo, CN, CF3, OH, OCH3, OCH2CH3; and the hydrogen on R2 is optionally substituted by one or more groups selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 Cycloalkyl or heterocycloalkyl substitution; M is arbitrarily and independently selected from Z is independently selected from the group consisting of absent, C(R d1 )(R d2 ), NR d1 ,-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-、-N(R d7 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic group, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z is further optionally substituted with 1 to more substituents, wherein the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluorosulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1- 3 alkyl, C 1-3 Alkoxy; Y is independently selected from -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、- C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic group, C 4-10 saturated or partially saturated heteroaryl; Q arbitrarily represents a 3-20 membered cyclic structure, which may be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure may be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; and the hydrogen on the ring Q is optionally preferably replaced by one or more selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, alkyl, alkenyl, alkynyl, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; Each R may be the same or different and is independently selected from hydrogen, deuterium, -CN, haloalkyl, haloalkoxy, deuterated alkyl, deuterated alkoxy, -OH, -SH and -NH2, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamido, methylsulfonylamino or -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute; and the hydrogen on R is further optionally substituted by 1 to more substituents, the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 Alkoxy; R a and R b Any independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein said C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by 1 to more than one selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups are substituted by saturated cycloalkyl or heterocyclic substituents; or R a and R b or R a and R2 or R a and R1 can also be connected to form a 3-30 membered cyclic structure, wherein the cyclic structure can be a monocyclic, bicyclic, bridged or spirocyclic structure, and can contain 0 to more heteroatoms or unsaturated bonds; furthermore, R a The hydrogen on the 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1- 6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 Cycloalkyl or heterocycloalkyl substitution; Every R d1 , R d2 , R d3 , R d4 , R d5 , R d6 , R d7 may be the same or different and are independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein said C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by 1 to more than one selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups are substituted by saturated cycloalkyl or heterocyclic substituents; or any R d1 , R d2 , R d3 , R d4 , R d5 , R d6 , R d7 The heteroaryl, saturated or partially saturated cycloalkyl, or saturated or partially saturated heterocyclic group may be formed by themselves or / and R1 or R2 and the atoms to which they are attached, and the hydrogen on the heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group may be selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; The heteroatom represents any heteroatom or group independently selected from O, N, S, P, -P=O, S=O or SO2 and isotopes thereof; The halogen is arbitrarily and independently selected from F, Cl, Br, I and isotopes thereof; m is an integer arbitrarily selected from 0, 1, 2 and 3; n is an integer arbitrarily selected from 0, 1, 2, 3, and 4; Preferably, the compound, its pharmaceutically acceptable salt, solvate, enantiomer or isotope substituted product has the structure of formula (IO): in, Y3 and Y4 are independently selected from -C(R d1 )(R d2 )-、O、-C(R d1 )(R d2 )C(R d1 )(R d2 )- or -C(=O)-; Each R1 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, -SH and -NH2, -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, amide, aminoacyl, sulfamoyl, sulfonamide, methylsulfonylamino or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute or M group; and the hydrogen on R1 is optionally replaced by 1 to more selected from H, deuterium, halogen, pentafluoride sulfur, OCH3, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 or any two adjacent R1s together with the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, or a 5-30 membered saturated or partially saturated heterocyclic group, and the hydrogen atoms on the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group are optionally selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 The hydrogen on R1 is optionally replaced by one or more selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; Each R2 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, amino, hydroxyl, mercapto, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10 Alkylamino, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamide, N,N-di(C 1-10 Alkyl)amino, C 1-10 Alkyloxy, C 1-10 Alkyl acyl, C 1-10 Alkyloxy, C 1-10 Alkylsulfonyl, C 1-10 Alkylsulfinyl, C 3-10 Cycloalkylamino, C3-10 heterocycloalkylamino, C 3-10 Cycloalkoxy, C 3-10 Heterocycloalkoxy, C 3-10 Cycloalkyl acyl, C 3-10 Cycloalkoxyacetyl, C 3-10 Cycloalkylsulfonyl and C 3-10 Cycloalkylsulfinyl, -YQ or M group; or optionally two R2 can form a 5-6 membered aryl or heteroaryl group together with the atoms to which they are attached, a 3-8 membered saturated or partially saturated cycloalkyl group, a 3-8 membered saturated or partially saturated heterocyclic group, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic group is optionally substituted by one or more groups selected from hydrogen, deuterium, alkyl, halogen, pentafluoride sulfur group, oxo, CN, CF3, OH, OCH3, OCH2CH3; and the hydrogen on R2 is optionally substituted by one or more groups selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 Cycloalkyl or heterocycloalkyl substitution; M is arbitrarily and independently selected from Z is independently selected from the group consisting of absent, C(R d1 )(R d2 ), NR d1 ,-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-、-N(R d7 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic group, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z is further optionally substituted with 1 to more substituents, wherein the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluorosulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1- 3 alkyl, C 1-3 Alkoxy; Y is independently selected from -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic group, C 4-10 saturated or partially saturated heteroaryl; Q arbitrarily represents a 3-20 membered cyclic structure, which may be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure may be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; and the hydrogen on the ring Q is optionally preferably replaced by one or more selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, alkyl, alkenyl, alkynyl, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; Each R may be the same or different and is independently selected from hydrogen, deuterium, -CN, haloalkyl, haloalkoxy, deuterated alkyl, deuterated alkoxy, -OH, -SH and -NH2, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamido, methylsulfonylamino or -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute; and the hydrogen on R is further optionally substituted by 1 to more substituents, the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 Alkoxy; R a and R b Any independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein said C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by 1 to more than one selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups are substituted by saturated cycloalkyl or heterocyclic substituents; or R a and R b or R a and R2 or R a and R1 can also be connected to form a 3-30 membered cyclic structure, wherein the cyclic structure can be a monocyclic, bicyclic, bridged or spirocyclic structure, and can contain 0 to more heteroatoms or unsaturated bonds; furthermore, R a The hydrogen on the 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1- 6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 Cycloalkyl or heterocycloalkyl substitution; Every R d1 , R d2 , R d3 , R d4 , R d5 , R d6 , R d7 may be the same or different and are independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein said C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by 1 to more than one selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups are substituted by saturated cycloalkyl or heterocyclic substituents; or any R d1 , R d2 , R d3 , R d4 , R d5 , R d6 , R d7 The heteroaryl, saturated or partially saturated cycloalkyl, or saturated or partially saturated heterocyclic group may be formed by themselves or / and R1 or R2 and the atoms to which they are attached, and the hydrogen on the heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group may be selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; The heteroatom represents any heteroatom or group independently selected from O, N, S, P, -P=O, S=O or SO2 and isotopes thereof; The halogen is arbitrarily and independently selected from F, Cl, Br, I and isotopes thereof; m is an integer arbitrarily selected from 0, 1, 2 and 3; n is an integer arbitrarily selected from 0, 1, 2, 3, and 4; Preferably, the compound, its pharmaceutically acceptable salt, solvate, enantiomer or isotope substituted product has the structure of formula (IP): in, Y3 and Y4 are independently selected from -C(R d1 )(R d2 )-、O、-C(R d1 )(R d2 )C(R d1 )(R d2 )- or -C(=O)-; Each R1 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, -SH and -NH2, -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, amide, aminoacyl, sulfamoyl, sulfonamide, methylsulfonylamino or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute or M group; and the hydrogen on R1 is optionally replaced by 1 to more selected from H, deuterium, halogen, pentafluoride sulfur, OCH3, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 or any two adjacent R1s together with the atoms to which they are attached form a 5-30 membered heteroaryl, a 5-30 membered saturated or partially saturated cycloalkyl, or a 5-30 membered saturated or partially saturated heterocyclic group, and the hydrogen atoms on the aryl, heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group are optionally selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 The hydrogen on R1 is optionally replaced by one or more selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; Each R2 may be the same or different and is independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, amino, hydroxyl, mercapto, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10 Alkylamino, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamide, N,N-di(C 1-10 Alkyl)amino, C 1-10 Alkyloxy, C 1-10 Alkyl acyl, C 1-10 Alkyloxy, C 1-10 Alkylsulfonyl, C 1-10 Alkylsulfinyl, C 3-10 Cycloalkylamino, C3-10 heterocycloalkylamino, C 3-10 Cycloalkoxy, C 3-10 Heterocycloalkoxy, C 3-10 Cycloalkyl acyl, C 3-10 Cycloalkoxyacetyl, C 3-10 Cycloalkylsulfonyl and C 3-10 Cycloalkylsulfinyl, -YQ or M group; or optionally two R2 can form a 5-6 membered aryl or heteroaryl group together with the atoms to which they are attached, a 3-8 membered saturated or partially saturated cycloalkyl group, a 3-8 membered saturated or partially saturated heterocyclic group, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclic group is optionally substituted by one or more groups selected from hydrogen, deuterium, alkyl, halogen, pentafluoride sulfur group, oxo, CN, CF3, OH, OCH3, OCH2CH3; and the hydrogen on R2 is optionally substituted by one or more groups selected from hydrogen, deuterium, halogen, pentafluoride sulfur group, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 Cycloalkyl or heterocycloalkyl substitution; M is arbitrarily and independently selected from Z is independently selected from the group consisting of absent, C(R d1 )(R d2 ), NR d1 ,-C(R d1 )(R d2 )C(R d1 )(R d2 )-、-C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-、-N(R d7 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic group, C 4-10 Saturated or partially saturated heteroaryl; and the hydrogen on Z is further optionally substituted with 1 to more substituents, wherein the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluorosulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1- 3 alkyl, C 1-3 Alkoxy; Y is independently selected from -C(R d1 )(R d2 )-、-C(=R d1 )-、-(R d1 )P(=O)-、=C(R d1 )-、NH、-C(R d1 )(R d2 )C(R d1 )(R d2 )-、- C(R d1 )=C(R d1 )-、-C(R d1 )(R d2 )C(R d1 )=C(R d1 )-、 -OC(R d1 )(R d2 )-、-C(R d1 )(R d2 )O-、-NHC(R d1 )(R d2 )-、-C(R d1 )(R d2 )NH-、-C(=O)N(R d3 )-、-N(R d4 )-、-C(=NR d5 )-、-S(=O)2N(R d6 )-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)–, -S(=O)2- or C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 4-10 Saturated or partially saturated aromatic group, C 4-10 saturated or partially saturated heteroaryl; Q arbitrarily represents a 3-20 membered cyclic structure, which may be a monocyclic, bicyclic or tricyclic structure, wherein the cyclic structure may be an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring, a bridged ring or a spirocyclic ring or a cyclic structure composed of an aromatic ring, a heteroaromatic ring, an alicyclic ring, a heterocyclic ring and a bridged ring; and the hydrogen on the ring Q is optionally preferably replaced by one or more selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, alkyl, alkenyl, alkynyl, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; Each R may be the same or different and is independently selected from hydrogen, deuterium, -CN, haloalkyl, haloalkoxy, deuterated alkyl, deuterated alkoxy, -OH, -SH and -NH2, dialkylphosphonyl, alkylsulfonyl, sulfonyl, alkylsulfinyl, sulfamoyl, sulfonamido, methylsulfonylamino or -COOH or selected from C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 2-10 Heteroalkyl, C 3-10 Saturated or partially saturated cycloalkyl, C 3-10 Saturated or partially saturated heterocycloalkyl, C 3-10 Cycloalkyl or C 3-10 Heterocycloalkyl substituted C 1-10 Alkyl, C 3-10 Cycloalkyl substituted C 2-10 Heteroalkyl, C 3-10 Heterocyclic group, C 1-10 Alkyl substituted carboxyl or carboxyl substitute; and the hydrogen on R is further optionally substituted by 1 to more substituents, the substituents are arbitrarily selected from hydrogen, deuterium, halogen, pentafluoride sulfur, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C 1-3 Alkyl, C 1-3 Alkoxy; R a and R b Any independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein said C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by 1 to more than one selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups are substituted by saturated cycloalkyl or heterocyclic substituents; or R a and R b or R a and R2 or R a and R1 can also be connected to form a 3-30 membered cyclic structure, wherein the cyclic structure can be a monocyclic, bicyclic, bridged or spirocyclic structure, and can contain 0 to more heteroatoms or unsaturated bonds; furthermore, R a The hydrogen on the 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1- 6 alkyl)2, oxy, halogenated alkyl, deuterated alkyl, and saturated or partially saturated C 3-6 Cycloalkyl or heterocycloalkyl substitution; Every R d1 , R d2 , R d3 , R d4 , R d5 , R d6 , R d7 may be the same or different and are independently selected from hydrogen, deuterium, halogen, sulfur pentafluoride, NH2, C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 Heterocyclic group; wherein said C 1-10 Alkyl, C 2-10 Alkynyl or C 1-10 Alkoxy, C 1-10 Alkyl acyl, C 1-10 Alkylsulfonyl, C 2-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl, C 3-10 Cycloalkyl-substituted C 1-10 Alkyl or C 3-10 Cycloalkyl, C 3-10 Heterocycloalkyl substituted C 3-10 The heterocyclic group is optionally substituted by 1 to more than one selected from hydrogen, deuterium, halogen, pentafluorosulfur, oxo, CN, OH and C 3-10 Saturated or partially substituted groups are substituted by saturated cycloalkyl or heterocyclic substituents; or any R d1 , R d2 , R d3 , R d4 , R d5 , R d6 , R d7 The heteroaryl, saturated or partially saturated cycloalkyl, or saturated or partially saturated heterocyclic group may be formed by themselves or / and R1 or R2 and the atoms to which they are attached, and the hydrogen on the heteroaryl, saturated or partially saturated cycloalkyl, or heterocyclic group may be selected from hydrogen, deuterium, halogen, sulfur pentafluoride, -CN, -OH, CF3, C 1-6 Alkyl, C 1-6 Alkoxy, -NH2, -NHC 1-6 Alkyl, -N(C 1-6 alkyl)2, =O, and saturated or partially saturated C 3-6 Cycloalkyl substituted, and C 1-6 Alkyl and C 1-6 The alkoxy group is optionally substituted with one or more alkyl radicals selected from hydrogen, deuterium, halogen, sulfur pentafluoride, oxo, CN, CF3, OH, OCH3, OCH2CH3, saturated or partially saturated C 3-6 radical substitution of cycloalkyl groups; The heteroatom represents any heteroatom or group independently selected from O, N, S, P, -P=O, S=O or SO2 and isotopes thereof; The halogen is arbitrarily and independently selected from F, Cl, Br, I and isotopes thereof; m is an integer arbitrarily selected from 0, 1, 2 and 3; n is an integer arbitrarily selected from 0, 1, 2, 3, and 4.

12. The compound according to any one of claims 1 to 11, or a pharmaceutically acceptable salt, solvate, enantiomer or isotope thereof, characterized in that: It has the structure of formula (III), in, X is selected from N or CR; R is selected from H, C 1-6 Alkyl, halogenated C 1-6 alkyl; E is selected from O, S, NR e ; R e Selected from H, C 1-6 Alkyl, C 3-6 Cycloalkyl, halogenated C 1-6 alkyl; Each R1 is the same or different and is independently selected from H, C 1-6 Alkyl, C 1-6 Alkoxy, S(O)2C 1-6 Alkyl, P(O)(C 1-6 Alkyl)2; Each R2 is the same or different and is independently selected from H, P(O)(C 1-6 Alkyl)2, -NH-Q; Q is selected from unsubstituted or optionally substituted by one, two or more R q Substituted with the following groups: 5-6 membered heterocyclic group; each R q are the same or different and are independently selected from H, halogen, C 1-6 Alkyl, halogenated C 1-6 alkyl; R d1 , R d2 The same or different, independently selected from H, C 1-6 Alkyl, C 1-6 Alkoxy; R y1 , R y2 The same or different, independently selected from H, C 1-6 Alkyl, C 1-6 Alkoxy; or, R y1 , R y2 The atoms to which they are attached form a 5-12 membered heterocyclyl or a 5-10 membered heteroaryl; m is selected from 0, 1, 2 or 3; n is selected from 0, 1, 2, 3 or 4; Preferably, R is selected from H, C 1-3 Alkyl, halogenated C 1-3 alkyl; Preferably, R is selected from H, CH2CF3; Preferably, R e Selected from H, C 3-6 Cycloalkyl, halogenated C 1-3 alkyl; Preferably, R e Selected from cyclopropyl, CH2CF3; Preferably, Selected from Preferably, each R1 is the same or different and is independently selected from H, S(O)2C 1-3 Alkyl, P(O)(C 1-3 Alkyl)2; Preferably, each R1 is the same or different and is independently selected from H, S(O)2CH3, P(O)(CH3)2; Preferably, each R2 is the same or different and is independently selected from H, P(O)(C 1-3 Alkyl)2, -NH-Q; for example, H, P(O)(C 1-3 Alkyl)2, (like )、 (like )； Preferably, Q is selected from unsubstituted or optionally substituted with one, two or more R q Substituted: 6-membered heterocyclic group; for example, piperidinyl; Preferably, each R q are the same or different and are independently selected from H, halogen, C 1-6 Alkyl; for example, H, F, methyl; Preferably, each R2 is the same or different and is independently selected from H, P(O)(CH3)2, (For example )、 (For example )、 (For example )； Preferably, R y1 , R y2 The same or different, independently selected from H, C 1-3 Alkoxy; for example, H, methoxy; Preferably, R y1 , R y2 The atoms to which they are attached form a 5-7 membered heterocyclic group, a 12 membered heterocyclic group or a 5-6 membered heteroaryl group; for example, a furan ring, a dihydrofuran ring, Preferably, Selected from Preferably, Selected from 13. The compound according to any one of claims 1 to 12, or a pharmaceutically acceptable salt, solvate, enantiomer or isotope thereof, characterized in that: The compound is selected from novel compounds with structures disclosed in the specification of the present invention.

14. A pharmaceutical composition comprising a therapeutically effective amount of at least one of the compound according to any one of claims 1 to 13, or a pharmaceutically acceptable salt, solvate, enantiomer or isotope thereof.

15. Use of the compound according to any one of claims 1 to 13, its pharmaceutically acceptable salt, solvate, enantiomer or isotope substitution, or the pharmaceutical composition according to claim 14 in the preparation of a medicament for preventing and / or treating diseases related to abnormalities in the P53 signaling pathway.

Images